CURRICULUM VITAE

Date Prepared: March 2017

Name: David Parker Faxon, M.D.

Office Address: Department of Medicine Division of Cardiology Brigham and Women’s Hospital 70 Francis Street, SH5152 Boston, MA 02115 Home Address: 56 Mount Vernon Boston, MA 02108 Work Phone: 617-525-8358 Work Email: [email protected] Work FAX: 857-307-1955 Place of Birth: Manchester, New Hampshire

Education:

9/1963-5/1967 BA Hamilton College, Clinton, NY 8/1967-6/1971 MD Boston University School of Medicine, Boston

Postdoctoral Training: 6/1971-7/1972 Intern in Medicine, Mary Hitchcock Hospital, Dartmouth-Hitchcock Medical Center, Hanover, NH

7/1972-7/1974 Resident in Medicine Mary Hitchcock Hospital, Dartmouth-Hitchcock Medical Center 7/1974-7/1976 Cardiology Fellow The University Hospital, Boston, University Medical Center, Boston, MA

Academic Appointments: 1976-1977 Instructor in Medicine Boston University School of Medicine 1977-1982 Assistant Professor of Boston University School of Medicine Medicine 1982-1991 Associate Professor of Boston University School of Medicine Medicine 1991-1993 Professor of Medicine Boston University School of Medicine 1993-2000 Professor of Medicine University of Southern California 2000-2006 Professor of Medicine University of Chicago 2006- present Senior Lecturer in Medicine Harvard Medical School

David P. Faxon, M.D. Curriculum Vitae

Hospital Appointments:

July 1976- May 1993 Visiting Physician The University Hospital, Boston, MA June 1993- May 2000 Attending Physician USC University Hospital, Los Angeles, CA June 1993- May 2000 Attending Physician Los Angeles County Hospital, Los Angeles, CA June 2000- Feb 2006 Attending Physician University of Chicago Hospitals, Chicago, Ill Sept 2006- Sept 2015 Attending Physician West Roxbury VA Hospital, West Roxbury, MA May 2008- present Attending Physician Brigham and Women's Hospital, Boston, MA

Hospital and Health Care Organization Service Responsibilities:

1995-2000 Attending Staff Huntington Hospital, Pasadena, CA 1996-2000 Attending Staff Glendale Memorial Hospital, Glendale, CA 2017- Present Clinical Service Director -Cardiology Brigham and Women’s Hospital

Major Administrative Responsibilities:

1976-1990 Director, Cardiac Catheterization Laboratory University Hospital, Boston 1989-1993 Associate Director of Cardiology The University Hospital, Boston 1990-1993 Director, Interventional Cardiology The University Hospital, Boston 1990-1991 Acting Chief of Cardiology The University Hospital, Boston 1993-2000 Chief, Division of Cardiology C LAC+USC Medical Center, USC University Hospital, Los Angeles, CA 1993-2000 Director, Cardiovascular Diseases Fellowship University of Southern California Program School of Medicine, Los Angeles, CA 2000-2006 Chief, Section of Cardiology The University of Chicago, Chicago 2006-2006 Vice Chair of Medicine for Integrated Clinical Brigham and Women’s Hospital, Services Boston 2006-2008 Director of Strategic Planning, Department of Brigham and Women’s Hospital, Medicine Boston 2006-2008 Chief of Cardiology Boston Health Care System, West Roxbury VA Hospital, West Roxbury 2008-2015 Vice Chair of Medicine for Strategic Planning Brigham and Women’s Hospital, Boston 2013-2015 Interim Chief of Cardiology Boston Health Care System, West Roxbury VA Hospital, WR 2014-2016 Cardiology Physician Lead (CUPID) eCARE, Partners Health Care, Boston 2015- 2016 Clinical Director of Ambulatory Brigham and Women’s Hospital Cardiovascular Services 2017- Present Associate Chief, Division of Cardiology Brigham and Women’s Hospital

A 2 David P. Faxon, M.D. Curriculum Vitae

Other Professional Positions:

Year Role Organization 1992-2004 Chair DSMB EPIC trial Centecor/Eli Lilly, Indianapolis, Indiana 1995-2006 Chair DSMB EPILOG trial Centecor/Eli Lilly, Indianapolis, Indiana 1996-2007 DSMB IMPACT trial Sherring Plough, Kenilworth, NJ 1998-2000 Advisory Board US Surgical, Norwalk, CT 2003-2004 DSMB TAXUS I trial Boston Scientific, Natick, MA 2004-2005 DSMB TAXUS II-III trial Boston Scientific, Natick, MA 2004-2005 DSMB EVEREST trial E-Valve, Menlo Park, CA 2004-2005 DSMB TAXUS IV trial Boston Scientific, Natick, MA 2005-2007 Advisory Board Sanofi, Paris, Fr 2005-2012 DSMB SYNTAX trial Boston Scientific, Natick, MA 2005-2009 DSMB Champion Medicines Co, Parsippany, NJ 2005-2008 Chair DSMB SPIRIT III trial Guidant, St Paul, MN 2005-2009 Public Policy Advisory Board Johnson &Johnson, Piscataway, NJ 2006-present DSMB IRIS trial NIH-NINDS, Washington, DC 2006-present DSMB Global TAXUS Boston Scientific, Natick, MA 2005-2009 DSMB Early ACS trial GSK, Philadelphia, PA 2005-2006 DSMB ACUITY trial Medicines Co, Parsippany, NJ 2006-2007 DSMB HORIZONS trial Medicines Co, Parsippany, NJ 2006-2008 Advisory Board GSK, Philadelphia, PA 2008-2010 Chair DSMB GRAVITAS trial Accumetrics, San Diego, CA 2008-2010 Chair DSMB ELITE trial Cordis, New Jersey 2009-2010 Chair DSMB BRIDGE trial Medicine Co, Parsippany, NJ 2009-2011 DSMB SOLSTICE trial GSK, Philadelphia, PA 2009-2010 DSMB CYPRESS trial Cordis, New Jersey 2009-2011 DSMB Infuse-AMI Atrium Medical, Hudson, NH 2010-2013 Chair DSMB RESCUE & Medtronic Vascular, MN DISSECTION 2010-2012 TAO study, US coordinator Sanofi- Aventis, NJ 2010-present Chair DSMB CoreValve study HCRI/Medtronic, MN 2010-2011 DSMB AMIHOTEU Trial Therox, Irving CA 2011-2013 DSMB CHAMPION PHOENIX Medicine Co. Parsippany, NJ 2011-2012 DSMB MASTER Trial Sanofi Aventis, Malvern, PA 2011-2012 DSMB PRESERVATION Trial Duke/Ikaria LLC 2011-2013 DSMB RIVER-PCI Trial CRF/Gilead, , NY,NY 2011-2013 DSMB Direct Flow trial Medpace, Blaine, Minn 2011-present DSMB SURTAVI trial* Medtronics, MN 2012-2016 DSMB REPRISE trial Boston Sci, Natick, MA 2013-2016 DSMB BIOHELIX-1* Biotronik,Lake Oswego, OR 2013-2015 DSMB EVOLVE II Boston Sci, Natick MA 2013-2015 DSMB STENTYS AppV HCRI/Stentys, 2014-2016 DSMB HARMONEE Chair Duke/OrusNeich, Tokyo, Japan 2014-2016 DSMB CER12 Cobra Harvard Clinical Research Inst 2014-present DSMB AEGIS Behring CLS Cleveland Clinic/Behring CLS 2014-present DSMB TWILIGHT Mt Sinai School of Medicine A 3 David P. Faxon, M.D. Curriculum Vitae

2015-present DSMB Akebia PRO2TECT Akebia Therpeutics Inc 2015-2016 DSMB SOLUS Chair Yale Medical School/Direct Flow 2015-2016 DSMB GEMINI Stanford/Jansen Pharm 2016-present DSMB CoreValve EUS HCRI/Medtronic, MN 2016-present DSMB EVOLUTE R low risk HCRI/Medtronic, MN 2016-present DSMB Akebia INNOVATE Akebia Therpeutics Inc

Major Administrative Leadership Positions:

Local: University of Chicago Hospitals 2000-2006 Executive Committee of the Medical Staff Member 2001-2002 Search Committee – Chief of Radiology Member 2001-2003 Search Committee – Director of Cardiovascular Research Chair Boston VA Health Care System 2007-2009 CCU Director 2007-2009 Clinical Research task force Member 2007-2009 Intensive Care Committee Chairman Brigham and Women’s Hospital 2006-present DOM Strategic Plan Committee Chairman 2006-2007 BPO Finance committee Member 2007-present Clinical Innovations Grant Awards Committee Chairman 2010-2011 DOM Length of Stay committee Co-chair 2010-present Kenneth Baughman Mentorship Awards Committee Member 2010-present DOM Career Consultation Service Member 2011-present SCAMPS task force Member 2014-2016 Clinical Content Physician Lead Cardiac Disease- eCARE Lead 2014-present Cardiology Fellowship Advisory Committee Member

National Accreditation Council for Graduate Medical Education 1996-2005 Interventional Cardiology GAQ Advisor 2000-present Standing Panel for Accreditation Appeals, Specialty of Member Interventional Cardiology 2005-2008 Residency Review Committee for Internal Medicine Member 2012-2013 International Cardiology subspecialty program Advisor, site visitor

Agency for Health Care Research and Quality HHS 2008-2009 Stent Steering Committee Member

Alliance for a Healthier Generation (Founded by AHA and WClinton Foundation) 2006- present Board of Directors Member 2010-2012 Board of Directors Chairman A 4 David P. Faxon, M.D. Curriculum Vitae

2013-present Board of Directors Member

American Medical Association 2010-present RAND-AMA physician consortium for performance improvement Member

American Board of Internal Medicine 1997-2003 Subspecialty Board on Cardiovascular Disease Member 2009-present Interventional Cardiology SEP board Member

American College of Cardiology 1986-2005 17th Bethesda Conference on Adult Cardiovascular Training Member 1986-present Abstract Grader Annual Scientific Sessions Member 1986-1987 ACC/AHA Task Force - Indications for Angioplasty Member 1989-1992 Scientific Sessions Committee Member 1990-2000 Educational Programs Committee Member 1993 25th Bethesda Conference: Future Personnel Needs for Member Cardiovascular Health Care 1993 Consultant to HICFA Member 1993-1995 ACC/American Association of Critical Care Nurses Liaison Member Committee 1993-1995 Ad Hoc Task Force on Communications Member 1993-2002 Young Investigators Awards Committee Member 1993-1999 Technology and Practice Executive Committee Member 1995-present JACC (Journal of the American College of Cardiology) Editorial Member Board 1995-1998 ACC/AHA Task Force on Guidelines: Committee to Revise the Member 1987 Guidelines for Coronary Angiography 1996-1999 Ad Hoc Task Force on Telemedicine Member 1997-1999 Catheterization and Interventional Committee, Subcommittee to Member write: Training Standards in Interventional Cardiology 1997-1999 ACC Expert Consensus Committee: Standards for the Cardiac Member Catheterization Laboratory 1999-2004 ACC/AHA Guidelines Committee Member 2010 AHRQ Stent advisory committee Member 2011 ACCF/AHA Guidelines- ACS and CABG Expert Reviewer 2011-present ACCF/AHA/SCAI/AMA-PCPI/NCQA PCI Work Group Member

American Heart Association, Massachusetts Affiliate 1982-1984 Research Peer Review Committee Chairman 1982-1993 Board of Directors Member 1982-1993 Executive Committee Member 1984-1988 Research Policy Committee Chairman 1988-1990 Affiliate Vice President 1988-1991 Program Council Co-Chairman 1990 Site Committee Delegate, A 5 David P. Faxon, M.D. Curriculum Vitae

AHA Assembly 1990-1991 Affiliate President Elect 1990-1992 Site Committee Member 1992 Search Committee for Executive Director Member 1992-1993 Affiliate President

American Heart Association, Los Angeles Affiliate 1994-1998 Board of Directors Member 1995-1998 Executive Committee Member 1996-1997 Affiliate President-elect 1997-1998 Affiliate President

American Heart Association, Western States Affiliate 1998-2000 Executive Committee Member 1998-2000 Board of Directors Member 1999 Program Committee for the 67th Annual Fall Symposium Chairman 1999-2000 Professional Education Task Force Chairman

American Heart Association, Midwest Affiliate 2000-2001 Affiliate Board Ex-officio Member 2001-2005 Board of Directors, Chicago Metropolitan Division Member

American Heart Association, National 1983-1986 Program Committee; Clinical Council Member 1986-present Abstract Grader Annual Scientific Sessions Member 1993-2000 Scientific Publishing Committee Member 1996-2000 Committee on Diagnostic & Interventional Cardiac Vice-Chair Catheterization 1998-2000 Scientific Publishing Committee Chairperson 1998-2000 Interventional Cardiology Program Committee Co-Chair 1998-2003 Pharmaceutical Roundtable Member 1998-2003 Board of Directors Member 1998-2003 Administrative Cabinet Member 1998-2003 Scientific Advisory Coordinating Committee Member 1998-2000 Committee on Scientific Councils Member 1998-2000 Conflict of Interest Review Committee Member 1998-present National Spokespersons Panel Member 1999-2000 Clinical Science Committee Council Liaison 1999-2001 Non Task Force – focus Field Structure Member 1999-2001 ACC/AHA/ESC Joint Electronic Publishing Committee Member 1999-2001 Task Force on Scientific Sessions 21st Century Member 1999-2001 AHA/ACC Unstable Angina Guidelines Committee Liaison 1999-2002 Strategic Leadership Group Member 1999-2003 Web Strategy Task Force Member 1999-2004 AHA/ACC Guidelines Committee Member A 6 David P. Faxon, M.D. Curriculum Vitae

2000-2001 Scientific Advisory Coordinating Committee Vice-Chair 2000-2002 Acute Event Strategic Group Member 2000-2002 Early Career Investigator Task Force Member 2000-2003 Asian Pacific Program Committee Member 2000-2003 Corporate Operations Coordinating Committee Member 2000-2003 Nominating and Awards Committee Member 2000-2001 Association President-elect 2001 Invasive Procedures for Management of Diabetes Writing Group Member 2001-2002 Scientific Advisory Coordinating Committee Chair 2001-2002 Effectiveness & Impact Task Force Member 2001-2002 Association President 2002-2003 Association Immediate Past- President 2001-2003 Public Policy Subcommittee Member 2001-2003 Digital Strategies Task Force Member 2002-2003 Nominating and Awards Committee Vice-Chair 2002-2003 Awards Subcommittee Chair 2002-2003 Manuscript Oversight Committee Chair 2002-2006 International Subcommittee Member 2002-2004 Disease Management Advisory Group Project Chair 2003-present Vascular Disease Foundation Liaison 2004-2006 Disease Management Advisory Working Group Chairman 2004-2005 ACC/AHA Valvular Heart Disease Writing Committee Member 2004-2005 ACC/AHA Echocardiography Writing Committee Member 2004-2009 Strategic Planning Committee Member 2005-2008 Nominating Committee, Clinical Council Member 2005-2008 Acute MI Task Force Member 2007-2008 TCT meeting task force Member 2007-2009 Strategic Planning Committee, Clinical Council Member 2007-2010 International Committee Member 2008-2010 International Committee Strategic Planning Committee Member 2009-2013 AHA/DeHaan Myogenesis Oversight Advisory Group Member 2009-2010 Stroke Editor Search Committee Member 2015-present Vascular Disease Thought Leaders Meeting Member

Institute of Medicine 2010 Cardiovascular Disability: updating the Social Security Listings Ad hoc reviewer

International Society of Coronary Sinus Interventions 1987-1988 Society Executive Committee President 1988 Organizing Committee, 3rd International Symposium Chairman

Interamerican Society of Cardiology 1990-1992 Organizing Committee Member 1990-1992 Program Committee Co-Chairman 1992 Annual meeting Delegate

A 7 David P. Faxon, M.D. Curriculum Vitae

Maryland Health Care Commission 2004-2005 Research Proposal Review Committee Member 2006-2007 Research Proposal Review Committee Chairman

National Heart, Lung and Blood Institute 1976-present Coronary Artery Surgery Study (CASS): Member 1976-1983 Angiography Subcommittee Member 1976-1983 Angiographic Quality Control Member 1978-1981 Type II Hyperlipidemia Study Angiographic Consultant 1979-present Percutaneous Transluminal Angioplasty Registry Site-PI 1983 Thrombolysis in Myocardial Infarction Co-Investigator 1988-present BARI (Bypass Angioplasty Revascularization Investigation): Member 1988-present BARI Executive Committee Member 1988-present BARI Writing Committee Member 1988-present BARI Policy and Publications Committee Chairman 1989-1990 Program Projects Committee Ad Hoc Reviewe 1990 US-USSR Joint Symposium - Moscow, USSR Member 1990 Cardiopulmonary Study Section Ad Hoc Reviewe 1990-1993 BARI- Site Visit Committee - Prague, Czechoslovakia Member 1990-2000 New Approaches to Coronary Intervention Registry, Executive Member Committee 1993 Clinical Trials Study Section Ad Hoc Reviewer 2000-present BARI-2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes): 2000-present Ancillary Study Committee Chairman 2002-2003 Loan Repayment Program, Review Committee Member 2004-present IRIS DSMB Member

Society for Cardiac Angiography and Interventions 1988-1990 Angioplasty Subcommittee Member 1989-2000 Squibb Fellowship Selection Committee Member 1991-2000 Program Committee Member 1993 Scientific Sessions Co-Chairman 1993-present Board of Trustees Member 1996-2000 SCA&I/Bracco Diagnostics Fellowship Awards Committee Member 1996-2000 Ad Hoc Publications Committee Member 1996-present Interventional Committee Member 1996-2000 Nominating Committee Member 1996-1997 Society President-elect 1997-1998 Society President 1998-present Training program committee Member 1998-2000 Budget & Finance Committee Member

Veterans Administration 1986-1988 VA Cooperative Trial - Angioplasty vs. Medical Consultant A 8 David P. Faxon, M.D. Curriculum Vitae

Therapy (ACME Study)

Vascular Disease Foundation 2004-present Board of Directors Member 2005-2009 Executive Committee Treasurer 2005-present Fundraising committee Member 2005-present Finance committee Chair/Member 2011 CEO search committee Member 2011-2013 Foundation President Elect 2013-2015 Foundation President

Professional Societies: Regional 2000-2005 AHA, Midwest Affiliate, Member 2000-2005 Chicago Cardiology Group, Member 2000-2005 Central Society for Clinical Research, Member 2009-present Massachusetts Medical Society, Member National 1976-present American Heart Association, Member 1978-present American College of Cardiology, Fellow 1978-present Council of Clinical Cardiology, American Heart Association, Fellow 1978-present Society for Cardiac Angiography and Intervention, Fellow 1985-present Association of University Cardiologists, Member 2000-2006 Association of Professors of Cardiology, Member 2003-present Council on Atherosclerosis, Thrombosis and Vascular Biology, AHA, member

International 1985-present International Andreas Gruentzig Society 2008-2009 Clinton Global Initiative

Reviewer: Journal of the American College of Cardiology JACC: Cardiovascular Interventions American Journal of Cardiology American Heart Journal European Heart Journal Journal of Interventional Cardiology Catheterization and Cardiovascular Interventions New England Journal of Medicine Journal of the American Medical Association Annals of Internal Medicine Eurointervention Journal of Invasive Cardiology Circulation BMJ Open A 9 David P. Faxon, M.D. Curriculum Vitae

Editorial Boards: 1992-present Member Circulation 1993-1999 Member International Journal of Cardiology 1995-present Member American Journal of Cardiology 1998-present Member American Heart Journal 1999-2008 Editor in Chief Reviews in Cardiovascular Medicine 2002-present Member Journal of Interventional Cardiology 2002-2005 Member Coronary Artery Disease 2003-2010 Editor in Chief My American Heart Clinical Updates 2003-present Editorial Board My American Heart Clinical Updates 2003-present Member European Heart Journal 2005-2008 Member Annals of Internal Medicine 2006-present Member Cardiology Today 2006-present Associate Editor Circulation 2008-present Editor in Chief Circulation: Cardiovascular Interventions 2010-present Guest Editor American Heart Journal 2010-present Member Up-to-Date

2012-present Member Current Treatment Options in Cardiovascular Medicine

Awards and Honors:

1991 Fulbright Traveling Scholar, South America 1991 Outstanding Medical Specialists in the United States - Leading 50 Cardiologists Town & Country 1994-1995 The Best Doctors in America® 1996-1997 The Best Doctors in America: Pacific Region® The Best Cardiologists in the United States Good Housekeeping Magazine, 1996 1996 The Best Doctors in Los Angeles, The Los Angeles Magazine, October 1996 1997-2012 The Best Doctors in America 2000-2006 The Top Doctors in Chicago, The Chicago Magazine 2001 America’s Top Doctors 2001 Top Doctors: Chicago Metro Area 2002 Distinguished National Leadership Award, American Heart Association 2004 Distinguished Alumni Award, Boston University School of Medicine 2004 Samuel Ells Award, Alpha Beta Phi Fraternity 2004 Elite Reviewer JACC 2005 Gold Heart Award, American Heart Association 2006 The Best Doctors in Boston 2008 America’s Top Cardiologists 2008 Anandi L Sharma Visiting Professor in Cardiology, Mt Sinai Medical Ctr, NY 2011 Roche Distinguished Visitor, University of Alberta Medical Ctr 2011 Visiting Professor, New York University Medical Ctr, NY A 10 David P. Faxon, M.D. Curriculum Vitae

2016 Braun Visiting Professor, UCLA, CA 4/12/2016

Part II: Report of Funded and Unfunded Projects

Funding Information

Past 1988-1994 Robert Wood Co-PI Comparison of Economics and Quality of Life Johnson Outcomes in Patients Randomized to Bypass Surgery or Coronary Angioplasty in The BARI Study 1987-1999 NIH/NHLBI Co-PI Bypass Angioplasty Revascularization Investigation 1990-1992 Hoffman-LaRoche Study PI Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis 1991-1992 NHLBI Consultant Rotational Angiographic Digital Imaging, Small Business Research Program 1991-1993 DVI Co-PI CAVEAT: A randomized trial of angioplasty vs. atherectomy 1994-1996 Eli Lilly & Co. PI MITI: Efegatran Sulfate as an Adjunct Streptokinase versus Heparin as an Adjunct to Tissue Plasminogen Activator in Patients

1994-1997 Merck Research PI A Randomized, Double-Blind Study to Investigate Labs the Safety and Clinical Efficacy of MK-383 in Patients with Unstable Angina/Non-Q-Wave Myocardial Infarction Study 1995-1996 Guidant, ACS INC Co-PI Local Drug Delivery Using a Novel Intravascular Adventitial Delivery System 1995-2000 NIH/NHLBI Co-Invest Coronary Angiographic Trial of Estrogen 1996 Medtronics Co-PI Inhibition of Restenosis by Precision Intravascular Radiation Therapy 1996-1997 Parke Davis Co-PI Inhibition of Restenosis via Troglitazone Drug Therapy 1996-1997 Genentech, Inc PI A Phase II, Randomized, Open-Labeled Alteplase in Acute Myocardial Infarction 1997-1998 U.S. Surgical Corp Co-PI Inhibition of Restenosis by Precision Intravascular Radiation Therapy 1997-1998 Cordis, Inc PI Economic and Patient Outcomes Comparison Catheterization Procedure (ECOPO-STAM) 1997-2001 Guidant Corp Co-PI A Randomized Comparison of the ACS RX Multi- Link Coronary Stent System with or without Abciximab versus PTCA: CADILLAC Trial 1997-2002 NIH-NHLBI PI Should We Emergently Revascularization of Emergency PTCA/CABG-The SHOCK Trial A 11 David P. Faxon, M.D. Curriculum Vitae

1998-1999 U.S. Surgical Corp PI Angiorad Radiation Therapy for Instent Restenosis Intra Coronaries (ARTISTIC) 1998-1999 Genetech PI A Phase II, Double-Blind, Placebo Controlled Study to Assess the Effect of Intracoronary and Multiple Intravenous Administrations of rhVEGF on Exercise Tolerance in Adults with Viable but Underperfused Myocardium 1998-2000 Merck & Co. PI Treat Angina with Aggrestat and Determine the Cost of Therapy with an Invasive or Conservative Strategy (TACTICS-TIMI 18) 1998-2000 Hoffman-La Roche PI Phase II, Multicenter, International Randomized, Double-Blind, Aspirin- Controlled Study to Evaluate the Efficacy and Safety of Sibrafiban (RO 48-3657), an Oral Platelet Glycoprotein IIb/IIIa Antagonist as Therapy for the Prevention of Secondary Vascular Events in Patients After Acute Coronary Syndrome (SYMPHONY Trial) 1999 ICOS Corporation PI Hu23F2G Antiadhesion to Limit Cyto- Toxic Injury Following AMI (HALT-MI) 1999-2000 NIH PI Informatics for the National Heart Attack Alert Program 1999-2000 Chiron Corporation PI Phase II, Multicenter, Double Blind, Placebo Controlled, Dose Finding Study for Safety, Pharmakinetics and Efficacy of Recombinant Fibroblast Growth(rFGF-2) in Subjects with CA 2002 Rheologics PI Blood Viscosity and Extent of Coronary Disease 2008-2010 Boston Scientific PI Outcomes after Drug Eluting Stents in the VA population 1998-2012 NHLBI PI Dynamic Evaluation of Percutaneous Coronary Co-Invest Intervention 2002-2012 NHLBI PI Bypass Angioplasty Revascularization Co-Invest Investigation in Diabetes

2011-2015 VA merit award Co-Invest Outcomes after Drug Eluting Stents in the VA CSR&D Merit population 1I01CX000440- 01A1

C. Report of Current Research Activities

1. Participation in DSMB committees as listed above. Currently active are: BSC, SURTAVI, CoreValve, EVOLUTE R, PRO2TECT, INNOVATE (see list above) 2. Safety and efficacy of clopidogrel in the 41,000 patients receiving stents in the national VA system A 12 David P. Faxon, M.D. Curriculum Vitae

3. Complete revascularization versus incomplete revascularization in STEMI, COMPLETE Trial, US coordinator

Part III Report of Local Teaching and Training

1. Local contributions The following list is incomplete as detailed records were not previously required. a. Medical school courses

1976-1980 Boston University School of Medicine Clinical Pathologic Correlation for 2nd year medical students 2-hour lecture entitled Congestive Heart Failure Attendance 100-120 students, preparation 6 hours

1980-2000 Boston University School of Medicine: Clinical Pathological Correlation for 2nd year medical student 2-hour lecture entitled Coronary Artery Disease Attendance 100-120 students, preparation 6 hours

2000-2005 University of Chicago: Clinical Pathophysiological Course-2nd year med students, 1 hour lecture on coronary artery disease and a 2 hour laboratory case discussion Attendance 100-130 students, preparation 6 hours Senior Cardiology Lecture Series- 1 hour lecture to 4th year medical students on angioplasty, attendance 20-30 students, preparation 4 hours

2014-2016 Harvard Medical School Second year introduction to Clinical Medicine- 2 hour lecture on Coronary Revascularization Attendance 75-100 students, preparation 6 hrs

b. Graduate Medical Course

1976-1993 Boston University Medical Center:

Cardiology Cardiac Surgery Conference, weekly 1 hour conference, case discussant, attendance 20-30 residents, fellows and faculty, no preparation

Core Curriculum, weekly 1 hour conference, gave 4 lectures per year on cardiac catheterization, angioplasty, hemodynamic, coronary artery disease, attendance 20 A 13 David P. Faxon, M.D. Curriculum Vitae

residents and fellows, preparation 6-8 hours

1993-2000 University of Southern California: Cardiology Cardiac Surgery Conference, weekly 1 hour conference, case discussant, attendance 20-30 residents, fellows and faculty, no preparation

Core Curriculum, weekly 1 hour conference, gave 4 lectures per year on cardiac catheterization, angioplasty, hemodynamic, coronary artery disease, attendance 20 residents and fellows, preparation 6-8 hours

Cardiology Interventional Conference, weekly case discussant, attendance 2-30 fellows and staff, no preparation

2000-2005 University of Chicago: Cardiology Grand Rounds, twice/year, 1 hour lecture, attendance 40-50 fellows, residents and faculty, various topics, preparation 4 hours

Cardiology Surgical Conference, weekly case discussant, attendance 20, no preparation

Cardiology Interventional Conference, weekly case discussant, attendance 30-50, no preparation

Cardiology Core Curriculum, weekly 1-hour conference, gave 4 lectures per year on angioplasty, coronary artery disease, acute coronary syndrome and acute MI attendance 20 residents and fellows, preparation 6-8 hours

c. Local Invited Teaching

1993 "Direct PTCA - MI: Is it the gold standard for treatment at the referral center?" and "Acute Myocardial Infarction: What drugs do we take to the bedside?" Cardiology Today: Diagnosis, Drugs, Devices, and Surgery. Presented at Huntington Memorial Hospital, Pasadena, CA, 1 hour lecture for each, attendees were practicing cardiologists, generalists and nurses, attendance= 200, preparation 6 hours

1995 Director ACC/University of Southern California course "The Fifth Annual Symposium; Interventional Cardiology: Aspirations for 1995 and Beyond." Ritz Carlton Hotel, Rancho Mirage, CA , One day symposium attendees were practicing cardiologists, generalist and nurses, attendance=150, preparation 10 hours

1997 “Platelet Integrin Receptor Drugs in AMI and Unstable Angina” and “Acute Coronary Syndromes: New Drugs and Devices”. USC Symposium, DP Faxon, Course Director, Pasadena, CA,1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 150, preparation 4 hours

1997 “Restenosis: Is the War Nearly Won?” Cardiology Grand Rounds, Century City A 14 David P. Faxon, M.D. Curriculum Vitae

Hospital, Los Angeles, CA, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 100, preparation 2 hours

1998 “New Horizons in Acute Coronary Syndromes” Cardiology Grand Rounds, St. Joseph Medical Center, Burbank, CA, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 80, preparation 2 hours

1998 “Plaque Rupture: a Unifying Concept” and Course Director. USC Postgraduate Division - Acute Coronary Syndromes II: New Therapeutic Approaches, Los Angeles, CA attendees were practicing cardiologists, generalists and nurses, attendance= 80, preparation 2 hours

1998 “Lipids and the Progression of Atherosclerosis”, “Congestive Heart Failure”, USC Division of Cardiology one day symposium, Ritz Carlton, Pasadena, CA, 2 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 80, preparation 5 hours

1999 “Evaluation of CAD in People with Diabetes” USC Diabetes and Endocrinology Conference, Anaheim, CA, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 100, preparation 2 hours

1999 Third Annual Acute Coronary Syndromes: New Therapeutic Approaches. USC Postgraduate Division, David P. Faxon, Program Director. “Future Revascularization Therapies: Angiogenesis, PMR, external counterpulsation, dorsal nerve stimulation.” Regal Biltmore, Los Angeles, CA, One day program, attendees were practicing cardiologists, generalists and nurses, attendance= 120, preparation 6 hours

2000 “Radiation for Restenosis: Is This the Silver Bullet?” L.L. Braun Lecture, Illinois Masonic Medical Center, Chicago, IL1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 100, preparation 2 hours

2000 “Radiation for Restenosis: Is This the Silver Bullet?” Cardiology Grand Rounds, Northwestern University Medical School, Chicago, IL1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 100, preparation 2 hours

2000 “Restenosis: The Role of Radiation” John S. Graettinger M.D. Memorial Lecture and “Coronary Revascularization in Diabetics: What is Optimal?” Medical Grand Rounds, Visiting Professor, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 100, preparation 2 hours

2001 “Radiation for Restenosis.” Cardiology Grand Rounds, Christ Hospital and Medical Center, Oak Lawn, IL, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 80, preparation 2 hours

2001 “Women and Heart Disease.” Consumer Seminar, The University of Chicago, Chicago A 15 David P. Faxon, M.D. Curriculum Vitae

IL, 1 hour lecture for each, attendees were practicing cardiologists, generalists and nurses, attendance= 50, preparation 2 hours

2001 “Unstable Angina.” Cardiology Core Conference, The University of Chicago, Chicago, IL, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 50, preparation 2 hours

2001 “Revascularization in Diabetics.” Medicine Grand Rounds, The University of Chicago, Chicago, IL, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 150, preparation 2 hours

2001 “Revascularization in Diabetes.” The 26th Annual Louis N. Katz Memorial Lecture, Michael Reese Hospital, Research and Education Foundation and the Cardiovascular Institute. Chicago, IL, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 250, preparation 4 hours

2004 “Drug Eluting Stents”, Un of Chicago Interventional CME, Oak Brook, IL,1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 100, preparation 2 hours

2005 “DES in patients with ACS” ACC Cardiology Symposium, Chicago, IL, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 150, preparation 2 hours

2005 Program director, Advances in Cardiology, Chicago, IL, one day symposium, attendees were practicing cardiologists, generalists and nurses, attendance= 150, preparation 6 hours

2005 “Should I cath my patient with ACS’ Advances in Cardiology, Chicago, IL, 1 hour lecture, attendees were practicing cardiologists, generalists and nurses, attendance= 150, preparation 2 hours

2006 “Drug Eluting Stents: Are they safe?” Cardiovascular Grand Rounds, Brigham and Women’s Hospital, December 14,2006 1 hour lecture, attendees residents, cardiology fellows, attending physicians, attendance 75, preparation 4 hours

2007 “Anticoagulation in ACS”, Boston VA Houseofficers conference, 3/5/07, 1 hour lecture, attendees residents, cardiology fellows and faculty, attendance 50, preparation 2 hours

2007 “CABG vs. PCI vs. Medical Therapy”, BWH Cardiovascular review course, Boston, 5/22/07, 1 hour lecture, attendees residents, cardiology fellows and faculty, attendance 250, preparation 4 hours

2007 “Update on the management of ACS”, Boston VA Medical Grand Rounds, West Roxbury, MA, 9/5/07, 1 hour lecture, attendees residents, cardiology fellows and faculty, attendance 50, preparation 2 hours A 16 David P. Faxon, M.D. Curriculum Vitae

2008 “Treatment, timing triage and transfer in ACS” at BA Boston Healthcare System Cardiology Update 11/15/08, 1 hour lecture, attendees residents, cardiology fellows and faculty, attendance 75, preparation 2 hour.

2008 “Left main angioplasty: is it time to change the guidelines”. BVAH Cardiology grand rounds 12/5/081 hour lecture, attendees residents, cardiology fellows and faculty, attendance 50, preparation 2 hours

2010 “Update on the Management of ACS” Medical Residents conference, West Roxbury VA hospital, Boston, MA 2/27/10

2010 “PCI for Chronic Stable Angina”, BWH Interventional Fellows Core Curriculum. BWH, Boston 2/24/10

2010 “PCI for ACS” BWH, Interventional Fellows Core Curriculum. BWH, Boston 3/3/10

2010 “PCI for STEMI”, BWH Interventional Fellows Core Curriculum. BWH, Boston 3/10/10

2011 “PCI for Chronic Stable Angina”, BWH Interventional Fellows Core Curriculum. BWH, Boston 2/22/10

2011 “PCI for ACS” BWH, Interventional Fellows Core Curriculum. BWH, Boston 3/1/11

2011 “PCI for STEMI”, BWH Interventional Fellows Core Curriculum. BWH, Boston 3/8/11

2012 “Strategic Planning- a primer” Department of Medicine Faculty, BWH, Boston

2012 “PCI for ACS/NSTEMI, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/28/13

2012 “PCI for Chronic Stable Angina”, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/14/12

2012 PCI for STEMI”, BWH Interventional Fellows Core Curriculum. BWH, Boston 3/6/12

2013 “PCI for STEMI, BWH Interventional Fellows Core Curriculum, BWH, Boston 1/29/13

2013 “PCI for Chronic Stable Angina”, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/12/13

2014 “Strategic Planning- a primer” Department of Medicine Faculty, BWH, Boston

A 17 David P. Faxon, M.D. Curriculum Vitae

2014 “PCI for STEMI, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/12/14

2014 “PCI for Chronic Stable Angina”, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/6/14

2015 “PCI for Chronic Stable Angina”, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/6/14

2015 “PCI for STEMI, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/12/14

2016 “PCI for SIHD, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/28/16

2016 “PCI for nonSTEMI, BWH Interventional Fellows Core Curriculum, BWH, Boston 3/14/16

2016 “Strategic Planning- a primer” Department of Medicine Faculty, BWH, Boston 3/28/16

2017 “Antithrombotic therapy for patietns with atrial fibrillation undergoing PCI- do we have concensus BWH Cardiology Grand Rounds 2/23/17

2017 “PCI for Chronic Stable Angina”, BWH Interventional Fellows Core Curriculum, BWH, Boston 2/27/17

2017 “PCI for ACS, BWH Interventional Fellows Core Curriculum, BWH, Boston 3/13/17

c. Advisory and Supervisory responsibilities

1976-1993 Boston University Medical Center Clinical Inpatient Rounds: 4 two-week rotations on the cardiology service during which resident in internal medicine are supervised and bedside and didactic teaching. The teaching time 7 hours/week/rotation including lectures and bedside teaching

Outpatient Clinic: Bedside teaching weekly to fellows. Teaching time 1-2 hours per week

Cardiac Catheterization Laboratory: Teaching of cardiology fellows as they rotate through the cardiac catheterization laboratory one day per week

1993-2000 University of Southern California Medical Center Clinical Inpatient Rounds: 4 two-week rotations on the cardiology service during which residents in internal medicine are supervised and bedside and didactic teaching. The teaching time 7 hours/week/rotation including lectures and bedside teaching

A 18 David P. Faxon, M.D. Curriculum Vitae

Outpatient Clinic: Bedside teaching weekly to fellows. Teaching time 1-2 hours per week

Cardiac Catheterization Laboratory: Teaching of cardiology fellows as they rotate through the cardiac catheterization laboratory one day per week

2000-2005 University of Chicago Clinical Inpatient Rounds: 4 two-week rotations on the cardiology service during which resident in internal medicine are supervised and bedside and didactic teaching. The teaching time 7 hours/week/rotation including lectures and bedside teaching

Outpatient Clinic: Bedside teaching weekly to fellows. Teaching time 1-2 hours per week

Cardiac Catheterization Laboratory: Teaching of cardiology fellows as they rotate through the cardiac catheterization laboratory as well as interventional fellows one day per week

2006-present West Roxbury VA Hospital Cardiac Catheterization Laboratory: Teaching of cardiology fellows as they rotate through the laboratory as well as supervise and teach interventional cardiology fellows. Average teaching time is one day per week In addition I participate in teaching house officers and Cardiology fellows on the Cardiology inpatient service 6 weeks per year. d. Teaching Leadership

1993-2000 University Southern California: Director, Cardiology Fellowship Responsibilities of the director included evaluating candidates for fellowship, orientation of fellows, monitoring of performance, instituting corrective measures if necessary, supervising faculty and evaluation of both the fellows and faculty, development of a curriculum, organizing teaching conferences, preparing for ACGME site visits and interacting with the IM program director and DIO at USC. e. Advisees/Trainees

At Boston University, University of Southern California and University of Chicago I have trained more than 120 cardiology fellows (4 cardiology fellows per year). Prior trainees who have gained national recognition are listed below: ______Year Name Current Position Facility 1977-1979 Mark Creager MD Director, Heart and Vascular Dartmouth-Hitchcock Med Center Ctr, Lebanon, NH 1977-1979 Jonathan Halperin MD Assistant Chief of Cardiology Mt. Sinai, NY 1979-1982 Alice Jacobs MD Dr Interventional Cardiology Boston University 1979-1982 Timothy Sanborn MD Chief of Cardiology Evanston Northwestern 1982-1985 Gary Balady MD Dr. Preventive Cardiology Boston University A 19 David P. Faxon, M.D. Curriculum Vitae

1980-1983 Ted Bass MD Chief of Cardiology Un. of Florida, Jacksonville 1986-1990 Peter Berger MD Dr. Interventional Cardiology Guthrie Clinic 1986-1990 Jessie Currier MD Director, Cath Lab VA/UCLA, Los Angeles 1991-1993 Tsunekazu Kakuta, MD Chief of Cardiology Kyoto General Hospital 1993-1995 Anil Mehra MD Director, Cath Lab USC, Los Angeles 2000-2001 Parker Ward MD Associate Program Director Un. of Chicago IM 2001-2003 Martha Gulati MD Chair Women’s CV Health Ohio State 2003-2006 William Borden MD Dr. Preventive Cardiology Cornell Med Ctr 2003-2006 James Min Dr SV Imaging Cornell Med Ctr 2004-2007 Ron Blankstein MD Faculty CV Imaging Brigham and Women’s 2008-2010 Sripal Bangalore MD Dir. Interventional Research NYU 2008-2010 Kevin Bainey MD Interventional Cardiology Un of Alberta

Part III. Report of Regional, National or International Invited Teaching and Presentations

Only those activities since 1993 are included, as detailed records were not kept previously.

a. Invited presentations

Regional

1993 "How the General Surgeon Can Preoperatively Assess a Cardiac Risk" The Forty- Fourth Surgical Forum, Los Angeles, CA

1993 "New Interventional Devices: Atherectomy, Laser, Rotoblater, TEC-Their Role in Contemporary Practice." ACC Cardiology Update, Los Angeles, CA

1994 “PTCA After Angioplasty." The Challenge of Interventional Therapeutics in Cardiology: 1994. Dana Point, CA

1997 “Expanding Therapies for Common Cardiovascular Disorders: From Clinical Trials to Practice”. Experts Panel, AHA-LA Affiliate Fall Symposium, Los Angeles, CA

1998 “Is Multivessel Angioplasty Justified? “ Cardiology Grand Rounds, University of California, San Diego, CA

1998 “Revascularization in Diabetics” Cardiology Grand Rounds, Long Beach Memorial Hospital, CA

1998 “Advances in the Management of Coronary Artery Disease” and ”Coronary Intervention in Unstable Angina and Non-Q-Wave MI” Loma Linda Medical Center, A 20 David P. Faxon, M.D. Curriculum Vitae

Loma Linda, CA

2000 “Management of the Patient Who Cannot be Revascularized” and “Update on Management of Acute Myocardial Infarction” San Fernando Valley Heart Institute’s Sixth Annual Cardiology Symposium, Woodland Hills, CA

2000 “Angiogenesis & TMR, PMR, External Counterpulsation and Dorsal Nerve Stimulation” Current Trends in Cardiology and Cardiac Surgery, The Orange Coast Memorial Heart Institute, Doubletree Hotel, Costa Mesa, CA

2000 “Radiation for Restenosis: Is This the Silver Bullet?” Distinguished Visiting Professor, Cardiology Grand Rounds and Journal Club, University of California San Francisco, San Francisco, CA

2004 “The Importance of Mentorship” Hamilton College ADP lecture series, Clinton, NY

2004 “Facilitated PCI” Genetech Symposium, Minneapolis, MN

2006 “Anticoagulation in the ACS patient: From presentation to PCI”, Baystate Medical Center, Pittsfield, MA September 18, 2006

2006 “Left Main Disease: a new look at an old scourge, at Cardiology for the Consulting Cardiologist” Boston MA, Oct 19, 2006

2007 “Anticoagulation in the ACS patient”, Lahey Clinic Cardiology Grand Rounds 4/26/07

2007 “Treating Ischemia in patients with chronic stable angina”, Primed Cardiology Update, Chicago, 6/1/07

2008 “Management of patients with ACS”, Medical Grand Rounds, Sturdy Memorial Hospital, Attleboro MA 1/16/08

2008 “Drug Eluting Stents: Are they Safe, Mt Sinai Medical Center”, Cardiology Grand Rounds, New York, 9/22/08

2008 “Should all left main and triple vessel coronary artery disease be treated surgically?”, Controversies in Cardiology, Anandi L Sharma Visiting Professorship and The Simon Dack M.D. Memorial Lecturer, at the Zena & Michael A. Wiener Cardiovascular Institute and Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Mt Sinai Medical Center, New York, 9/22/08

2008 “Left main angioplasty: is it time to change the guidelines”, Tufts NEMC Cardiology grand rounds 12/4/08 A 21 David P. Faxon, M.D. Curriculum Vitae

2008 “Guidelines and current management of ACS” CRF meeting, New York NY, 12/11/

2009 “Can stent thrombosis after DES be prevented?” Visiting Professor in Interventional Cardiology, Massachusetts General Hospital, Boston, MA 6/3/09

2009 “Quality, performance measures and outcomes: A cardiology perspective” Modestino Criscitello MD Visiting Professor in Cardiology, Tufts University School of Medicine, Boston, MA 6/12/09

2012 “Controversies in ACS” Boston Fellows Dinner, Boston MA 12/5/12

National

1994 "Summary of Pharmacologic Clinical Trials" and Case Moderator. Transcatheter Cardiovascular Therapeutics 6th Annual Symposium, Washington, DC

1994 "Women and Coronary Revascularization: Are They at High Risk?" "Multivessel Angioplasty: Is it Justified?" "Angioplasty in Acute Myocardial Infarction: Is There a Role?" and "Restenosis: Pathophysiology and Current Status of Clinical Trials." 22nd Annual Diagnostic and Therapeutic Skills in Internal Medicine, Kohala Coast, HI

1994 “What is Restenosis?" Interventional Cardiology in Perspective Demonstration Course XXVIII, Emory University, Atlanta, GA

1994 "Medical Treatments for Restenosis: Are Any Effective?" and "Pathophysiology: Do We Really Understand It?" American College of Cardiology 43rd Annual Scientific Sessions, Atlanta, GA

1995 "The Best Choices for Local Drug Delivery Agents to Prevent Restenosis" and "Perspectives on the Pharmacologic Trials: Lessons Learned and Future Directions" Transcatheter Cardiovascular Therapeutics VII, Washington, DC

1995 "Mechanisms of Restenosis after Coronary Angioplasty" Seventh Research Initiatives in Vascular Disease Conference, Bethesda, MD

1995 ”Is There a Role for Rescue Angioplasty? The North American View" and "Coronary Atherectomy: Which Tool and When?" American College of Cardiology 44th Annual Scientific Sessions, New Orleans, LA

1995 "Experimental Model Insights" Restenosis Summit VII, Cleveland, OH

1995 "Restenosis: Are We Aiming at the Wrong Target?" The Cleveland Clinic Heart Center, Cleveland, OH

1995 "Diabetics Have Significantly Poorer 8 Year Outcome After Angioplasty - Results of A 22 David P. Faxon, M.D. Curriculum Vitae

the BARI Trial" (Poster), "Restenosis Following Vascular Interventions", and "Primary Determinants of Restenosis Remodeling vs. Neointimal Hyperplasia" American Heart Association 68th Scientific Sessions, Anaheim, CA

1996 "New Approaches to Reducing Restenosis" and "The Role of Atherectomy Devices (Directional, Rotablator), and Stents: When, Where, Why?" 23rd Cardiovascular Conference at Snowbird, Snowbird, UT

1996 "Remodeling in Restenosis: Insights from Experimental Studies." Transcatheter Cardiovascular Therapeutics 8th Annual Symposium, Washington, DC

1996 "Coronary Devices: Attributes and Limitations of Balloons" and "When is Cardiac Catheterization/Coronary Angiography Indicated?" American College of Cardiology 45th Annual Scientific Sessions, Orlando, FL

1996 "Chronic Inflammation" and "Low Dose Endovascular Irradiation", Restenosis Summit VIII, Cleveland, OH

1996 "Radiation for Restenosis: Is the Silver Bullet a Gamma or Beta Emitter?" State-of- the-Art Lecture and "Vascular Remodeling in Restenosis: Insights from Animal Models" Cardiovascular Seminar, American Heart Association 69th Scientific Sessions, New Orleans, LA

1996 "Respective Roles of Direct PTCA Versus Thrombolytics in the Management of Acute Myocardial Infarction" and "What Have We Learned From the Randomized Trials of Angioplasty Versus Coronary Artery Bypass Surgery?" Fourteenth Annual Advances in Heart Disease, San Francisco, CA

1997 Stents vs. Angioplasty: Rational Uses in 1997. 24th Conference at Snowbird, UT

1997 “Management of Ischemic Heart Disease in the Diabetic” ACC 46th Scientific Sessions, Anaheim, CA

1997 “Restenosis: Are We Aiming at the Wrong Target?” and “Revascularization in Diabetics: Lessons Learned from the BARI Trial”. Visiting Professor, Ochsner Institute, New Orleans, LA

1997 “Stent Mania: Is It Justified?” Cardiology Grand Rounds, St. Louis University School of Medicine, St. Louis, MS

1997 ”Restenosis: Is the War Nearly Won?” and “Is Multivessel PTCA Justified?” Comed Symposium, San Francisco, CA

1998 Lessons from the BARI Trial: Revascularization for Diabetics and Radiation: Is This the Silver Bullet? Visiting Professor, University of Texas, Galveston, TX

1998 “Post-Angioplasty Restenosis: Scope of the Problem” and “Experimental and Clinical A 23 David P. Faxon, M.D. Curriculum Vitae

Experience with the Angiorad USSC System” Advances in Cardiovascular Radiation Therapy, program sponsored by Washington Hospital Center, Washington, DC

1998 “Coronary Revascularization in Diabetes: What is Optimal?” and “Stent Mania: Is It Justified? and Radiation for Restenosis: Is This the Silver Bullet?” Diagnostic and Therapeutic Skills in Internal Medicine, program sponsored by USC School of Medicine, Mauna Kea, HI

1998 Symposium: Intravascular Radiation Therapy for Restenosis (co-chair) and Symposium for Directors of Adult Cardiology Training Programs (co-chair), ACC 47th Annual Scientific Sessions, Atlanta, GA

1998 “Restenosis: Is the War Nearly Won?” Visiting Professor, University of Virginia, Richmond, VA

1998 “Systemic Pharmacology Approaches”, SCAI Debates at Transcatheter Cardiovascular Therapeutics - X, Washington, DC

1998 “The Use of Radiation in Endovascular Procedures: Fact or Fancy?” ACC Cardiology for the Consulting Cardiologist, Boston, MA

1998 “In-stent Restenosis: A Problem Without a Solution?” and “Revascularization in the Diabetic Patient” 71st American Heart Association Scientific Sessions, Dallas, TX

1998 “Platelet Receptor Antagonist in AMI” and “Unstable Angina” Management of Acute Coronary Syndromes Symposium, University of California, Los Angeles, CA

1999 “The ARTISTIC and ARREST Trials”, Third Annual Symposium: Radiotherapy to Reduce Restenosis, La Jolla, CA

1999 “Difficulties in Diagnosing CAD in Women”, USC University Guild, Cardiology Symposium, Los Angeles, CA

1999 “Alternative Pharmacological Approaches to Treat Restenosis” Cardiovascular Radiation Therapy Meeting III, Washington, DC

1999 “Primary PTCA is the Treatment of Choice for Acute MI in the Advanced Elderly”, Society of Geriatric Cardiology Fifth Annual Scientific Session, New Orleans, LA

1999 “Radiation for the Preventions of Restenosis” ACCIS-99 Opening Plenary Session, American College of Cardiology 48th Scientific Sessions, New Orleans, LA

1999 “Intracoronary Radiation to Prevent Restenosis in Native Coronary Lesions: The Results of the Pilot Phase of the ARREST Trial” abstract presentation, American College of Cardiology 48th Scientific Sessions, New Orleans, LA

A 24 David P. Faxon, M.D. Curriculum Vitae

1999 “Telemedicine for Coding and Reimbursement”, American College of Cardiology 48th Scientific Sessions, New Orleans, LA

1999 “Improved In hospital Outcome with Expanded Use of Coronary Stents: Results from the NHLBI Dynamic Registry” abstract presentation, American College of Cardiology 48th Scientific Sessions, New Orleans, LA

1999 “Acute Management of Myocardial Infarction” and “What is the Optimal Treatment for the Post-Myocardial Patient?” Contemporary Clinicians Approach to the Treatment of Cardiovascular Disease, Lake Tahoe, NV

1999 “What is the Optimal Treatment for Instent Restenosis?” and “Gamma Radiation will be the Clear Winner for Prevention of Restenosis” 3rd Annual Frontiers in Interventional Cardiology, Houston, TX

1999 “Restenosis: Defining the Problem and The ARTISTIC and ARREST Trials” Society for Cardiac Angiography and Interventions 22nd Annual Scientific Sessions, Co-Chair, Intravascular Radiation Therapy Symposium, Monterey, CA

1999 “When is Angioplasty Preferable to Coronary Bypass Surgery?” and “Anticoagulants and Antiplatelet Agents in Unstable Coronary Syndromes” Tenth Annual Symposium, Cardiovascular Disease: State of the Art 1999, Barnstable, MA

1999 “Management of Unstable Angina in 1999”, “Radiation for Restenosis: Is This the Silver Bullet?” and “Angiogenesis: Bypassing the Bypass “and “GPIIb/IIIa Antagonists: Breakthrough or Just Another Antiplatelet Drug?” USC 42nd Postgraduate Refresher Course, Maui, HI

1999 “PTCA vs. Thrombolysis for Acute MI in the Elderly”, Cardiology Grand Rounds, University of California, San Diego, CA

1999 ”Intravascular Brachytherapy – Part I: The Tools and Techniques that Interventional Cardiologists Use to Perform Percutaneous Transluminal Coronary Angioplasty (PTCA)” American Society for Therapeutic Radiology and Oncology 41st Annual Meeting Refresher Course, San Antonio, TX

1999 “Interventional Cardiology: Bench to Bedside to Beyond” One day program sponsored by the American Heart Association, Co-Chairs, David P. Faxon, M.D. and Alice Jacobs, M.D., Atlanta, GA

1999 ”A New Adjunctive Strategy to Protect Ischemic/Infarcting Myocardium: Blockage of Adhesion Molecules” 15th Annual George Washington University Workshop on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, Atlanta, GA

1999 “Gamma Trials” Cardiovascular Seminar, American Heart Association 72nd Scientific Sessions, Atlanta, GA

A 25 David P. Faxon, M.D. Curriculum Vitae

1999 “Halt MI” Late Breaking Clinical Trials Presentations, American Heart Association 72nd Scientific Sessions, Atlanta, GA

1999 “Restenosis: Will It Ever Be Solved?” Gary Garber Memorial Lecture, Boston University School of Medicine, Boston, MA

1999 “Radiation for Restenosis” Cardiology Grand Rounds, University of New Mexico School of Medicine, Albuquerque, NM

2000 “Approaches to Infarction in Patients with Prior Bypass” and “What is the Status of the Gamma Emitter Trials?” ACC Problem Solving in Interventional Cardiology, Bethesda, MD

2000 “Radiation for Restenosis – Is This the Silver Bullet?” and “Treatment of Non- Operative Patient with Intractable Angina; Spinal Cord Stimulation; TMR and Angiogenesis” The New World of Cardiology, Bal Harbor, FL

2000 “The Use of GPIIb/IIIa Antagonists: With All Interventions or Just High Risk?” “Radiation for Restenosis: Is This the Silver Bullet?” Simon Dack Visiting Professor, The Mount Sinai Medical Center, Zena & Michael Wiener Cardiovascular Institute, Controversies in Cardiology Conference and Cardiology Grand Rounds, New York, NY

2000 “Optimizing Coronary Stenting” “Current Controversies” (moderator) 23rd Annual Meeting of The Society for Cardiac Angiography and Interventions, Charleston, SC

2000 “Controversies in Clinical Cardiology – antagonist: Based on the AVERT Trial, Catheter-Based Intervention Should be Performed less Frequently in Stable CAD” and “Current Issue in MI Management – Should Everyone Get an Angiogram?” American Heart Association Scientific Sessions 2000, New Orleans, LA

2001 “Interpreting the New ACC/AHA Guidelines for the Management of Acute Coronary Syndromes in Patients with Unstable Angina and Non ST-Segment Elevation MI” and “Revascularization in Diabetics.” Tommy Lasorda Heart CME Conference: Standard and Novel Treatments of Cardiac Diseases at the Dawn of the 21st Century. Vail, CO

2001 “Multivessel Disease” and “Use of White Cell Anti-Inflammatory Agents.” American College of Cardiology 50th Annual Scientific Sessions, Orlando, FL

2001 “AHA President’s Welcome.” First National CDC preventions Conference on Heart Disease and Stroke, Atlanta, GA

2001 “Revascularization in Diabetes Mellitus: Who, What and Where?” Current Concepts in the Management of Cardiovascular Disease in the Diabetic – Joint Symposium, The University of Chicago and Northwestern University, David P. Faxon and Robert O. Bonow, co-chairs. Ritz Carlton, Chicago, IL

A 26 David P. Faxon, M.D. Curriculum Vitae

2001 “The Chain of Scientific Discovery: The Critical Role of the Physician-Scientist” Presidential Address, American Heart Association Scientific Session 2001, Anaheim, CA

2001 “Revascularization in Management of CVD in Diabetes.” Diabetes and CVD: A Summary of the Prevention VI Conference, American Heart Association Scientific Sessions 2001, Anaheim, CA

2001 Moderator, Novel Mediators of Restenosis 1, Abstract Oral Presentations. American Heart Association Scientific Sessions 2001, Anaheim, CA

2001 Moderator, Late Breaking Clinical Trials, Plenary Session III. American Heart Association Scientific Sessions 2001, Anaheim, CA

2002 Chair-Session, Reperfusion Therapy for Acute Myocardial Infarction; Judge, Young Investigators Awards: Physiology, Pharmacology, and Pathology; Co-Chair-Session, CABG vs. PCI: What Have We Learned from the Randomized Trials? and Lecturer- Session, Diabetic Syndrome: Impact on PCI, “The Results of Intervention.” American College of Cardiology Scientific Sessions, Atlanta, GA

2002 “Choosing a Research Project/Mentor” and Co-Director of AHA Program: Launching a Career in Cardiovascular Research, Chicago, IL

2002 “Dancing With Our Customers,” Keynote Address and “The Future of Cardiovascular Therapy”, AHA Western States Delegates Assembly, San Jose, CA

2003 “Restenosis: Has it Been Solved?” Cardiology Grand Rounds, The University of North Carolina. Chapel Hill, NC

2003 “Revascularization in Diabetics: What is Optimal” Basic Science Grand Rounds, St. Lukes Episcopal Hospital. Houston, TX

2003 “Anti-Thrombotic Therapy in Acute Coronary Syndromes: the 10A Hypothesis” William Beaumont Hospital. Royal Oak, MI

2003 “Interventional Cardiology-Major Advances and Challenges” Second Asia Pacific Scientific Forum. New Discoveries in Cardiovascular Disease and Stroke: Bench to Bedside to Community. Honolulu, HI

2003 “Ischemic Heart Disease Interventions: State of the Art and Future Directions” ACC Taste of Chicago Cardiovascular Symposium. Chicago, IL

2003 “Management of a Non-Revascularizable Patient” Contemporary Issues in the Management of Cardiovascular Disease. Nantucket Island, MA

2004 “AMI; New Frontiers: Pharmacological Protection”, ACC Annual Scientific Sessions, New Orleans, LA A 27 David P. Faxon, M.D. Curriculum Vitae

2004 Cardiology Pursuits, Judge ACC Annual Scientific Sessions, New Orleans, LA

2004 “Drug Eluting Stents: Have they solved Restenosis”, UCLA Cardiology Visiting Professor, Los Angeles, CA

2004 “Management of ACS” University of Chicago Cardiology CME, Chicago, IL

2004 Judge, Astra Zeneca Young Investigators Forum, San Diego, CA

2004 J&J Advisory Board Meeting, New York, NY

2004 Late Breaking Trials, Chair, AHA Scientific Sessions, New Orleans, LA

2004 Early Career: Developing a Career in Academic Cardiology, Panel member, AHA Scientific Sessions, New Orleans, LA

2004 “Public Policy Perception of Primary and Secondary Prevention and Risk Management”’ Atherothrombosis Advisory Board, Sanofi, Miami, FL

2005 “Coronary Interventions and their impact on post-MI infarction survival” Post MI management symposium, New York, NY

2005 “Unprotected left main lesion should be treated by coronary artery bypass graft: protagonist” debate ACC Scientific Sessions, Orlando, FL

2005 “Antiplatelet therapy in ACS” Satellite symposium at ACC, Orlando, FL

2005 “Unprotected left Main: PCI or Surgery” Duke interventional conference and Heart.org video conference, Durham, NC

2005 “Bifurcation lesions” Thought Leaders Summit, Kiawah Island, SC

2005 “Optimal Timing of an Invasive strategy for ACS” Duke Cardiovascular Cath Lab Conference and theheart.org videoconference

2005 “Role of biomarker assessment in acute coronary syndromes” TCT, Washington, DC

2005 “What should program Directors of IC fellowships watch for” TCT, Washington DC

2005 Featured lecture “Triage of patients with chest pain in the biomarker era-role of CRP, BNP, MPO and more” TCT, Washington, DC

2005 “The approach to Acute Coronary Syndromes” TCT, Washington, DC

2005 Featured Lecture “Fondaparinux in ACS-The Michelangelo OASIS-5 randomized trial” TCT, Washington, DC A 28 David P. Faxon, M.D. Curriculum Vitae

2005 “Left Main PCI: indications and outcomes” Interventional Course, AHA Sci Sessions, Dallas, TX

2005 “Postprimary PCI Patient with Multivessel Disease” AHA, Sci Sessions Dallas, TX

2005 “Disease Management: What is it and Why is it Important” AHA Sci Sessions, Dallas, TX

2005 “Beta Blocker therapy to improve outcomes following PCI” North American Center for Continuing education Webcast 1/15/06

2006 “Left main disease: CABG without Question!” Enter the drug–eluting stent revolution V: a critical appraisal Atlanta, GA March 11, 2006

2006 Panel member, Live case presentation, ACC Scientific Sessions, Atlanta, GA, March 12, 2006

2006 "Should drug eluting stent use be curtailed given the growing safety concerns” TCT meeting, Washington, DC 10/22/06

2006 “Critical Comment on the HAAMU-Stent trial”, TCT meeting, Washington, DC 10/22/06

2006 “Fondaparinux in ACS and AMI: perspective for the interventionalist” TCT meeting, Washington, DC 10/22/06

2006 “ACC/AHA Valvular Heart Disease Guidelines: What’s new, what’s different” TCT meeting, Washington, DC 10/22/06

2006 “Interventional Cardiology Curriculum: Does it change?” TCT meeting, Washington, DC, 10/22/06

2006 "Approach to the Management of ACS’ TCT meeting, Washington, DC 10/22/06

2006 "Anticoagulant therapy: Direct and Indirect Thrombin Inhibitors, AHA Scientific Sessions Chicago Ill , Nov 11, 2006

2006 "Discussion of the ICTUS Trial", Circ Editors meeting, AHA Scientific Sessions Chicago Ill, Nov 11, 2006

2007 "Current Perspectives in ACS; risks, therapeutic approaches, and a visit to the guidelines", ACS forum, Satellite symposium ACC Annual Scientific Sessions meeting, New Orleans, 4/24/07

2007 "Compliance with the Residency Review Committee for internal medicine program requirements for cardiology, interventional cardiology, and clinical cardiac A 29 David P. Faxon, M.D. Curriculum Vitae

electrophysiology", ACC Annual Scientific Sessions meeting, New Orleans, 4/25/07

2007 "Bleeding and Transfusions in ACS", Chairman of Symposium, ACC Scientific Sessions meeting, New Orleans, 4/25/07

2007 Live Case panelist, I2 summit, ACC Scientific Sessions meeting, New Orleans, 4/25/07

2007 “Acute Myocardial Infarction: Mapping the Ideal Path”, New Jersey CHAPS conference, New Brunswick, NJ, 5/30/07

2007 “Door to Balloon – Managing the emergent patient, the cath lab perspective”, AHA Cardiology Summit, Parsippany, NJ, 6/11/07

2007 'Interventional Training, perspectives from the ACGME', Society of Cardiac Intervention , Orlando Fl, 5/9/07

2007 “Treating Ischemia in patients with chronic stable angina”, Primed Cardiology Update, San Francisco, 5/3/07

2007 “Anticoagulation in the ACS patient”, Visiting Professor, University of Florida, Jacksonville, 5/8/07

2007 “Drug Eluting Stents; is their use associated with a higher rate of late stent thrombosis and mortality?” University of Tenn, Knoxville TN, 9/7/07

2007 “PCI in Acute Coronary Syndromes”, 10th Annual Interventional Cardiology Self Assessment and Review Course, TCT Washington, DC, 10/22/07

2007 “Certification and recertification”, Interventional Cardiology Fellows symposium, TCT, Washington, DC, 10/23/07

2007 “Comment on Long term outcomes with drug eluting stents and bare metal stents in Sweden”, GroundBreaking studies in the practice of cardiovascular medicine-Circ editors choices, AHA Scientific Sessions, Orlando, FL, 11/4/07

2007 “The future of antiplatelet therapy: What will new trials tell us”, Antiplatelet Therapy across the cardiovascular risk spectrum, Satellite symposium, AHA Scientific Sessions, Orlando, FL, 11/5/07

2007 Chair, Quality measures in CV disease, AHA Scientific Sessions, Orlando, FL, 11/6/07

2007 “STEMI: The Challenges of Timing and Practical Solutions” ACC New York Symposium, New York, 12/ 8/06

2008 “PCI in Acute Coronary Syndromes”, Board Review Course, TCT Washington, DC, A 30 David P. Faxon, M.D. Curriculum Vitae

10/13/08

2008 “The challenges of managing a successful cardiovascular medical journal in 2008: a roundtable discussion”, TCT Washington, DC, 10/13/08

2008 “Behind closed doors; functions of a data safety monitoring committee”, TCT Washington, DC, 10/14/08

2008 “Critique and clinical perspectives on the HORIZONS-AMI trial”, TCT Washington, DC, 10/14/08

2008 Featured Lecture “The global impact of coronary artery disease: Changing epidemiology and demographics and the relative impact of pharmacologic vs. revascularization therapies”, TCT Washington, DC, 10/15/08

2008 “Quality, outcomes and performance measures: Practical implications “and panel discussion at Early Career and FIT program Track B for the clinical investigator, AHA 2008 Scientific Sessions, New Orleans, LA 11/8/08

2008 “Discussion of the COURAGE trial”, at Groundbreaking studies in the practice of cardiovascular medicine: Circulation editors choices 2007-2008, AHA 2008 Scientific Sessions, New Orleans, LA 11/9/08

2008 Chair, Late-Breaking Clinical Trials II, AHA 2008 Scientific Sessions, New Orleans, LA 11/10/08

2009 “Left main angioplasty: is it time to change the guidelines” Beth Israel Hospital, New York NY, 1/12/09

2009 Panel member, Late Breaking Trials I, ACC Annual Scientific Sessions, Orlando, FL 3/28/09

2009 “Evolving approaches for antithrombins and GP IIb/IIIa inhibitors in ACS and PCI” ACC Annual Scientific Sessions, Orlando, FL 3/29/09

2009 “PCI in acute coronary syndromes (non-STEMI): guidelines and outcomes, TCT San Francisco, CA 9/12/09

2009 Case presentations; A symptomatic patient with complex multivessel disease, Moderator, TCT San Francisco, CA 9/21/09

2009 “PCI in Acute Coronary Syndromes”, Board Review Course, TCT San Francisco, CA 9/21/09

2009 “Antithrombotic therapy options in STEMI invasive management: Is there a preference?” TCT San Francisco, CA 9/22/09

A 31 David P. Faxon, M.D. Curriculum Vitae

2009 “Prolonged use of clopidogrel reduces death and myocardial infarction following drug eluting stent but not bare metal stent placement: The VA DES study” AHA Scientific Sessions, Orlando, FL, 11/17/09

2010 “Stent Strategy for STEMI:BMS is the safest initial approach” in Primary PCI in STEMI, ACC Annual Scientific Sessions, Atlanta 3/14/10

2010 “My interpretation and View of the Bioabsorbable Stent Field: I am reserved” in New DES and Bioabsorbale Platforms, ACC Annual Scientific Sessions, Atlanta 3/14/10

2010 “European vs. US STEMI guidelines: Similarities and Differences” in Guidelines and Appropriateness Criteria, TCT Washington, DC 9/23/10

2010 “The clopidogrel nonresponder” Session chairman, TCT Washington, DC 9/23/10

2010 “A view from the top: workforce issues: the vision of our professional societies” Session chairman, TCT Washington, DC 9/24/10

2010 “Twenty-first century imperatives”, discussant, TCT Washington, DC 9/24/10

2010 “Most important publications of the last year: Circulation: Cardiovascular Interventions editors’ choices, session chairman, TCT Washington, DC 9/24/10

2010 “Perspectives on ZEST LATE/REAL LATE” TCT Washington, DC 9/24/10

2010 “Interventional cardiology: the basics of building a successful career as a clinical investigator” in Early Career: Breakout for the clinical investigator, AHA Scientific Sessions, Chicago, Ill 11/13/10

2010 “Discussant for Time-based strategy to reduce clopidogrel associated bleeding during CABG: Results for the TARGET CABG study” AHA Scientific Sessions, Chicago, Ill 11/16/10

2010 AHA/Asia Pacific Society of Cardiology: Tips and trick of transcatheter cardiovascular interventions – West vs. East, moderator, AHA Scientific Sessions, Chicago, Ill 11/15/10

2011 “Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting: Do we have consensus? NYU Cardiology grand rounds, NYU, NY 10/21/11

2011 Novel anticoagulants for high risk ACS: Rationale and study designs focused on safety and efficacy of Facto Xa inhibition in the setting of NSTEMI” Emerging paradigms and new frontiers in the science and application of antithrombotic intervenes for high risk ACS, TCT symposium, San Francisco, CA 11/8/2011

2011 “Late Breaking Clinical Trials” Discussant, TCT, San Francisco, CA 11/9/11

A 32 David P. Faxon, M.D. Curriculum Vitae

2011 “Special Circulation Journal Session: The most important interventional papers from the last year” Moderator and discussant, TCT, San Francisco, CA 11/10/11

2011 “Percutaneous repair or surgery for mitral regurgitation- Discussant”, AHA Scientific Sessions, Orlando, FL, 11/13/11

2011 “International Lunch Forum: Australia” Moderator, AHA Scientific Sessions, Orlando, FL, 11/13/11

2011 “Mulitvessel Coronary disease: Knife or needle? The voice of reason” AHA Scientific Sessions, Orlando, FL, 11/14/11

2011 “The PARTNER trial: A new paradigm for treating valvular heart disease” Moderator, AHA Scientific Sessions, Orlando, FL, 11/15/11

2011 “Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting: Do we have consensus?” Washington Hospital Center Cardiology Webinar, 11/16/11

2012 ‘New therapeutic options for ACS: From antiplatelets to antibiotics” Moderator, ACC Scientific Sessions, Chicago 3/24/12

2012 “Acute Coronary Syndromes: Therapy II” Moderator, ACC Scientific Sessions, Chicago 3/25/12

2012 “Making Sense of Alphabet Soup: Best Management of Acute Coronary Syndromes” ACC Florida Chapter meeting, Orlando, FL 8/25/12

2012 “Burden of Vascular Disease”, VESSEL: Vascular Disease Annual Meeting, Washington, DC Sept 2012

2012 “Special Circulation Journal Session: The most important papers from last year”, TCT 2012 Transcatheter Cardiovascular Therapeutics, Miami Beach, FL 11/3/12

2012 “Discussant: Cost-Effectiveness of Transcatheter Aortic Valve Replacement.” AHA Scientific Sessions Los Angeles, CA 11/4/12

2012 “International Forum: Brazil” AHA Scientific Sessions Los Angeles, CA 11/4/12

2012 “Acute care antithrombotic management in patients presenting on long-term anticoagulation” AHA Scientific Sessions Los Angeles, CA 11/5/12

2012 “Walking a tightrope without a net: Percutaneous coronary intervention without surgical backup”, Moderator, AHA Scientific Sessions Los Angeles, CA 11/6/12

2012 “Cutting edge technologies for multivessel disease: Bringing innovation to the A 33 David P. Faxon, M.D. Curriculum Vitae

patient”, AHA Scientific Sessions Los Angeles, CA 11/7/12

2013 “Multivessel disease management in STEMI” ACC Scientific Sessions 3/10/13

2013 “Special Circulation Journal Session: The most important papers from last year”, TCT 2013 Transcatheter Cardiovascular Therapeutics, Miami Beach, FL 10/30/13

2013 “Discussant- FREEDOM trial” Circulation: best papers of the year, AHA Scientific Sessions 11/17/13

2014 “Special Circulation Journal Abstract Session” TCT 2014 Washington DC 10/6/2014

2015 “ Discussant- PROMISE trial “ AHA Scientific Sessions 11/8/15

2016 “The Year in Cardiology- A Transatlantic View of EHJ- International Papers EHJ Special Session, AHA Scientific Sessions 11/12/16

International

1994 "Bypass Surgery vs. Angioplasty." Seminar on Innovations in the Treatment of Heart Disease, Whistler, British Columbia, Canada

1994 "Restenosis after Angioplasty: Have We Been Aiming at the Wrong Target?" Xth International Symposium on Atherosclerosis, Montreal, Canada

1995 "Vascular Remodeling: Experimental Models" Fifth European Workshop on Future Directions in Interventional Cardiology, Monaco

1996 "PTCA vs. CABG: Making Sense of Randomized Trials" Hellenic Cardiology Society, Rhodes, Greece

1996 "When to Choose PTCA and Surgery for Multivessel Disease: the BARI Trial Results" The "Whistler” Conference - Innovations in the Treatment of Heart Disease, Whistler, British Columbia, Canada

1996 "Research - New Developments", Fifth Interventional Cardiology Fellowship Course, Montreal, Canada

1997 “Animal Studies to Prevent Restenosis: What Have We Learned and What is Relevant?” Back to the Cradle, 20 Years of PTCA 1977-1997, Zurich, Switzerland

1997 “Radioactive Stents vs. Catheter Based Systems: Lessons Learned from Animal Studies” Building a Bridge to Clinical Trials. Second European Course on Intracoronary Radiation, Rotterdam, Netherlands

1998 “Revascularization in Diabetics: Lessons Learned from the BARI Trial” and “Stents and Restenosis”, and “Radiation Therapy for Restenosis: Is This the Silver Bullet? A 34 David P. Faxon, M.D. Curriculum Vitae

“ SOLACI II (Society for Latin American Interventional Cardiology) 1998, Montevideo, Uruguay

2006 Faculty - 1998 International Cardiology Forum, Cannes, France

2007 “Radiation for the Treatment of Restenosis” Keynote Lecture at the 64th Annual Scientific Meeting of the Japanese Circulation Society. Osaka, Japan

2002 Has Stenting in Multivessel Disease Leveled the Playing Field with Surgery?” “Restenosis – A Solution in Sight?” and “Carotid and Peripheral Stenting – Status Report.” ACC program, Cardiology at Cancun, Mexico

2002 “Potential Impact of Drug Eluting Stents on Mortality, Infarction and the Need for CABG.” XIVth World Congress of Cardiology, Satellite Program: Interventional Cardiology Conference, Sydney, Australia

2002 Co-Chair Session: AHA/WCC Symposium – CAD in Women. XIVth World Congress of Cardiology, Sydney, Australia

2003 “Restenosis: Has it Been Solved?” 24th Panhellenic Cardiological Congress. Rhodes, Greece

2003 Panel Member: 6th ICF international Experts’ Meeting. Lisbon, Portugal

2004 “Revascularization in ACS: Who, How and When”, South African Society of Cardiology, Durban, South Africa

2004 “Reperfusion Injury”, South African Society of Cardiology, Durban, South Africa

2004 “Spectrum of PCI in the era of Drug Eluting Stents”, South African Society of Cardiology, Durban, South Africa

2004 “Personal Approach to PCI”, South African Society of Cardiology, Durban, South Africa

2004 “Optimal Inter-hospital treatment in the United States of America”, ESC Congress 2004, Munich, Germany

2004 New Developments in Thrombolysis: Fibrinolysis, Session Chair, ESC Congress 2004, Munich, Germany

2005 “Management of ACS” Cardiology 2005, Sydney, Australia

2005 “My 10 tips to prevent complications in the cath lab” Cardiology 2005, Sydney, Australia

2006 “Optimizing the Treatment of CV Disease: How can physicians address a global A 35 David P. Faxon, M.D. Curriculum Vitae

problem?” ELITE Forum, Paris, France 10/2/06

2007 Chair, Peripheral vascular interventions, Andreus Greuntig 30th Anniversary Symposium, Zurich SW, 9/15-16/07

2009 “Optimal dosing of antiplatelet therapy in patients undergoing an early invasive strategy” The Korean Society of Cardiology Seoul, Korea 10/10/09

2009 “Can stent thrombosis be prevented” The Korean Society of Cardiology Seoul, Korea 10/11/09

2010 “Antiplatelet therapy in ACS: Current Recommendations” The Best of the AHA Scientific Sessions India-The Vital Summit, Jaipor, Mumbai and Chennai, India 10/12-17/10

2010 “Managing the diabetic patient with coronary artery disease” The Best of the AHA Scientific Sessions India-The Vital Summit, Jaipor, Mumbai and Chennai, India 10/12-17/10

2011 “Anti-platelet therapy in ACS: Current recommendations and remaining controversies”, Roche Distinguished Visitor, University of Alberta, CA 3/2/11

2011 “Culprit lesion angioplasty vs complete revascularization; Rationale for the CULPRIT trial, Roche Distinguished Visitor, University of Alberta, CA 3/2/11

2011 “The COURAGE for medical therapy” 2011 20th Interventional Cardiology Symposium, Montreal, Canada, 6/17/11

2011 Live Case Panelist, 2011 20th Interventional Cardiology Symposium, Montreal, Canada, 6/17/11

2011 “Optimizing management of unstable angina/NSTEMI ”, The Best of the AHA Scientific Sessions India-The Vital Summit, Cochin, Ahmedabad, Chandagarh, India 9/21/11-9/25/11

2011 “Tricks and Tips for medical therapy in stable angina”, The Best of the AHA Scientific Sessions India-The Vital Summit, Cochin, Ahmedabad, Chandagarh, India 9/21/11-9/25/11

2013 “Culprit lesion in ACS” The Best of the AHA Scientific Sessions India-The Vital Summit, Cochin, Mumbai and Delhi, India 10/12-21/2013

2013 “Lipids in Chronic Kidney Disease” The Best of the AHA Scientific Sessions India- The Vital Summit, Cochin, Mumbai and Delhi, India 10/12-21/2013

2014 “Common mistakes in the diagnosis of coronary artery disease” Annual Risk A 36 David P. Faxon, M.D. Curriculum Vitae

Management Seminar, Cabo San Luca, 1/6-8/2014

2014 “Angioplasty: what is un-necessary?” Annual Risk Management Seminar, Cabo San Luca, 1/6-8/2014

2014 “Valve Disease: an unappreciated killer” Annual Risk Management Seminar, Cabo San Luca, 1/6-8/2014

2015 “What is a high quality paper in the editors eye” and “Update on ACC AHA antiplatelet guidelines” 6 talks in Beijing, Haerban, Shenyang China 4/13 to 4/19/2015

2015 “How to get a paper published in a high quality journal” and “Update in Interventional Cardiology “ 8 talks in Beijing, Shanghai, Zhengzhou and Guangzhou 9/4 to 9/13/2015

2017 “The Future of Scientific Publishing” The Koren Society of Interventional Cardiology, Seoul, Korea 1/14/17 b. Professional and educational leadership role related to teaching

1988 International Society of Coronary Sinus Interventions-Chair of the 3rd International Symposium: This international Society was formed to promote and disseminate information concerning coronary sinus interventions in the treatment of acute MI and Ischemic heart disease. I organized the meeting obtained financial support and conducted the meeting in Boston.

1997-2003 ABIM Cardiovascular Board- member The CV board is responsible for creating the board examination for cardiovascular disease and overseeing the board examinations in electro physiology and interventional cardiology. The committee meets 4 times a year for three to four days and preparatory work involved preparing questions and evaluation of existing questions. The preparation time for each meeting is approximately 20 hours.

1990-1992 Inter-American Society of Cardiology-Co-Chair of Interventional Cardiology: This society represents the major cardiology societies in both North and South America and has an annual meeting once every 4 years. I was responsible for organizing the interventional cardiology component of the meeting in conjunction with a South American counterpart. Over 2000 attendees were at the meeting.

1993 Society of Coronary Angiography and Interventions- Co-Chair of Annual Scientific Sessions: The Society is the principle organization for interventional cardiologist and I was responsible for organizing its annual meeting, obtaining speakers, abstracts and financial support. Over 100 participants attended the meeting.

1983-1986 AHA Clinical Council Program Committee Member- This committee was responsible for the creating the clinical cardiology programs for the annual scientific sessions of A 37 David P. Faxon, M.D. Curriculum Vitae

the AHA the largest cardiology meeting in the world. As a member I was responsible for suggesting plenary sessions, and other major lectures, grading abstracts and arranging abstract sessions and proving input into the meeting structure and content.

1998-2000 AHA Interventional Cardiology Program-Co-Chair: In conjunction with the Annual Scientific Sessions, I co-chaired an interventional cardiology meeting. I was responsible for the program, obtaining speakers and assisting in fundraising. Over 2000 attended the meeting

2005-2008 ACGME- Residency Review Committee for Internal Medicine- committee member The RRC-IM is responsible for recommending the credentialing standards for all Internal Medicine and subspecialty programs and recommending credentialing of all internal medicine residency programs to the ACGME. The committee members review the site visitors report, the PIF report and associated history and prepare a recommendation for the committee. The committee meets 4 times a year for 3-4 days and the preparation time for each meeting is approximately 30-40 hours

2006- Present ABIM SEP committee- committee member. The SEP committee is responsible for writing test questions for preparation for the re-certification examination for the interventional cardiology boards. The committee meets 4 times a year for ½ day to draft questions and review performance.

2012 ACGME International- site review committee- Member. The ACGME International committee provides guidance to international hospitals seeking certification for the training of internal medicine residents. The site review committee provides an onsite mock review of the program and provides advice to site to help prepare them for the official site reviews.

3. Major curriculum offerings, teaching cases, or innovative educational programs developed

USC: 1993-2000 Developed the core cardiology curriculum for the cardiology fellowship program. The curriculum detailed the goals of each rotation, and the practical and didactic knowledge to be learned during the training period. In addition, I initiated a yearly voluntary practical and didactic examination for the fellows to provide feedback as to their skills during the course of training

GME Courses: (this list is incomplete since records were not required prior to 1995)

1995- Director of the ACC Course in Cardiology at Ranch Mirage, CA. As Director I obtained approval and support for the course from the ACC, obtained the speakers and funding. Over 200 attended the course

1997- Director of the USC Course on Cardiology in Pasadena CA. As Director I developed the program, obtained speakers and funding. Over 200 attended the meeting.

1998- Director of the 2nd USC Course on Cardiology in Pasadena CA. I developed the A 38 David P. Faxon, M.D. Curriculum Vitae

program obtained the speakers and funding. Over 300 attended the meeting

1999- Director of the 3rd USC Course on Cardiology in Los Angeles CA. I initiated the course, obtained the speakers and funding.

2003- Co Director of Contemporary Issues in the Management of Cardiovascular Disease: A Case Based Course in Nantucket MA. I developed a unique case based lecture discussion format for this course attended by 120 physicians.

2003-2005 Co-Director of the Annual University of Chicago Course on Cardiology entitled Advances in Cardiology in Chicago Il. I initiated the course, obtained the speakers and funding and moderated the meeting. Over 250 were in attendance

2008- Co-Director, Cardiology Update, Boston VA health care system symposium

Part IV. Report of Clinical Activities and Innovations

1. Current Licensure and Certification

1974-present State of Massachusetts License Registration 1974-present American Board of Internal Medicine, Internal Medicine 1977-present American Board of Internal Medicine, Cardiovascular Disease 1993-2014 State of California License Registration 2000-2006 State of Illinois License Registration 2006-2016 American Board of Internal Medicine, Interventional Cardiology

2. Clinical practice

Since 1996 I have seen patients weekly in an outpatient setting of the primary teaching hospital of the institutions that I have worked in. The patients have largely been referred by generalists for a specific cardiology problem. I have also been active in caring for in-patients with a wide variety of cardiology problems covering an in-patient service and coronary care unit for 2-3 months per year. I have also been active in cardiac catheterization laboratory and interventional cardiology since 1976 and 1999 respectively and currently cath and perform interventional cardiology at BWH one day per week.

3. Patient load

I have maintained ½ day to 1-day work of outpatient activity since 1976. While largely concentrating on the evaluation and management of patients with coronary artery disease, I have cared for all types of cardiology problems, including valvular heart disease, congestive heart failure, arrhythmias, pericarditis, myocarditis, and endocarditis. Currently I see patients at the BWH twice a week.

In the inpatient setting I have covered the inpatient cardiology service and CCU for 2-3 months per year. The patients have ranged in acuity from stable patients with common A 39 David P. Faxon, M.D. Curriculum Vitae

cardiology problems to those critically ill with cardiogenic shock and requiring life support and emergent revascularization

Earlier in my career I performed cardiac catheterization and interventions for 2-3 days per week but over the past 10 years have performed procedures on an average of 1 day per week as well as cover the laboratory for emergencies at nights and weekends. The patients range from stable outpatients to those who are critically ill requiring emergency hemodynamic support and angioplasty or stent placement.

Part V: Report of Technological and Other Scientific Innovations

Catheter for delivery of therapeutic and/or diagnostic agents to the tissue surrounding body passageway U.S. Patent #5,464,395, Nov 7, 1995

Part VI: Report of Education of Patients and Service to the Community

Activities Years Role Organization 1976-present Heart Walks American Heart Association 1982-present Heart Balls American Heart Association Recognition Year Award Organization 2002 Distinguished National Leadership Award American Heart Association 2006 Gold Heart Award American Heart Association

Part VII: Bibliography (457 peer reviewed and invited publications)

Original Articles

1. Loening S, Carson C, Faxon D, Mortin L. Urethral obstruction from Hodgkin's disease. Journal of Urology 1971:3; 345.

2. Gavras H, Flessas A, Ryan TJ, Brunner H, Faxon DP, Garvas I. Angiotensin II inhibition: Treatment of congestive cardiac failure in a high renin hypertension. JAMA1977; 238-44.

3. Gavras H, Faxon DP, Berkoben J, Brunner H, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978; 58:770-5.

4. Bauer E, Densen P, Faxon D, Kloster C, Melidossian C. Endotoxic reactions associated with the reuse of cardiac catheters. MA Morb Mortal Wkly Rep 1979; 28:25-6.

5. Chobanian AV, Volicer L, Tifft CP, Gavras H, Liang CS, Faxon DP. Studies on the mechanism A 40 David P. Faxon, M.D. Curriculum Vitae

or mineralocorticoid hypertension induced by fludrocortisone in patients with chronic orthostatic hypotension. N Eng J Med 1979; 301:68-73.

6. Faxon DP, Creager MA, Halperin JL, Gavras H, Coffman JD, Ryan TJ. The central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. Circulation 1980; 61:925-30.

7. Faxon DP, Gross S, Tilney C, Ryan TJ. The altered baroreceptor response to nitroglycerin in congestive heart failure. Clin Cardiol 1980; 3:7-13.

8. Faxon DP, Halperin JL, Creager MA, Gavras H, Schick EC, Ryan TJ. Angiotensin inhibition in severe heart failure: Acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J 1981; 101:548-56.

9. Creager MA, Halperin JL, Bernard DB, Faxon DP, Melidossian CD, Gavras H, Ryan TJ. Acute regional circulatory and renal hemodynamic effects of converting enzyme inhibition in patients with congestive heart failure. Circulation 1981; 64:483-9.

10. Faxon DP, McCabe CH, Kriegel DE, Ryan TJ. The therapeutic and economic value of a normal coronary angiogram. Am J Med1982; 73:500-5.

11. Faxon DP, Weber VJ, Haudenschild C, Gottsman SB, McGovern WA, Ryan TJ. Acute effects of transluminal angioplasty in three experimental models of atherosclerosis. Arteriosclerosis 1982; 2:125-32.

12. Halperin JL, Creager MA, Faxon DP, Bass T, Gavras H, Ryan TJ. Coronary hemodynamic effects of angiotensin inhibition in congestive heart failure. Am J Cardiol 1982; 50:967-72.

13. Faxon DP, Ryan TJ, Davis KB, McCabe CH, Myers W, Lesperance J, Shaw R, Tong T. Prognostic significance of angiographically documented left ventricular aneurysm from the Coronary Artery Surgery Study (CASS). Am J Cardiol 1982;50:157-64.

14. Sanborn TA, Faxon DP, Waugh D, Small DM, Haudenschild C, Gottsman SB, Ryan TJ. Transluminal angioplasty in experimental atherosclerosis: Analysis of embolization using an in vivo perfusion system. Circulation 1982;66:917-22.

15. Faxon DP, Halperin JL, Creager MA, Sussman HB, Gavras H, Ryan TJ. The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in patients without coronary artery disease. Int J Cardiol 1982;2:251-62.

16. Creager MA, Faxon DP, Halperin JL, Melidossian CD, McCabe H, Schick EC, Ryan TJ. Determinants of clinical response and survival of patients with congestive heart failure treated with captopril. Am Heart J 1982;104:1147-54.

17. Faxon DP, Creager MA, Halperin JL. Regional circulatory response to converting enzyme inhibition in congestive heart failure. Brit J Clin Pharmacol 1982;14:1795-1865.

A 41 David P. Faxon, M.D. Curriculum Vitae

18. Fisher LD, Judkins MP, Lesperance J, Cameron A, Swaye P, Ryan T, Maynard C, Bourassa M, Gosselin A, Hemp H, Faxon D, Wexler LF. Reproducibility of coronary arteriographic reading in the Coronary Artery Surgery Study (CASS). Cath and CV Diag 1982;8:565-75.

19. Faxon DP, Creager MA, Halperin JL. Regional circulatory response to converting enzyme inhibition in congestive heart failure. Brit J Clini Pharmacol 1982;14:179s-186s.

20. Chobanian AV, Tifft CP, Faxon DP, Creager MA, Sackel H. Treatment of chronic orthostatic hypertension with Ergotamine. Circulation 1983;67(3): 602-9.

21. Sanborn TA, Faxon DP, Kellett MA, Ryan TJ. Serial angiographic evidence of rapid resolution coronary artery stenosis. Chest 1983;84:302-4.

22. Sanborn TA, Faxon DP, Haudenschild C, Gottsman SB, Ryan TJ. The mechanism of angioplasty: Evidence for aneurysm formation in experimental atherosclerosis. Circulation 1983;68(5): 1136- 40.

23. Holmes DR, Vliestra RE, Fisher L, Smith HC, Mock MB, Faxon DP, Gosselin AJ, Ryan TJ, Judkins MP. The follow-up of patients from the Coronary Artery Study (CASS) suitable for but not treated with percutaneous transluminal coronary angioplasty (PTCA). Am Heart J 1983;106:981-8.

24. Faxon DP, McCabe CH. A normal coronary angiogram: Is it therapeutic? Int J Cardiol 1983;3:360-3.

25. CASS Principal Investigators and their Associates. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery. Survival Data. Circulation 1983;68:939-50.

26. CASS Principal Investigators and their Associates. Coronary Artery Surgery Study (CASS): A randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation 1983;68:951-60.

27. Faxon DP, Detre K, McCabe CH, Fisher L, Holmes D, Cowley M, Bourassa M, Van Raden M, Ryan TJ. The role of percutaneous transluminal coronary angioplasty in the treatment of patients with unstable angina. Report from the National Heart Lung and Blood Institute - Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Surgery Study Registries. Am J Cardiol 1983;53:131c-135c.

28. Faxon DP, Sanborn TA, Haudenschild C, Ryan TJ. Effect of antiplatelet therapy on restenosis following experimental angioplasty. Am J Cardiol 1984;53:72c-76c.

29. Fisher LD, Holmes DR, Mock MD, Pettinger M, Vliestra RE, Smith HC, Ryan TJ, Judkins MP, Gosselin AJ, Faxon DP. Design of comparative PTCA clinical studies (using estimates from the Coronary Artery Surgery Study, CASS). Am J Cardiol 1984;53:138c-145c.

30. Creager MA, Faxon DP, Melby JC, Gavras H, Coffman JD. Effect of angiotensin blockade on limb vessels in normal man. Am J Physiol 1984;246:H239-H244. A 42 David P. Faxon, M.D. Curriculum Vitae

31. Faxon DP, Creager MA, Halperin JL, Bernard DB, Ryan TJ. Redistribution of regional blood flow following angiotensin converting enzyme inhibition: A comparison of normal subjects and patients with heart failure. Am J Med 1984;76(5B): 104-10.

32. Faxon DP, Sanborn TA, Haudenschild C, Weber V, Gottsman SB, McGovern WA, Ryan TJ. Restenosis following transluminal angioplasty in experimental atherosclerosis. Arteriosclerosis 1984;4(3): 189-95.

33. Faxon DP, Kelsey SF, Ryan TJ, McCabe CH, Detre K. Determinants of a successful transluminal coronary angioplasty. Report from the National Heart, Lung and Blood Institute Registry. Am Heart J 1984;108:1019-23.

34. Schaff HV, Gersh BJ, Fisher LD, Frye RL, Mock MB, Ryan TJ, Chaitman BR, Alderman EL, Kaiser GC, Faxon DP. Detrimental effects of perioperative myocardial infarction on late survival after coronary artery bypass surgery (a report from the Coronary Artery Surgery Study - CASS). J Cardiovasc and Thoracic Surg 1984;88:972-81.

35. Stewart WJ, McSweeney SM, Kellett MA, Faxon DP, Ryan TJ. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization. Circulation 1984;70:788-92.

36. Creager MA, Faxon DP, Weiner DA, Ryan TJ. Hemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril. Br Heart J 1985;53:431-5.

37. Creager MA, Faxon DP, Rockwell SM, Gavras H, Coffman JD. The contribution of the renin- angiotensin system to limb vasoregulation in patients with heart failure: Observations during orthostasis and adrenergic blockade. Clin Sci 1985;68:659-67.

38. Sanborn TA, Faxon DP, Haudenschild CC, Ryan TJ. Experimental angioplasty: Circumferential distribution of laser thermal energy with a laser probe. J Am Coll Cardiol 1985;5:934-8.

39. Faxon DP, Jacobs AK, McSweeney SM, Coats WD, Kellett MA, Ryan TJ. Coronary sinus occlusion pressure and its relation to intracardiac pressure. Am J Cardiol 1985;56:457-60.

40. Creager MA, Massie BM, Faxon DP, Friedman SD, Kramer BL, Weiner DA, Ryan TJ, Melidossian CD. Acute and long-term effects of Enalapril on the cardiovascular response to exercise and exercise tolerance in patients with congestive heart failure. J Am Coll Cardiol 1985;6:163-70.

41. Chatterjee E, Parmley WW, Cohn JH, Levine TB, Awan MA, Mason TJ, Faxon DP, Gavras MA, Gavras HP, Faroud et al. The Captopril multicenter research group: I. A cooperative multicenter study of Captopril in congestive heart failure: Hemodynamic effects and long-term response. Am Heart J 1985;110:439-47.

42. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. The contribution of vasopressin to vasoconstriction in patients with congestive heart failure: Comparison of the A 43 David P. Faxon, M.D. Curriculum Vitae

renin-angiotensin system and the sympathetic nervous system. J Am Coll Cardiol 1986;7:758-65.

43. Faxon DP, Meyers WO, McCabe CH, David KB, Schaff HV, Wilson JW, Ryan TJ. The influence of surgery on the natural history of angiographically documented left ventricular aneurysm from the Coronary Artery Surgery Study (CASS). Circulation 1986;74:110-18.

44. Sanborn TZ, Faxon DP, Kellett MA, Ryan TJ. Percutaneous coronary laser thermal angioplasty. J Am Coll Cardiol 1986;8:1437-40.

45. Biddle TL, Benotti JR, Creager M, Faxon DP, Firth BG, Fitzpatrick PG, Konstam MA, Kregs C, Walton LH, Kershnerf A, Jacobsen J, Mozkowec CA, Montenaro MJ, Tardon PK, Fitzpatrick S, Schwartz RP. Comparison of intravenous Milrinone and Dobutamine in patients with congestive heart failure - A multicenter study. Am J Cardiol 1987;59(15): 1345-50.

46. Wilentz JR, Sanborn TA, Haudenschild CC, Valeri CR, Ryan TJ, Faxon DP. Platelet accumulation in experimental angioplasty: Time course and relation to vascular injury. Circulation 1987;75:636-42.

47. Sanborn TA, Haudenschild CC, Ryan TJ, Faxon DP. Angiographic and histologic consequences of laser thermal angioplasty: Comparison to balloon angioplasty. Circulation 1987;75:1281-86.

48. Faxon DP, Sanborn TA, Haudenschild CC. The mechanism of angioplasty and its relationship to restenosis. Am J Cardiol 1987;60:513-519.

49. Detre K, Holubkov R, Kelsey S, Cowley M, Kent K, Williams D, Myer R, Faxon DP et al. Percutaneous Transluminal Coronary Angioplasty in 1985-1986 and 1977-1981. The National Heart Lung and Blood Institute Registry. New Eng J Med 1988;318:265-70.

50. Leeman DE, McCabe C, Faxon DP, Lorell BL, Kellett MA, McKay RG, Varricchione T, Baim DS. Treatment of unstable angina: Utilization of percutaneous coronary angioplasty and bypass surgery despite improved medical therapy. Amer J Cardiol 61(14): May 1988;9:386-446.

51. Holmes DR, Holubkov R, Vlietstra RE, Kelsey S, Reeder GS, Dorros G, Williams D, Cowley M, Faxon D, Kent K, Bentivoglio L, Detre K. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: The National Heart, Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1988;12:1149-55.

52. Glazier JJ, Faxon DP, Melidossian C, Ryan TJ. The changing face of coronary artery spasm: A decade of experience. Am Heart J 1988;116:II: 572-6.

53. Faxon DP. The risk of reperfusion strategies in the treatment of patients with acute myocardial infarction. J Am Coll Cardiol 1988;12:52A-57A.

54. Glazier JJ, Varricchione TR, Ryan TJ, Ruocco NA, Jacobs AK, Faxon DP. Outcome of patients with recurrent restenosis after percutaneous transluminal balloon angioplasty. Br Heart J 1989;61:485-8. A 44 David P. Faxon, M.D. Curriculum Vitae

55. Glazier JJ, Varricchione TR, Ryan TJ, Ruocco NA, Jacobs AK, Faxon DP. Factors predicting recurrent restenosis after coronary balloon angioplasty. Am J Card 1989;63:902-5.

56. Glazier JJ, Faxon DP, Mills RM, Bresnahan MR, Ryan TJ, Gavras H. Effect of Arginine vasopressin on coronary and systemic hemodynamics in man. Int J Cardiol 1989;24:95-103.

57. Detre K, Holubkov R, Kelsey S, Bourassa M, Williams D, Holmes D, Dorros G, Faxon D, Myler R, Kent K, Cowley M, Cannon R, Robertson T. One-year follow-up results of the 1985-1986 National Heart, Lung and Blood Institutes percutaneous transluminal coronary angioplasty registry. New Eng J Med 1989;80(3): 421-8.

58. Bergelson BA, Ruocco NA, Ryan TJ, Hankin B, Jacobs AK, Faxon DP. Antecedent angina: A predictor of residual stenosis following thrombolytic therapy. J Am Coll Cardiol 1989;14:91-5.

59. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. The results of the thrombolysis in myocardial intervention (TIMI) phase II trial. New Eng J Med 1989;320-618-27

60. Faxon DP, Ruocco NA, Jacobs AK. Long-term outcome of patients after coronary angioplasty. Circulation 1990;81(3):IV-9-IV-13.

61. Mills RM, Berger PB, Garber GR, LaRosa D, Faxon DP. Clinical experience with percutaneous transluminal coronary angioplasty in a "Judkins" laboratory. Cath and Cardiovas Disease 1990;19:286-98.

62. Detre KM, Holmes DA, Holubkov R, Cowley MJ, Bourassa M, Faxon DP, Dorros GR, Bentivoglio L, Kent KM, Myler RK. Incidence and consequences of periprocedural occlusion: The 1985-86 National Heart, Lung and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-50.

63. Balady GJ, Jacobs AK, Faxon DP, Ryan TJ. Dynamic arm exercise during cardiac catheterization in the assessment of stenotic valvular disease. Clin Card 1990;13:632-7.

64. Kelsey SF, Miller DP, Holubkov R, Cowley MJ, Faxon DP, Detre KM. Results of percutaneous transluminal coronary angioplasty in patients 65 years of age. From the 1985-1986 National Heart Lung and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Am J Cardiol 1990;66:1033-9.

65. Ring ME, Vecchione JJ, Fluse L, Ruocco NA, Jacobs AK, Deykin D, Faxon DP. Detection of intracoronary fibrin degradation after coronary balloon angioplasty. Am J Card 1991;67:1330-4.

66. Leitschuh MA, Mills RM, LaRosa D, Jacobs AK, Ruocco NA, Faxon DP. Outcome after major dissection during coronary angioplasty using the perfusion balloon catheter. Am J Cardiol 1991;67:1056-60.

67. Jacobs AK, Faxon DP, Coats WD, Vogel WM, Ryan TJ. Coronary sinus occlusion: Effects on A 45 David P. Faxon, M.D. Curriculum Vitae

ischemic left ventricular dysfunction and reactive hyperemia. Am Heart J 1991;121:442-229.

68. Holmes D, Kent K, Myler RK, Williams DO, Faxon DP, King S, Block P, Bentivoglio L, Bourassa M, Cowley MJ, Leatherman L, Dorros G, Desvigne-Nickens P, Galichia J, Steenste H, Gosselin A, Kelsey S, Detre K. The NHLBI PTCA registry as a standard for comparison of new devices: When should we use it and what should we compare? Circulation 1991;84:1828-30.

69. Bresee SJ, Jacobs AK, Garber GR, Ruocco NA, Millis RM, Bergelson BS, Ryan TJ, Faxon DP. Prior restenosis predicts restenosis after coronary angioplasty of a new significant narrowing. Am J Cardiol 1991;68:1158-62.

70. Ruocco NA, Currier JW, Jacobs AK, Ryan TJ, Faxon DP. Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty. Am J Cardiol 1991;68:17:1609-13.

71. Currier JW, Pow TK, Haudenschild CC, Minihan AC, Faxon DP. Low molecular weight Enoxaparin reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit. J Am Coll Cardiol 1991;17:118B-125B.

72. Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Jacobs AK, Faxon DP. Incidence and prognostic implications of heart block complicating inferior infarction treatment in thrombolytic therapy: Results from TIMI II Trial. J Am Coll Card 1992;20(3):533-40.

73. Faxon DP, Ghallili K, Jacobs AK, Ruocco NA, Christellis EM, Kellett MA, Varricchione TR, Ryan TJ. The degree of revascularization and outcome after multivessel angioplasty. Am Heart J 1992;123:854-9.

74. Brush JE, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal Endothelium-dependent coronary vasomotion in hypertensive patients. Circulation: J Am Coll Card 1992;19:809-15.

75. Ruocco NA, Ring ME, Holubkov R, Jacobs AK, Detre KM, Faxon DP, Co-investigators of NHLBI. Results of coronary angioplasty of chronic total occlusions: the NHLBI 1985-1986 percutaneous transluminal angioplasty registry. J Am Coll Card 1992;69:69-76.

76. Ruocco NA, Bergelson BA, Jacobs AK, Frederick MM, Faxon DP, Ryan TJ, TIMI investigators. Invasive versus conservative strategy post-thrombolytic therapy for acute myocardial infarction in patients with antecedent angina: A report from TIMI II. J Am Coll Card 1992;20(7): 1445-51.

77. Lazar HL, Faxon DP, Paone G, Rajaii-Khorasani A, Jacobs AK, Faxon MP, Shemin RJ. Changing profiles of failed coronary angioplasty patients: Impact on surgical results. Ann Thorac Surg 1992;52:2:269-73.

78. Bergelson BA, Jacobs AK, Cupples LA, Ruocco NA, Kyller MG, Ryan TJ, Faxon DP. Prediction of risk for hemodynamic compromise during coronary angioplasty. Am J Card 1992;70:1540-45.

79. Faxon DP, Balelli LA, Sanborn T, Haudenschild C, Valeri R, Ryan TJ. The effect of antiplatelet A 46 David P. Faxon, M.D. Curriculum Vitae

therapy on platelet accumulation after experimental angioplasty. Intern J Cardiol 1992;36:41-47.

80. Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, Bourassa MG, CASS Participating Investigators and Staff. Five-year angiographic follow-up of factors associated with progression of coronary artery disease in CASS. J Am Coll Cardiol 1993;22:1141-54.

81. Landau C, Currier JW, Haudenschild CC, Minihan AC, Heymann D, Faxon DP. Microwave balloon angioplasty effectively seals arterial dissections in an atherosclerotic rabbit model. J Am Coll Cardiol 1994;7:1700-7.

82. Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit. Circulation 1994;89:2809-15.

83. Faxon DP, Spiro TE, Minor S, Cote G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, Ohman M, and the ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90:908-14.

84. Landau C, Jacobs AK, Currier JW, Leitschuh ML, Ryan TJ, Faxon DP. Long term clinical follow-up of patients successfully treated with a perfusion balloon catheter for coronary angioplasty induced dissections or abrupt closure. Am J Cardiol 1994;74:733-5.

85. Bentivoglio LG, Detre K, Kelsey SF, Yeh WL, Williams DO, Faxon DP. Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris: A report of the 1985-1986 NHLBI PTCA Registry. J Am Coll Cardiol 1994;24:1195-1206.

86. Faxon DP, Currier JW. Prevention of post-PTCA restenosis. Annals of the New York Academy of Sciences 1995;748:419-22.

87. Faxon DP, on behalf of the MARCATOR Study Group. Effect of high dose angiotensin- converting enzyme on restenosis: The final results of the MARCATOR Study: A multicenter double-blind placebo-controlled trial of Cilazapril. J Amer Coll Cardiol 1995;25: 362-9.

88. Detre K, Yeh W, Kelsey S, Williams D, Desvigne-Nickens P, Holmes D, Bourassa M, King III S, Faxon D, Kent K, for the Investigators of the NHLBI Percutaneous Transluminal Coronary Angioplasty Registry. Has improvement in PTCA intervention affected longterm prognosis? The NHLBI PTCA Registry Experience. Circulation 1995;91:2868-75.

89. Williams D, Faxon DP and the BARI Investigators. Coronary anatomic and procedural characteristics of patients randomized to coronary angioplasty in BARI. Am J Cardiol 1995;75:27C-33C.

90. Berger P, Holmes D, Ohman E, O'Hanesian MA, Murphy J, Schwartz R, Serruys P, Faxon DP for the MARCATOR Investigators. Restenosis, reocclusion, and adverse cardiovascular events following successful balloon angioplasty of occluded versus non-occluded coronary arteries: A 47 David P. Faxon, M.D. Curriculum Vitae

Results from the MARCATOR Trial. J Am Coll Cardiol 1996;27:1-7.

91. Faxon DP, Vogel R, Yeh W, Holmes DR Jr, Detre K and the NHLBI PTCA Registry Investigators. Value of visual versus central quantitative measurements of angiographic success after percutaneous transluminal coronary angiography. Am J Cardiol 1996;77(12):1067-72.

92. Alderman EL, Andrews K, Bost J, Bourassa M, Chaitman BR, Detre K, Faxon DP, et al., The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Eng J Med 1996;335:217-25.

93. Coats WD, Currier JW, Mejias Y, Narciso HL, Faxon DP. Tin ethyl etiopurpurin significantly inhibits vascular smooth muscle cell proliferation in vivo. Biochemistry and Cell Biology 1996;4(3): 325-31.

94. Coats WD, Cheung DT, Han B, Currier JW, Faxon DP. Balloon angioplasty significantly increases collagen content but does not alter collagen subtype I/III ratios in the atherosclerotic rabbit iliac model. J Moll Cell Cardiol 1996;28:441-6.

95. O'Brien J, Peterson E, Keeler G, Berdan L, Ohman E, Faxon DP, Jacobs A, Topol E, Califf R. The relationship between estrogen replacement therapy and restenosis following percutaneous coronary interventions. J Am Coll Cardiol 1996;28:1111-8.

96. Kip K, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW, for the Investigators of the NHLBI PTCA Registry. Coronary Angioplasty in Diabetic Patients: The NHLBI PTCA Registry. Circulation 1996;94:1818-25.

97. Law RE, Meehan WP, Xi XP, Graf K, Coats WD, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.

98. Weintraub WS, Mauldin PD, Talley JD, Diamond GA, Merlino J, Lindsay J, Bodenheimer MM, DeMaio S, Klein LW, Faxon D, et al. Determinants of hospital charges and costs in acute myocardial infarction: a report from the Myocardial Infarction Cost Study (MICS) group. Am J Man Care 1996;2:977-86.

99. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-25.

100. Coats, WD, Whittaker P, Cheung DT, Currier JW, Han B, Faxon DP. Collagen content is significantly lower in restenotic versus nonrestenotic vessels following balloon angioplasty in the atherosclerotic rabbit model. Circulation 1997;95:1293-1300.

101. The Writing Group for the Bypass Angioplasty Revascularization Investigation (Faxon DP member of Writing Group) Five-year clinical and functional outcome in a multicenter randomized trial comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A Multicenter Randomized Trial. J Am Coll Cardiol 1997;277;715-21 A 48 David P. Faxon, M.D. Curriculum Vitae

102. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattl S, de Guise P, for the Multivitamins and Probucol Study Group (Faxon DP member of study group). Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-72.

103. Jacobs AK, Kelsey SF, Yeh W, Holmes DR, Block PC, Cowley MJ, Bourassa MG, William DO, King SP, Faxon DP, Myler R, Detre KM. Documentation of decline in morbidity in women undergoing coronary angioplasty (A report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). Am J Cardiol 1997;80:979-84.

104. Alderman E, Bourassa M, Califf R, Chaitman B, Faxon D, Feit F, Frye R for the BARI Investigators. The influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96:1761-1769.

105. Kakuta T, Usui M, Coats W, Currier JW, Numano F, Faxon DP. Arterial remodeling at the reference site after angioplasty in the atherosclerotic rabbit model. Arterio Thrombo and Vasc Biol 1998;18:47-51.

106. Jacobs AK, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V, Mock MB, Weiner BH, Dean L, Winston C, Drew L, Sopko G. Better outcome for women compared with men undergoing coronary revascularization: A report from the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 1998;98:1279-85.

107. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH and the SHOCK Investigators, Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625-34.

108. Durairaj A, Faxon DP. The ARTISTIC and ARREST Trials. J Invasive Cardiol 2000;12:44-9.

109. Detre KM, Alderman E, Faxon D, Bourassa M, Califf R, Chaitman B, Faxon D for the NHLBI Bypass Angioplasty Revascularization Investigators (BARI). Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35:1122-9.

110. Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R, Berger PB, Shemin R, Attubato MJ, Williams DO, Frye R, Detre KM for the BARI Investigators (Faxon DP). Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry. Comparison with the randomized trial. Circulation 2000;101:2795-2802.

111. Williams DO, Holubkov R, Wanlin Y, Bourassa MG, Al-Bassam M, Block PC, Coady P, Cohen H, Cowley M, Dorros G, Faxon D, Holmes DR, Jacobs A, Kelsey DF, King SB, Myler R Slater J, Stanek V, Vlachos HA, Detre KM. Percutaneous coronary intervention in the current era compared with 1985-1986. The National Heart, Lung, and Blood Institute Registries. Circulation 2000;102:2945-51. A 49 David P. Faxon, M.D. Curriculum Vitae

112. Domanski MJ, Sutton-Tyrrell K, Mitchell GF, Faxon DP, Pitt B, Sopko G and the BARI Investigators. Determinants and prognostic information provided by pulse pressure in patients with coronary artery disease undergoing revascularization: The Balloon Angioplasty Revascularization Investigation (BARI). Am J Cardiol 2001;87:675-9.

113. Berger PB, Velianou JL, Feit F, Attubato F, Keller N, Jacobs A, Weiner B, Faxon D, Jacobs A, Aslanidou HV, Williams D, and the BARI Investigators. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). J Amer Coll Cardiol 2001;38:1440-9.

114. Laskey WK, Williams DO, Vlachos HA, Cohen H, Holmes DR, King SB, Kelsey SF, Slater J, Faxon D, Al-Bassam M, Block E, Detre KM. Dynamic Registry Investigators. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry. Am J Cardiol 2001;87:964-969.

115. Faxon DP. The Chain of Scientific Discovery: The Critical Role of the Physician-Scientist. American Heart Association Presidential Address, November 2001. Circulation 2002;105:1857- 60.

116. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Struckey R Turco M, Carroll JD, Rutherford BD, Lansky AJ for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab in acute myocardial infarction. N Eng J Med 2002;346:957-66.

117. Jacobs AK, Johnston JM, Haviland A, Brooks MM, Kelsey SF, Holmes DR, Faxon DP, Williams DO, Detre KM, Improved outcomes for women undergoing contemporary percutaneous coronary intervention. A report from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2002;39:1608-14.

118. Faxon DP, Gibbons RJ, Chronos NAF, Gurbel PA, Sheehan F, Martin JS for the HALT-MI Investigators. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI Study. J Am Coll Cardiol 2002:40(7):1199-1204.

119. Naidu SS, Selzer F, Jacobs A, Faxon D, Marks DS, Johnston J, Detre K, Wilensky RL. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol. 2003 Nov15;92(10):1160-4.

120. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach KH, Selzer RH. Hormone Therapy and the Progression of Coronary-Artery Atherosclerosis in Postmenopausal Women. N Engl J Med 2003;349:6.

121. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, A 50 David P. Faxon, M.D. Curriculum Vitae

Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach KH, Selzer RH; Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003 Aug 7;349(6):535-45.

122. Naidu SS, Selzer F, Jacobs A, Faxon D, Marks DS, Johnston J, Detre K, Wilensky RL. Renal insufficiency is an independent predictor of mortality after percutaneous coronary intervention. Am J Cardiol. Nov 15 2003:92(10):1160-4.

123. Glaser R, Selzer F, Faxon DF, Lansky WL, Cohen HA, Slater J, Detre KM, Wilensky RL, Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circ 2005;111:142-9.

124. Bokari SW, Bokari ZW, Zell JA, Lee DW, Faxon DP Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients, Coronary Artery Disease 2005;16:153-61.

125. Mehta SR, Steg PG., Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJG, Natarajan K, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox K, Yusuf S, for the ASPIRE Investigators. Randomized, blinded trial comparing fondaparinox with unfractionated heparin in patients undergoing contemporary percutaneous coronary interventions: Astrix study in percutaneous coronary interventions: A randomized evaluation (ASPIRE) Pilot trial. Cirulation 2005;111:1390-7.

126. Naidu SS, Vlachos H, Faxon D Jacobx AK, Selzer F, Detre K, Wilensky RL Usefulness of noncornary vascular disease in predicting adverse events in the year following percutaneous coronary intervention Am J Cardiol 2005; 95(5): 575-80

127. Michelangelo OASIS 5 Steering Committee. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2005;150(6);1107e1-10.

128. Holper EM, Blair J, Selzer F, Detre KM, Jacobs AK, Williams DO, Vlachos H, Wilensky RL, Coady P, Faxon DP. The impact of ejection fraction on outcomes after PCI in patients with congestive heart failure: An analysis of he NHLBI PTCA Registry and Dynamic Registry AHJ 2006;151(1):69-75.

129. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes investigators. Comparison of fondaparinux and enoxpararin in acute coronary syndromes NEJM 2006;354: 1464-76

130. The OASIS-6 trial group. Effect of fondaparinux on moratality and reinfarction inpatients with acute ST-segment myocardial infarction: The OASIS 6 randomized trial JAMA 2006;295:1519- 30

A 51 David P. Faxon, M.D. Curriculum Vitae

131. Detre KM, Frye RL, Genuth S, (suppplement editors) Treatment of coronary artery disease and type 2 diabetes mellitus: The rationale for the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial. Am J Card 2006; 97(12A): 1G-66G

132. Sobel BE, BARI 2D Investigators, Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial: Synergies and opportunities. Am J Cardiol. 2006 Jun 19;97(12A):53G-58G. Epub 2006 Apr 17.

133. Hlatky MA, Melsop KA, Boothroyd DB, BARI 2D trial Investigators, Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2006 Jun 19;97(12A):59G-65G. Epub 2006 Apr 7.

134. Barsness GW, Gersh BJ, Brooks MM, Frye RL, BARI 2D Trial Investigators, Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006 Jun 19;97(12A):31G-40G. Epub 2006 Apr 17

135. Magee MF, Isley WL, BARI 2D Trial Investigators, Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006 Jun 19;97(12A):20G-30G. Epub 2006 Apr 19.

136. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ, BARI 2D Trial Invstigators, Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006 Jun 19;97(12A):9G-19G. Epub 2006 Apr 17.

137. Steiner G, BARI 2D Trial Investigators, Statement of the problem. Am J Cardiol. 2006 Jun 19;97(12A):3G-8G. Epub 2006 Apr 7.

138. BARI Investigators, The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007 Apr 17;49(15):1600-6. Epub 2007 Apr 2.

139. Holper EM, Brooks MM, Kim LJ, Detre KM, Faxon DP. Effects of heart failure and diabetes mellitus on long-term mortality after coronary revascularization (from the BARI Trial). American Journal of Cardiology 2007;100:196-202.

140. Mehta SR, Ganger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP, Peters RJ, Budaj A, Afxal R Chrolavicius S, Fox KA, Yusuf S, Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51

141. Stone, G. W.White, H. D.Ohman, E. M.Bertrand, M. E.Lincoff, A. M.McLaurin, B. T.Cox, D. A.Pocock, S. J.Ware, J. H.Feit, F.Colombo, A.Manoukian, S. V.Lansky, A. J.Mehran, R.Moses, J. W. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial, Lancet 2007:369 (9565):907-919

142. Yatskar L, Holper E, Bansilal S, Schwartzbard A, Lomarfero M, Ramanathan K, Feit F, Fisher E, A 52 David P. Faxon, M.D. Curriculum Vitae

Faxon D, Hockman J, Farkouh, Long-Term Outcomes in Non Diabetic Patients with Metabolic Syndrome Undergoing Revascularization for Multi-vessel Coronary Artery Disease, Atherosclerosis. 2008 Jun;198(2):389-95.

143. Wu C, Hannan EL, Walford G, Faxon DP, Utilization and outcomes of unprotected left main coronary artery stenting and coronary artery bypass graft surgery, Ann Thor Surg: 2008: 86:1153- 9

144. Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG , Avezum A, R, AfzalR, Piegas LS, Faxon DP, Widimsky P, Budaj A, ChrolaviciusS, Rupprecht SJ, Jolly S, Granger CB, Fox KA, Bassand JPand Yusuf, for the OASIS 5 and 6 investigators. Antithrombotic therapy with Fondaparinux in Relation to Interventional Management Strategy in Patients with ST and non-ST Segment Elevation Acute Coronary Syndromes :An individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) Randomized Trials Circulation: 2008: 118:2038-46

145. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KAA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P Yusuf S, CURRENT OASIS 7 Steering committee, Design and rationale of CURRENT-OASIS 7: A randomized 2X2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patient s with ST and non-ST elevation acute coronary syndromes managed with an early invasive strategy, Am Heart J 2008;0:1-9.e1

146. Mehta SR, Horsman G, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolovicius S, Jolly S, Widimsty P, Avezum A, Rupprecht HJ, Zhu J, Col J, Matarajan MK, Fox KAA, Yusuf S, A randomized coparison of early versus delayed invasive management of acute coronary syndromes, New Eng J Med 2009;360:2165-75.

147. Jolly S, Faxon DP, Fox FAA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger C, Joyner CD, Chrolavicius S, Yusuf A, Mehta SR, Efficacy and safety of fondaparinux versus enoxaprin in patient with acute coronary syndromes treated with glycoprotein IIb IIIa inhibitors or thienopyridines:Resutls for the OASIS 5 trial, JACC 2009; 54: 468-76.

148. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, Afzal R, Chrolavicius S, Jolly SS, Widimsky P, Avezum A, Rupprecht HJ, Zhu J, Col J, Natarajan MK, Horsman C, Fox KA, Yusuf S; TIMACS Investigators. Early versus delayed invasive intervention in acute coronary syndromes N Engl J Med. 2009 May 21;360(21):2165-75.

149. The BARI 2D Study Group, A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009 Jun 11;360(24):2503-15. Epub 2009 Jun 7

150. Bangalore S, Vlachos HA, Selzer F, Wilensky RL, Kip KE, Williams DO, Faxon DP Percutaneous coronary intervention of moderate to severe calcified coronary lesions: Insights from the national heart, lung and blood institute dynamic registry.Catheter Cardiovasc Interv. 2010 Apr 30.

151. CURRENT-OASIS 7 Investigators, Dose comparisons of clopidogrel and asprin in acute coronary syndromes, New Eng J Med 2010: 363;930-42 A 53 David P. Faxon, M.D. Curriculum Vitae

152. Mehta S, Tanguay JF, Eikelboom JW, Jolly SS Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macoya C, Di Pasquale G, Neimela K, Ajani A, White HD, Chrolavicius S, Gao P, Fox KAA, Yusuf S, Double-dose versus standard-dose clopisogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7);: a randomized factorial trial, Lancet 2010:376:1233-43

153. Bangalore S, Vlachos HA, Selzer F, Wilensky RL, Kip KE, Williams DO, Faxon DP. Percutaneous coronary intervention of moderate to severe calcified coronary lesions: Insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv. 2011 Jan 1;77(1):22-8

154. Holper EM, Abbott JD, Mulukutla S, Vlachos H, Selzer F, McGuire D, Faxon DP, Laskey W, Srinivas VS, Marroquin OC, Jacobs AK. Temporal changes in the outcomes of patients with diabetes mellitus undergoing percutaneous coronary intervention in the National Heart, Lung, and Blood Institute dynamic registry. Am Heart J. 2011 Feb;161(2):397-403.e1

155. Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, Hueb W, Weiss M, Slater J, Frye RL Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Circulation. 2011 Apr 12;123(14):1492-500

156. Parikh SV, Saya S, Divanji P, Banerjee S, Selzer F, Abbott JD, Naidu SS, Wilensky RL, Faxon DP, Jacobs AK, Holper EM. Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). Am J Cardiol. 2011 Apr 1;107(7):959-64

157. Hamon M, Mehta S, Steg PG, Faxon D, Kerkar P, Rupprecht HJ, Tanguay JF, Afzal R, Yusuf S. Impact of transradial and transfemoral coronary interventions on bleeding and net adverse clinical events in acute coronary syndromes. EuroIntervention. 2011 May;7(1):91-7

158. Bangalore S, Kumar S, Poddar KL, Ramasamy S, Rha SW, Faxon DP. Meta-analysis of multivessel coronary artery revascularization versus culprit-only revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. Am J Cardiol. 2011 May 1;107(9):1300-10.

159. Lee MS, Faxon DP. Revascularization of left main coronary artery disease. Cardiol Rev. 2011 Jul-Aug;19(4):177-83

160. Chung SC, Hlatky MA, Faxon DP, Ramanathan D,Adler DA, Mooradian A, Rihal C, Bromberger JT,Kelsey SF,Brooks MM and the BARI 2D Study Group. The effect of age on clinical outcomes and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D), JACC 2011 Aug 16;58(8):810-9

161. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, A 54 David P. Faxon, M.D. Curriculum Vitae

Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011 Oct;106(4):572-84.

162. Bainey KR, Selzer F, Cohen HA, Marroquin OC, Holper EM, Graham MM, Williams DO, Faxon DP, Comparison of Three Age Groups Regarding Safety and Efficacy of Drug-Eluting Stents from the National Heart, Lung, and Blood Institute Dynamic Registry. Am J Cardiol. 2011 Oct 14.

163. Faxon DP. Transcatheter aortic valve implantation: coming of age. Circulation. 2011 Oct 25;124(17):e439-40.

164. Bainey KR, Selzer F, Cohen HA, Marroquin OC, Holper EM, Graham MM, Williams DO, Faxon DP. Comparison of three age groups regarding safety and efficacy of drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol. 2012 Jan 15;109(2):195-201

165. Faxon DP. Very late stent thrombosis and late target lesion revascularization: no end in sight. Circulation. 2012 Jan 31;125(4):562-4.

166. Faxon DP. Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012 Feb 1;79(2):181-97

167. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA; Technical Panel, Masoudi FA, Dehmer GJ, Patel MR, Smith PK, Chambers CE, Ferguson TB Jr, Garcia MJ, Grover FL, Holmes DR Jr, Klein LW, Limacher MC, Mack MJ, Malenka DJ, Park MH, Ragosta M 3rd, Ritchie JL, Rose GA, Rosenberg AB, Russo AM, Shemin RJ, Weintraub WS; Appropriate Use Criteria Task Force, Wolk MJ, Bailey SR, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Shaw L, Stainback RF, Allen JM; ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography.Coronary Revascularization Writing Group, American College of Cardiology Foundation; American College of Cardiology Foundation Appropriate Use Criteria Task Force; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Thoracic Surgery; American Heart Association; American Society of Nuclear Cardiology; Society of Cardiovascular Computed Tomography. J Thorac Cardiovasc Surg. 2012 Apr;143(4):780-803

168. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM; INFUSE-AMI Investigators. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.JAMA. 2012 May 2;307(17):1817-26.

169. Faxon DP, Williams DO. The changing face of interventional cardiology. Circ Cardiovasc Interv. A 55 David P. Faxon, M.D. Curriculum Vitae

2012 Jun;5(3):325-7

170. Faxon DP, Lawler E, Young M, Gaziano M, Kinlay S.Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv. 2012 Jun;5(3):372-80.

171. Gössl M, Faxon DP, Bell MR, Holmes DR, Gersh BJ. Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease. Circ Cardiovasc Interv. 2012 Aug 1;5(4):597-604

172. Siddiqi OK, Faxon DP. Very late stent thrombosis: current concepts. Curr Opin Cardiol. 2012 Nov;27(6):634-41.

173. Mulukutla SR, Marroquin OC, Vlachos HA, Selzer F, Toma C, Kip KE, Abbott JD, Holper E, Lee JS, Khandhar S, Kutcher M, Kelsey S, Smith C, Faxon D, Williams DO. Benefit of Long- Term Dual Anti-Platelet Therapy in Patients Treated With Drug-Eluting Stents: From the NHLBI Dynamic Registry. Am J Cardiol. 2012 Dec 1. ahead of print

174. Faxon DP. Changes in medical publishing: the challenges for an interventional journal. Circ Cardiovasc Interv. 2013 Feb;6(1):2-4.

175. Faxon DP. How to manage antiplatelet therapy for stenting in a patient requiring oral anticoagulants. Curr Treat Options Cardiovasc Med. 2013 Feb;15(1):11-20

176. Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group. Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. J Am Coll Cardiol. 2013 Feb 19;61(7):702-11

177. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Généreux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 4;368(14):1303-13

178. Faxon DP, Rihal C. A new series: Clinical Dilemmas in Interventional Cardiology. Circ Cardiovasc Interv. 2013 Oct 1;6(5):493.

179. Bangalore S, Faxon DP. The great taboo of non-infarct-related artery revascularization during primary percutaneous coronary intervention. Am Heart J. 2013 Oct;166(4):611-3

180. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F.Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013 Nov 8; 347:6625

A 56 David P. Faxon, M.D. Curriculum Vitae

181. Bainey KR, Rao-Melacini P, Tong W Steg PG, Faxon DP, Lamy A, Granger CB, Yusuf S Mehata SR fro the TIMACS Investigators The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study. J Med Econ. 2014 Jun;17(6):415-22. doi: 10.3111/13696998.2014.911184. Epub 2014 Apr 16.

182. Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart. 2015 Oct 1;101(19):1569- 76 183. Siddiqi OK, Smoot KJ KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart. 2015 Jul 24. 1569-76

185 Thukkani AK, Agrawal K, Prince L, Smoot KJ, Dufour AB, Cho K, Gagnon DR, Sokolovskaya G, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. J Am Coll Cardiol. 2015 Sep 8;66(10):1091-101.

186 Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med. 2015 Aug 13;373(7):610-20

187 Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, Ly S, Temiyasathit S, Faxon DP, Gaziano JM, Kinlay S. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease Heart. 2015 Oct;101(19):1569-76.

185 Creager,MA; Beckman,JA; Conte,MS, FAHA; Cushman,M; Faxon,DP; Hiatt, W; Hirsch,AT ; McDermott,MM; Bonaca,MP MD;Collins,T;Kaufman, JK; Olin,JW;Sadwin,L; Fordham- Duff,A;Grable, C; Hamburg,NM;Kahn,S; Powell, RJ; Spertus,J; Upchurch,GR ;Girgus,M;Wayte,PW;Peters,V; Sheehan, KA Improving Vascular Disease Detection and Treatment: A Roadmap for the American Heart Association- A Conference Report from the American Heart Association Vascular Disease Thought Leaders Summit 2015, AHA.org on line

188 Wimmer NJ, Dufour AB, Cho K, Gagnon DR, Quach L, Ly S, Do JM, Ostrowski S, Michael Gaziano J, Faxon DP, Kinlay S. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting. Catheter Cardiovasc Interv. 2016 Nov 10. doi: 10.1002/ccd.26831

189 Vaduganathan M, Qamar A, Singh A, Venkateswaran RV, Szumita PM, Croce KJ, Mauri L, Leopold JA, Shah PB, Sobieszczyk P, Faxon DP, Bhatt DL., Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. J Am Coll Cardiol. 2016 Nov 23. pii: S0735-1097

A 57 David P. Faxon, M.D. Curriculum Vitae

190 Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group. SYNTAX Score and Long- Term Outcomes: The BARI-2D Trial. J Am Coll Cardiol. 2017 Jan 31;69(4):395-403.

Reviews, Chapters and Editorials:

1. Ryan TJ, Faxon DP, Weber VJ, Haudenschild C, Gottsman SB, McGovern WA. Acute and chronic effects of transluminal angioplasty in three models of experimental atherosclerosis. In: Kaltenbach M, editor, Transluminal Coronary Angioplasty and Intracoronary Thrombolysis, Heidelberg, Springer-Verlag, 1982:185-188.

2. Fryquist F, Faxon DP, Williams G, Leibau G, Coreg L, Bunhouse SP, Mimran A. Heart failure in the community. Wood C, Rue Y, (Eds) Royal Society of Medicine, Forum Series 6, 1982. (Pages not available)

3. Faxon DP. Percutaneous Transluminal coronary angioplasty and thrombosis: State of the art. Lahey Clinic Found Bull 1983; 32(1):9-16.

4. Faxon DP, Jacobs AK, McSweeney SM, Coats WD, Kellett MA, Ryan TJ. Coronary sinus assessment of left ventricular pressure in man. In: Mohl W, editor, Myocardial Protection via the Coronary Sinus, Vienna, Steinkopff 1984:424-429.

5. Jacobs AK, Faxon DP, Apstein CS, Coats WD, Gottsman SB, Ryan TJ. The hemodynamic consequences of coronary sinus occlusion. In: Mohl W, editor, Myocardial Protection via the Coronary Sinus, Vienna, Steinkopff 1984:430-436.

6. Jacobs AK, Faxon DP, Mohl W, Coats WD, Gottsman SB, Ryan TJ. The effect of pressure- controlled intermittent coronary sinus occlusion during ischemia. In: Mohl W, editor, Myocardial Protection via the Coronary Sinus, Vienna, Steinkopff 1984:483-489.

7. Baim DS, Faxon DP. Coronary Angioplasty. In: Grossman B editor, Cardiac Catheterization and Angiography, Philadelphia, Lea and Feiberger, JP Lippincott, 1985:473-493.

8. Faxon DP, Kellett MA, Sanborn TA. Transluminal coronary angioplasty - balloon and laser techniques. In: Weiner D, Frishman W, editors, Angina Pectoris Therapy, New York, Marcel Dekker Inc., 1986:225-285.

9. Faxon DP. Pros and cons - coronary sinus interventions vs. conventional therapy. In: Mohl W, Faxon D, Wolner E, editors, CSI - A New Approach to Intervention Cardiology , New York, Springer-Verlag, 1986:84-90.

10. Faxon, DP. Pathophysiologic considerations of transluminal angioplasty. In: Jang, GG, editor, Transluminal Angioplasty, McGraw-Hill, New York 1986:409-416.

11. Faxon DP, Hugenholtz PG. Pros and cons for coronary sinus interventional versus conventional A 58 David P. Faxon, M.D. Curriculum Vitae

therapy. In: Mohl W, Faxon DP, editors, Clinics of CSI, New York, Springer-Verlag, 1986:380- 390.

12. Faxon DP. Summary Statement - PICSO. In: Mohl W, Faxon DP, editors, Clinics of CSI, New York, Springer-Verlag, 1986:379-381.

13. Faxon DP. Selection of patients for myocardial revascularization. In: Roberts A, Conti R, editors, Advances in Cardiovascular Surgery, Philadelphia, JB Lippincott1987:179-188.

14. Faxon DP. Current status of coronary angioplasty. (Review) Hospital Practice 1987;22:59-71

15. Faxon DP. What is responsible for restenosis early after successful PTCA? Choice in Cardiology 1988;2:108-11.

16. Faxon DP, Jacobs AK. Coronary sinus retroperfusion and intermittent occlusion. In: Topol E, editor, Acute Coronary Intervention, New York, Alan R Liss, Inc., New York, 1988:255-269.

17. Faxon DP. ACE inhibitor for the failing heart: Experience with Captopril. Am Heart J 1988;115:1085-93.

18. Faxon DP. Case Records of the Massachusetts General Hospital Weekly Clinicopathological Exercise. Case #61987. New Eng J Med 1988;316(6): 321-CPC.

19. Faxon DP. Coronary Angioplasty: Present status and future directions. (Review) J Jap Ath Soc 1989;17:91-4.

20. Garber G, Faxon DP. Percutaneous revascularization: New developments. (Review) Choices in Cardiology1989;3(5): 242-5.

21. Faxon DP. The impact of interventional techniques in the practice of cardiology. (Review) Keio J Med 1989;38(1): 60-4.

22. Faxon DP. Probing the frontiers of angioplasty. (Editorial) Mayo Clin Proc 1989;64:360-2.

23. Currier JW, Faxon DP. Coronary angioplasty for the treatment of unstable angina. Cardiology 1990;4(1): 112.

24. Jacobs AK, Faxon DP. Retroperfusion and PTCA. In: Topol EJ, editor, Textbook of Interventional Cardiology, Orlando, Florida, WB Saunders Co., 1990:477-496.

25. Haudenschild CC, Sanborn TA, Stroh J, Faxon DP. Alternative Angioplasty: Laser, heat probes, atherectomy. In: Imaging and Intervention in the Cardiac Catheterization Laboratory: New Directions, Freedman Publ Inc: 1991.

26. Faxon DP. Percutaneous coronary angioplasty in stable and unstable angina. In: Abrams J, editor, Cardiology Clinics 1991:9:99-113

A 59 David P. Faxon, M.D. Curriculum Vitae

27. Bilazarian SD, Faxon DP, Jacobs AK. Circulatory support devices in clinical cardiology: Coronary sinus retroperfusion - A Critical Review. Cor Art 1991;2:640-8.

28. Faxon DP. Case records of the Massachusetts General Hospital weekly Clinicopathological Exercise. New Engl J Med 1991;324(12):831-40.

29. Kar S, Jacobs AK, Faxon DP. Synchronized coronary sinus retroperfusion during coronary angioplasty. In: Shawl F, editor, Supported Complex and High Risk Coronary Angioplasty, Boston, Massachusetts, Kluwer Academic Publisher, 1991:215-230

30. Faxon DP. Percutaneous coronary angioplasty in stable and unstable angina. Cardiol Clin 1991;1:99-113.

31. Faxon DP, King SB, Holmes D, Dorros G, Hartzler G. The ABC's of coronary angioplasty: Have we simplified it too much? (Editorial) Cath and CV Diag 1992;25:1-3.

32. Currier JW, Haudenschild CC, Faxon DP. Pathophysiology of restenosis: Clinical implications. In: Strategies in Primary and Secondary Prevention of Coronary Disease, Munich, Zuckschwerlt Verlag, 1992:181-192.

33. Landau C, Faxon DP. Acronyms in angioplasty and restenosis: A summary of recent and ongoing clinical randomized trials. J Invasive Card 1992;5:1:29-37.

34. Faxon, DP. Restenosis after angioplasty. What have we learned from clinical trials? (Review) Card in Review 1993;1(4): 209-17.

35. Franklin SM, Faxon DP. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Cor Art Dis 1993;4:232-42.

36. Currier JW, Faxon DP. Animal models of restenosis. In: Schwartz R, editor Coronary Restenosis, Cambridge, Mass, Blackwell Seventieth Publication, 1993:294-325.

37. Faxon DP, Balcon R. Angiotensin converting enzyme inhibition in the prevention of restenosis: The MERCATOR and MARCATOR trials. In: Reiber J, editor, Coronary Angioplasty, Dordrecht, Kluwer Academic Publisher, 1993:365-372.

38. Faxon DP. Introduction and historical background. In: Faxon, D, editor, Practical Angioplasty, New York, NY, Raven Press, Ltd., 1994:1-4.

39. Faxon DP. Mechanisms of angioplasty and pathophysiology in restenosis. In Faxon, D, editor, Practical Angioplasty, New York, NY, Raven Press, Ltd 1994:5-12.

40. Faxon DP. Selection of balloon catheters. In: Faxon, D, editor, Practical Angioplasty, New York, NY, Raven Press, Ltd., New York, NY, 1994:53-70.

41. Faxon DP, Ryan TJ. Medical management of coronary artery disease after angioplasty and thrombolytic therapy. Adv Internal Med 1994;39:435-65. A 60 David P. Faxon, M.D. Curriculum Vitae

42. Mehra A, Faxon DP. Current status of percutaneous transluminal coronary angioplasty. Curr Probl Cardiol 1994:5:231-83.

43. Goldstein S, Pearson TA, Colwill JM, Faxon DP, Fletcher RH, Moodie DS. Task Force 4: The relationship between cardiovascular specialists and generalists. ACC 25th Bethesda Conference. J Am Coll Cardiol 1994;24:275-328.

44. Faxon DP. Saphenous Vein Graft Angioplasty. Interventional Cardiology Newsletter 1994;2:17-22.

45. Faxon DP. Coronary angioplasty for stable angina pectoris. In: Beller G, Braunwald E, editors, Atlas of Heart Diseases: Volume 5 Chronic Ischemic Heart Disease, New York, NY, Mosby, 1995:9.2-9.17.

46. Vetrovec, GW and the Trustees of The Society for Cardiac Angiography and Interventions. Editorial: Right sizing interventional training: a statement by the Society for Cardiac Angiography and Interventions. Catheterization and Cardiovascular Diagnosis 1995;35:89-90.

47. Faxon DP. Complete vs. incomplete revascularization. In: Ellis & Holmes, editors, Strategic Approaches in Coronary Intervention, Baltimore, MD, Williams & Wilkins, 1995:444-454.

48. Holmes DR, Faxon DP. Current antiplatelet and antithrombotic medications for interventional procedures. In: Ellis & Holmes, editors, Strategic Approaches in Coronary Intervention, Baltimore, MD, Williams & Wilkins, 1995:663-667.

49. Faxon DP, Currier JW. Prevention of Post-PTCA Restenosis in Atherosclerosis III: Recent Advances in Atherosclerosis Research Numano F, Wissler R (eds) from presentations at Third Saratoga International Conference on Atherosclerosis, published by Annals of the New York Academy of Sciences, New York, NY 1995;Vol 78 pgs 419-27.

50. Currier JW, Faxon DP. Restenosis after percutaneous transluminal coronary angioplasty: Have we been aiming at the wrong target? J Amer Coll Cardiol 1995;25:516-20.

51. Faxon DP. Management of acute angioplasty complications: Revisitation. ACC Current Journal Review 1996;5:15-7.

52. Lau SK, Faxon DP. Restenosis in coronary artery intervention. In: Bertrand, Serruys & Sigwart, editors, Handbook of Cardiovascular Interventions, London U.K; Churchill Livingstone: 1996:97- 112.

53. Faxon DP. Thrombolytic therapy versus primary PTCA: Which offers the best outcome after myocardial infarction? Postgraduate Medicine 1997; 102:97-110.

54. Faxon, DP. Identifying the Predictors of Restenosis. Do We Need Glasses? (Editorial) Circulation 1997;95:2244-6.

55. Faxon DP, Coats W, Currier J. Remodeling of the coronary artery after vascular injury. Progress in A 61 David P. Faxon, M.D. Curriculum Vitae

Cardiovascular Diseases 1997;40:129-40.

56. Faxon, DP. Revascularization in Diabetics: Lessons from the BARI Trial. Cardiology in Review, 1997:102-7

57. Faxon DP. The cardiac catheterization laboratory: set-up and management. In: Uretsky, B, editor, Cardiac Catheterization - Concepts, Techniques, and Applications, Cambridge, MA: Blackwell Scientific Publications, Inc.; 1997:63-93.

58. Faxon DP, Currier J. Pharmacologic perspectives of remodeling inhibition. In: Lafont, Topol, editors, Arterial Remodeling: A Critical Factor in Restenosis, Norwell, MA: Kluwer Academic Publishers;1997:519-534.

59. Faxon DP, Borst C. Remodelling: historical perspectives and definition of terms, Seminars in Interventional Cardiology 1997;2:3, 145-6.

60. Coats WD, Currier JW, Faxon DP. Remodelling and restenosis: insights from animal studies. Seminars in Interventional Cardiology 1997;2:3,153-8.

61. Coats WD, Faxon DP. The role of the extracellular matrix in arterial remodelling. In: Seminars in Interventional Cardiology 1997;2:3,167-76.

62. Faxon DP. Myocardial revascularization in 1997: Angioplasty versus bypass surgery. American Family Physician 1997;56:1409-18.

63. LaFont A, Faxon DP. Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? (Review) Cardiovasc Res 1998;39:50-9.

64. Holmes DR, Hirshfeld J, Faxon DP, Vlietstra RE, Jacobs A, King SB. ACC Expert Consensus Document on Coronary Artery Stents. J Am Coll Cardiol 1998;32:1471-82.

65. Faxon DP, Liprie SF. The Angiorad Gamma Wire System. In: Waksman R, editor, Vascular Brachytherapy, Second Edition , NY, NY: Futura Publishing Company, Inc.;1998:553-559.

66. Faxon DP (AHA Scientific Publishing Committee Chair). AHA journals lead with definitive new online site. (Editorial) Circulation 1998;98:1047.

67. Lafont A, Faxon DP. Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? (Review) Cardiovasc Res 1998;39:50-9.

68. Faxon DP. AHA journals lead with definitive new online site. Stroke 1998;29:2013.

69. Faxon DP, Dave R. Radiation for Restenosis: An Overview. In: Holmes DR, editor, Current Interventional Cardiology Reports:1999;1:1-8.

70. Faxon DP, Heger JW. Primary angioplasty – enduring the test of time (editorial). N Eng J Med 1999;341:1464-5. A 62 David P. Faxon, M.D. Curriculum Vitae

71. Mehra A, Faxon DP. Is primary angioplasty the best treatment for AMI in the elderly? Am J Geriatric Cardiol 1999;8:282-8.

72. Durairaj A, Mehra A, Singh RP, Faxon DP. Therapeutic angiogenesis. Cardiology in Review 2000;8:279-87.

73. Faxon DP. Predicting restenosis: Bigger is better but not best (editorial). Circulation 2000;101:946- 7.

74. Faxon DP. Catheterization and Angiography. In: Goldman, Bennett, editors, Cecil Textbook of Medicine, 21st Edition, Philadelphia, PA: W.B. Saunders Company; 2000:204-207.

75. Faxon DP, Christodoulou C. Complete vs. incomplete revascularization. In: Ellis & Holmes, editors, Strategic Approaches in Coronary Intervention, Second Edition, , Baltimore, MD: Lippincott Williams & Wilkins; 2000:374-381.

76. Mody V, Faxon DP. Update on the management of unstable angina. Rev Cardiovasc Med 2000;1:104-19.

77. Mody VH Faxon DP Management of unstable angina: integrating the new approaches. Rev Cardiovasc Med. 2000 ; 1: 104-19

78. Faxon DP. AHA announces editor designee for Stroke. Stroke 2000;31:1.

79. Kereiakes DJ, Smith SC, Jacobs AK, Kern MJ, Faxon DP. Angioplasty for acute myocardial infarction in community hospital without surgical back up: response to Wharton and Angelini publications “should guidelines be changed? – Not whether but when.” J Amer Coll Cardiol 2000;36:299-303.

80. Creager MA, Faxon DP, Fonarow, GC, Gersh B, Hachamovitch R, Jacobs A, Lepor N, Pandian N, Vogel R, Weyman A, Yeung A, Best of the AHA Scientific Sessions 2000. Highlights from the American Heart Association Scientific Sessions 2000, November 12-15, 2000, New Orleans, LA. Rev Cardiovasc Med 2000; 2:6-24.

81. Faxon, DP, Fonarow GC, Gross S, Creager M, Hachamovitch R, Jacobs A, Lepor N, Prykowsky E, Nesto R, Shah P, Vogel R, Yeung A Best of the ACC Scientific Session 2001. Highlights from the American College of Cardiology 50th Annual Scientific Session, March 18-21, 2001, Orlando, FL. Rev Cardiovasc Med 2001;1001; 3:143-59. Meeting review.

82. Jolly N, Faxon DP. Multivessel PCI: Pros and Cons of Staged Procedures. ACC Current Journal Review 2001;10:64-6.

83. Faxon DP. Stenting plus abciximab vs. tPA in acute myocardial infarction. Rev Cardiovasc Med. 2001; 2(2): 107-8.

84. Faxon DP, Lenfant C. Timing is everything. Motivating patients to call 9-1-1 at onset of acute A 63 David P. Faxon, M.D. Curriculum Vitae

myocardial infarction. (Editorial) Circulation 2001;104:1210-1.

85. French M, Faxon DP. Update on radiation for restenosis. Rev Cardiovas Med 2001;3:1-6.

86. Fusman B, Faxon DP, Feldman T. Hemodynamic rounds: Transvalvular pressure gradient measurement. (Review) Cath & Cardiovasc Interventions. 2001;53:553-61.

87. Feeney T, Faxon DP. Defining the Clinical Problem. In: Faxon, editor, Restenosis: A Guide to Therapy, London, UK: Martin Dunitz Ltd; 2001:1-8.

88. Arimie R, Faxon DP. In-stent restenosis. In: Surreys, Leon, Colombo, Kurt, editors, Coronary Lesions: A Pragmatic Approach, London, UK: Martin Units Limited; 2001:131-140.

89. Faxon DP. Pathophysiology, pharmacology and patient factors in restenosis. In: Colombo, Meier, DiMario, editors, The Year in Interventional Cardiology 2001, Oxford, UK: Nova Professional Media; 2001:124-35

90. Faxon DP Biodegradable stents: are they finally here? Rev Cardiovasc Med. 2001 Spring; 2(2):106- 7.

91. French MH, Faxon DP. Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. Rev Cardiovasc Med. 2002 Fall; 3(4):176-82.

92. Faxon DP. Restenosis: Do we need to understand it to treat it? (Editorial) J Am Coll Cardiol 2002;40(12):2090-1.

93. French M, Faxon, DP. Current anticoagulation options in percutaneous intervention: Designing patient specific strategies. Rev Cardiovasc Med 2002;3(4):176-82.

94. Faxon DP. Pathophysiology, pharmacology and patient factors in restenosis. In: White, de Feijter, Meier, Colombo, Banning, Schrader, editors, The Year in Interventional Cardiology – 2002, Oxford, UK: Clinical Publishing Services, Ltd; 2002:177-188.

95. Faxon DP. Revascularization in diabetes: have stents made a difference? Rev Cardiovasc Med. 2002 ;3(1):60-2.

96. Smith SC, Faxon DP, Cascio W, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease Writing Group VI: Revascularization in diabetic patients. Circulation 2002;105:165-9.

97. Mak KH, Faxon DP. Clinical Studies on Coronary Revascularization in Patients with Type 2 Diabetes. Euro J Cardiol.2003;24:1087-103

98. Califf RM, Faxon DP. The need for centers for patients with acute coronary syndromes. Circulation 2003;107:1467-70

99. Holper EM, Faxon DP. Percutaneous coronary intervention in women. J Am Med Womens Assoc. 2003 l;58(4):264-71. A 64 David P. Faxon, M.D. Curriculum Vitae

100. Holper EM, Faxon DP. Percutaneous coronary intervention in women. J AM Med Womens Assoc. 2003;58(4):264-71.

101. Bettman M, Costa F, Faxon DP, Robertson RM, Mentoring concerns in clinical cardiovascular science. In: Alpert J, AHA Mentoring Handbook, American Heart Association National Center, Dallas Tx 2003, p 49-63

102. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.Circulation. 2003 Oct 7;108(14):1664-72.

103. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.Circulation. 2003 Oct 14;108(15):1772-8.

104. Faxon DP. Catheterization and angiography. In: Goldman, Bennett, editors, Cecil Textbook of Medicine, 22nd Edition, Philadelphia, PA: W.B. Saunders Company; 2004: 287-90

105. Faxon DP. Beta-blocker therapy and primary angioplasty: what is the controversy? (Editorial) J Am Coll Cardiol.2004 May 19;43(10):1788-90.

106. Bonow RO, Zipes DP, Anderson JL, Cheitlin MD, Goldstein LB, Grant AO, Faxon DP, Lima JA, Robertson RM. Task force 5: Expert testimony and opinions. J Am Coll Cardiol. 2004 Oct 19;44(8):1747-9. Review.

107. Casey C, Faxon DP. Multi-vessel coronary disease and percutaneous coronary intervention. Heart. 2004 Mar;90(3):341-6.

108. Faxon DP. Bringing reality to drug-eluting stents. Circulation. 2004 Jan 20;109 (2):140-2.

109. Faxon DP. Highlights from the European Society of Cardiology Congress, August 28-September 1, 2004, Munich, Germany, Rev Cardiovascular Med. 2004;5(4):223-5.

A 65 David P. Faxon, M.D. Curriculum Vitae

110. Faxon DP. Beta-blocker therapy and primary angioplasty: what is the controversy? (Ed) J Am Coll Cardiol. 2004 May 19;43(10):1788-90.

111. Bokhari SW, Faxon DP Current advances in the diagnosis and treatment of renal artery stenosis Rev Cardiovasc Med. 2004 ;5(4):204-15.

112. Faxon DP, Creager MA, Smith SC Jr, Pasternak RC, Olin JW, Bettmann MA, Criqui MH, Milani RV, Loscalzo J, Kaufman JA, Jones DW, Pearce WH; American Heart Association. Atherosclerotic vascular disease conference: executive summary: atherosclerotic vascular disease conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004 Jun 1;109(21):2595-604.

113. Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, rundback JH, Fabunmi RP, Robertson RM, Loscalzo J; American Heart Association. Atherosclerotic vascular disease conference: Writing Group III: Pathophysiology. Circulation. 2004 Jun1;109(21):2617-25.

114. Casey C, Faxon DP. Multi-vessel coronary disease and percutaneous coronary intervention. Heart. 2004,90(3):341-6

115. Faxon DP. Can Beta Blocker use lower mortality and improve myocardial tissue recovery after acute myocardial infarction? Nature Clinical Practice Cardiovascular Medicine 2004;1,14-5

116. Faxon DP. Treating In-stent Restenosis with Drug Eluting Stents: When should they be used? SA Heart 2004;1(4):34-44.

117. Faxon DP. Early reperfusion strategies after acute ST-segment elevation myocardial infarction: the importance of timing. Nature: Clinical Practice: Cardiovascular Medicine 2005;2:(1) 22-9.

118. Faxon DP, Jacobs AK, Lepor NE, Yeung AC. Best of TCT 2005. Rev Cardiovasc Med. 2005 fall;6(4):214-21.

119. Faxon DP, Coronary interventions and their impact on post myocardial infarction survival Clin Cardiol 2005;289(Suppl. I):I-38-I-44

120. Hong TE, Faxon DP, Coronary artery disease in patients with Bergers Disease, Rev Cardiovasc Med 2005;6:222-6

121. Faxon DP Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices, Rev in CV Medicine 2005;6(suppl 4):S3-S14.

122. Faxon DP, Johnson DA, Critical GI issues for the cardiologist:new insights and understanding. Introduction Rev Cardioovasc Med 2005;6 suppl 4:S1-2

123. Faxon DP, Nesto RW, Antiplatelet therapy in populations at high risk for atherothrombosis, (Review) J Natl Med Ass: 2006 May;98(5):711-21

A 66 David P. Faxon, M.D. Curriculum Vitae

124. Faxon DP Efficacy of beta blocker usage post-percutaneous coronary intervention J Inv Card 2006; 18 (Supp B):4B-7B

125. Kerieakes DJ, Faxon DP, Left main coronary revascularization at the crossroads (Editorial), Circ 2006; 113: 2480-84

126. Bashore Tm, Faxon DP, Fonarow GC, Gersh BJ, Jacobs AK, Kandzari DE, Lepor NE, Shah PK Watson KE, Weber MA, Meeting Review: Best of the ACC scientific Sessions 2006, Rev Cardiovasc Med 2006; 7:84-101

127. Borden WB, Faxon DP, Facilitated percutaneous coronary intervention, JACC 2006; 48:1120-8

128. Faxon DP, Antithrombotic agents: Fondaprinux in acute coronary syndromes: improved safetly and efficacy, Rev Cardiovasc Med 2006;7:166-7

129. Faxon DP, Nesto RW, The CHARISMA and REACH Registry, J Natl Med Ass 2006; 98:1713

130. Singh PP, Nesto Rw, Faxon DP, Lepor Ne, Watson KE, Jacobs AK, McCullogh PA, Best of the AHA Scientific Sessions 2006. Rev Cardiovasc Med. 2007 Winter;8(1):25-35.

131. Faxon DP, Antithrombotic agents. Fondaparinux in acute coronary syndromes: improved efficacy and safety. Rev Cardiovasc Med. 2006 Summer;7(3):166-7.

132. Faxon DP, Jacobs AK, Strategies to Improve Early Referfusion in ST-Elevation Myocardial Infarction. Rev Cardiovasc Med. 2007;8(3):127-134.

133. Faxon DP, Development of systems of care for ST-elevation myocardial infarction patients: current state of ST-elevation myocardial infarction care. Circulation. 2007 Jul 10;116(2):e29-32.

134. Faxon DP, New perspectives on reperfusion in ST-segment elevation myocardial infarction, Acute Coronary Syndromes 2007; 8:83-89

135. Faxon D, Brown M, The use of antiplatelet therapy in the post-discharge medical management of patients with acute coronary syndromes, Am J Med 2008;121(3):170-178

136. Faxon DP. Catheterization and angiography. In: Goldman, Bennett, editors, Cecil Textbook of Medicine, 23nd Edition, Philadelphia, PA: W.B. Saunders Company; 2007

137. Faxon DP, Kinlay S, Stable angina and silent ischemia-ACC/AHA guideline synopsis. In: CathSAP 3, ed Moliterno DJ, ACCF, Washington ,DC 2007

138. Kakkar R, Sobieszczyk P,Binkert CA, Faxon DP, Mortele KA, Singh AJ, Prevention of Intravenous Contrast Induced Nephropathy in Hospital Inpatients Critical Pathways in Cardiology 2008:7:1-4

139. Faxon DP, New data on early management of patients with ST elevation myocardial infarction, Curr A 67 David P. Faxon, M.D. Curriculum Vitae

Cardiol Rep. 2008 Jul;10(4):291-8

140. Faxon DP, Assessing appropriateness of coronary angiography: another step in improving quality. Ann Intern Med. 2008 Aug 19;149(4):276-8

141. Faxon DP, Circulation:Cardiovascular Interventions, keeping pace with progress Circ Cardiovasc Intervent 2008:1:1-2

142. Flaherty JD, Davidson CJ, Faxon DP Percutaneous coronary interventions for myocardial infarciton with left ventricular dysfunction Am J Cardiol 2008;102:38G-41G

143. Bettman MA, Costa F, Faxon DP, Robertson RM, Mentoring concerns in clinical cardiovascular science in Mentoring Handbook second Edition, American Heart Association, Dallas Texas, 2008, page 47-65

144. Faxon DP, Freedman J, Facts and Controversies of aspiring and clopidogrel therapy Am Heart J 2008; 157:412-22

145. Jones DW, Peterson ED, Bonow RO, Givvons RJ, Franklin BA, Sacco RL, Faxon DP, Buffalino VJ, Redberg RF, Metzler NM, Grigus M, Rogers K, Wayte p, Gardner TJ, Partnering to reduce risks and improve cardiovascular outcomes:Americn Heart Association initiaties in action for consumers and patients, Circ 2009; 119: 340-50

146. Faxon DP, The Many Costs of Bleeding. Ed. J Interv Cardiol. 2009 Jun;22(3):274-6.

147. Faxon DP, Women are like men-sometimes. Ed, JACC 2009 Nov 17;54(21):1946-8.

148. Faxon DP, SYNTAX and CARDia trials: Have they defined the role of PCI in multivessel disease? Ed. www.InCirculation.net 12.17.09

149. Lamas GA, Escolar E, Faxon DP, Examing treatment of ST-elevation myocardial infrction:The importance of early intervention, J Cardiovasc Pharm and Therapeutics 2010 (Mar);15(1):6-16.

150. Faxon DP, Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.Nat Rev Cardiol. 2010 Mar;7(3):124-5

151. Faxon DP, Holmes D, Periprocedural MI following PCI, Up-to-Date 2010;

152. Leopold JA, Faxon DP, Diganostic cardiac catheterization and coronary angiography. In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, March 2010

153. Faxon DP, Bhatt DL, Percutaneous Coronary Interventions and other interventional procedures, In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, March 2010

154. Leopold JA, Bhatt DL, Faxon DP, Atlas of percutaneous interventions. In Fauci, Braunwald, A 68 David P. Faxon, M.D. Curriculum Vitae

Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, March 2010

155. Bangalore SV, Faxon DP, Coronary Intervention in Patients With Acute Coronary Syndrome: Does Every Culprit Lesion Require Revascularization, Curr Cardiol Rep. 2010 Jul;12(4):330-7

156. Lee M-S, Faxon DP. Revascularization for left main coronary artery disease. Cardiology in Review 2011; 19:177-83

157. Faxon DP, Optimizing Antiplatelet therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention Cath CV Inter 2011: May 26

158. Winston B, Faxon DP, ST-Elevation Myocardila Infarction: ACC/AHA Guidelines in 1001 Questions: An interventional cardiology board review , ed Muckerjee D, Cho L, Molityerno DJ, LWW :

159. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011;106:572-84

160. Faxon DP, Eikelboom JW, Berger PB, Holmes DR Jr, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv. 2011 Oct 1;4(5):522-34.

161. Faxon DP. Transcatheter aortic valve implantation: coming of age.Circulation. 2011 Oct 25;124(17):e439-40.

162. Faxon DP Very Late Stent Thrombosis and Late Target Lesion Revascularization: No End in Sight. Circulation. 2011 Dec 27.

163. Faxon DP, Kinlay S, Stable angina and silent ischemia-ACC/AHA guideline synopsis. In: CathSAP 4, ed Moliterno DJ, ACCF, Washington ,DC 2012: 2013

164. Gössl M, Faxon DP, Bell MR, Holmes DR, Gersh BJ. Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease.Circ Cardiovasc Interv. 2012 Aug 1;5(4):597-604

165. Faxon DP, Williams DO.The changing face of interventional cardiology.Circ Cardiovasc Interv. 2012 Jun;5(3):325-7.

166. Siddiqi OK, Faxon DP.Very late stent thrombosis: current concepts.Curr Opin Cardiol. 2012 Nov;27(6):634-41.

167. Faxon DP., How to Manage Antiplatelet Therapy for Stenting in a Patient Requiring Oral Anticoagulants.Curr Treat Options Cardiovasc Med. 2012 Nov 20.

A 69 David P. Faxon, M.D. Curriculum Vitae

168. Bohula May EA, Faxon DP, Transcatheter Aortic Valve Replacment: Hisory and Current Status, Trends Cardiovasc Med. 2013 Jan 30

169. Faxon DP. Changes in medical publishing: the challenges for an interventional journal.Circ Cardiovasc Interv. 2013 Feb 1;6(1):2-4.

170. Leopold JA, Faxon DP, Diganostic cardiac catheterization and coronary angiography. In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, 2013 in press

171. Faxon DP, Bhatt DL, Percutaneous Coronary Interventions and other interventional procedures, In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, 2013 in press

172. Leopold JA, Bhatt DL, Faxon DP, Atlas of percutaneous interventions. In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, 2013 in press

173. Rubboli A, Faxon DP, Schlitt A, Lip GYH, General Aspects inPercutaneous Coronary Intervention inthe Patient on Oral Anticoagulation Ed Rubboli A, Edeechout E, Lip GYH, Oxford Unversity Press, Oxford UK, 2013

174. Berry N, Faxon DP, Focused Reveiw: Lessons from the PARTNERS Trial: Cost effectiveness of TAVR in Heart Disease, ed Braunwald E, Elsevier, Philadelphia, 2014; in press

175. Faxon DP, Comment on Assessment of Coronary Blood Flow in the Cardiac Catheterization Laboratory, Current Problems in Cardiology, 2014: in press

176. Huang PS,Faxon DP, Native and Prosthetic Valve Stenosis, in Multimodality Imaging for Transctheter Aortic Calve Replacement ed by Min JM, Berman DS, Leipsic J, Springer New York 2014

177. Faxon DP, Rihal C A new series: Clinical Dilemmas in Interventional Cardiology Circ Cardiovasc Interv 2013;6:493

178. Faxon DP, Variability in the use of invasice services: sign of poor quality of care or an opportunity to improve care? Cir Cardiovas Interv 2014;7:133-5

179. Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marín F, Bhatt DL, Lip GY. Thromb Haemost. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview. Thromb Haemost. 2014 Dec;112(6):1080-7.

180. Leopold JA, Faxon DP, Diganostic cardiac catheterization and coronary angiography. In A 70 David P. Faxon, M.D. Curriculum Vitae

Fa uci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, 2015

181. Faxon DP, Bhatt DL, Percutaneous Coronary Interventions and other interventional procedures, In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, 2015

182. Leopold JA, Bhatt DL, Faxon DP, Atlas of percutaneous interventions. In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, 2015

183. Faxon DP, Guidelines and appropriateness criteria for interventional cardiology in Bhatt, DL, Interventional Cardiology: A Companion to Braunwald’s Heart Disease Elsevier, Philadelphia, PA 2015

184. Faxon DP. Coronary venous interventions: failed strategy or inadequately explored? Circ Cardiovasc Interv. 2015 May;8(5)

185. Cavender MA, Faxon DP. Can BRIGHT restore the glow of bivalirudin? JAMA. 2015 Apr 7;313(13):1323-4.

186. Faxon DP, Williams DO Interventional Cardiology: Current Status and Future Directions in Coronary Disease and Valvular Heart Disease. Circulation. 2016 Jun 21;133(25):2697-711

187. Faxon DP, Burgess A Cardiovascular Registries: Too Much of Good Thing? Circ Cardiovasc Interv. 2016 Apr;9(4):e003866

188. Faxon DP. The BIOSOLVE II trial: a step forward for the bioresorbable scaffold? Eur Heart J. 2016 Sep 14;37(35):2710-2.

189. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. Circ Cardiovasc Interv. 2016 Nov;9(11). pii: e004395

190. Leopold JA, Faxon DP, Diganostic cardiac catheterization and coronary angiography. In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, Update 2017

181. Faxon DP, Bhatt DL, Percutaneous Coronary Interventions and other interventional procedures, In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, Update 2017

A 71 David P. Faxon, M.D. Curriculum Vitae

182. Leopold JA, Bhatt DL, Faxon DP, Atlas of percutaneous interventions. In Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo, editors, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw Hill, New York, Update 2017

Books, Monographs and Textbooks:

1. Mohl W, Faxon D, Wolner E, editors, CSI - A New Approach to Interventional Cardiology, New York, Springer-Verlag1986.

2. Mohl W, Faxon DP, editors, Clinics of CSI, New York, Springer-Verlag, 1986.

3. Faxon DP, editor, Practical Angioplasty, New York, Raven Press, 1994.

4. Faxon, DP, editor, Restenosis: A Guide to Therapy, London, UK, Martin Dunitz Ltd., 2001.

Practice Guidelines:

1. Conti CR, Faxon DP, Greuntzig A, Gurner RM, Lesch M, Reves TJ. Task force III: Training in cardiac catheterization, 17th Bethesda Conference, Adult Cardiology Training. J Am Coll Cardiol 1986;7:1205-06.

2. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, Loop FD, Peterson KL, Reaves TJ, Williams DO, Winters W. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 1988;12:529-45.

3. Cowley MJ, Faxon DP, Holmes DR. Guidelines for training, credentialing, and maintenance of competence for the performance of coronary angioplasty: A report from the Interventional Cardiology Committee and the Training Program Standards Committee of the Society for Cardiac Angiography and Interventions. Cath and Card Diag 1993;30:1-4.

4. Hirshfeld JW Jr, Ellis SG, Faxon DP. Recommendations for the assessment and maintenance of proficiency in coronary interventional procedures: Statement of the American College of Cardiology. J Am Coll Cardiol 1998;31:722-43.

5. Scanlon PJ, Faxon DP (co-chairs) and the Committee on Coronary Angiography. ACC/AHA Guidelines for Coronary Angiography. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999;3:1756-1824.

6. Scanlon PJ, Faxon DP (co-chairs) and the Committee on Coronary Angiography. ACC/AHA A 72 David P. Faxon, M.D. Curriculum Vitae

Guidelines for Coronary Angiography: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 1999;99:2345-57.

7. Hirshfeld JW Jr, Banas JS Jr, Brundage BH, Cowley M, Dehmer GJ, Ellis SG, Ewy GA, Faxon DP, Holmes DR Jr, Jacobs AK, Little WC, Magorien RD, Nocero MA Jr, Oesterle S, Pepine CJ, Taubman M, Tommaso C, Vlietstra RE, Vogel R, Forrester JS, Douglas PS, Faxon DP, Fischer JD, Gregoratos G, Wolk MJ, et al. American College of Cardiology training statement on recommendations for the structure of an optimal adult interventional cardiology training program: a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 1999;34:2141-47.

8. O’Rourke RA, Brundage B, Froelicher VF, Greenland P, Grundy SM, Hachamovitc R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL Jr, Forrester JS, Douglas PS, Faxon DP, Fisher JD, Gregoratos G, Hochman JS, Hutter AM Jr, Kaul S, Wolk MJ. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. Circulation 2000;102:126-40.

9. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Theroux P, Alpert JS, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2000; 102:1193-1209. and J Am Coll Cardiol 2000; 36:970-1062.

10. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty. ACC/AHA guidelines of percutaneous coronary interventions. J Am Coll Cardiol 2001;37:2215-39. and Circulation 2001;103:3019-41.

11. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, McNamara LS, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001;38:1231-66. and Circulation 2001;104:2118-50

12. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, et al. American College of Cardiology/American Heart Association Task A 73 David P. Faxon, M.D. Curriculum Vitae

Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure), International Society for Heart and Lung Transplantation, Heart Failure Society of America. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive Summary. Circulation 2001;104:2996-3007 and J Am Coll Cardiol 2001;38:2101-13 and J Heart & Lung Trans 2002; 21:189-203

13. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant RC, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for NonCardiac Surgery – Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol 2002;39:542-53 and Circulation 2002;105:1257-67 and Anesthesia & Analgesia 2002; 94:1052-64.

14. Jacobs AK, Faxon DP, Hirshfeld JW, Holmes DR. (Task Force 3: Training in Diagnostic Cardiac Catheterization and Interventional Cardiology). ACC revised recommendations for training in adult cardiovascular medicine core cardiology training II (COCATS 2) (Revision of the 1995 COCATS training statement). J Am Coll Cardiol 2002;39:1242-46

15. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines).J Cardiovasc Electrophysiol. 2002 Nov;13(11):1183-99.

16. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, Douglas PS, Faxon DP, Gillam LD, Kimball TR, Kussmaul WG, Pearlman AS, Philbrick JT, Rakowski H, Thys DM. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-- summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol. 2003 Sep 3;42(5):954-70 and Circulation. 2003 Sep 2;108(9):1146-62 and J Am Soc Echocardiogr. 2003 Oct;16(10):1091-110.

17. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ; European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society.J Am Coll Cardiol. 2003 Oct 15;42(8):1493-531 and Circulation. 2003 Oct 14;108(15):1871-909.

A 74 David P. Faxon, M.D. Curriculum Vitae

18. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, Carabello BA, Russell RO Jr, Cerqueira MD, St John Sutton MG, DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith SC Jr, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO; American College of Cardiology; American Heart Association; American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging).J Am Coll Cardiol. 2003 Oct 1;42(7):1318-33 and Circulation. 2003 Sep 16;108(11):1404-18.

19. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Gibbons RJ, Alpert JS, Antman EM, Hiratzka LF, Fuster V, Faxon DP, Gregoratos G, Jacobs AK, Smith SC Jr; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. Committee on the Management of Patients With Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003 Jan 7;107(1):149-58.

20. Faxon DP. Schwamm LH, Pasternak RC, Peterson ED, McNeil BJ, Bufalino V, Yancy CW, Brass LM, Baker DW, Bonow RO, Smaha LA, Jones DW, Smith SC Jr, Ellrodt G, Allen J, Schwartz SJ, Fonarow G, Duncan P, Horton K, Smith R, Stranne S, Shine K; American Heart Association’s Expert Panel on Disease Management. Improving quality of care through disease management: principals and recommendations from the American Heart Association’s Expert Panel on Disease Management. Circulation. 2004 Jun 1;109(21):2651-4 and Stroke. 2004 Jun;35(6):1527-30.

21. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Alperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology; American Heart Association Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004 Aug 3;110(5):588- 636.

22. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, GibbonsRJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Thoracic Surgery and the Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999Guidelines for Coronary Artery Bypass Graft A 75 David P. Faxon, M.D. Curriculum Vitae

Surgery). Circulation. 2004 Aug 31;110(9):1168-76.

23. Hunt SA, Abraham WT, Chin MH, Felman AM et al ACC/AHA 2005 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) Circulation 2005;112(12):1825-52 and e154-235.

24. Smith SC JR, Feldman TE, Hirshfeld JW Jr, Jacobs AK et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary intervention). Circulation 2006;113(1):156-75.

25. Bufalino V, Peterson ED, Burke GL, LaBresh KA, Jones DW, Faxon DP, Valadez AM, Brass LM, Fulwider VB, Smith R, Krumholz HM, Payment for Quality: Guiding Principles and Recommendations. Principles and Recommendations from the American Heart Association’s Reimbursement, Coverage, and Access Policy Development Workgroup Circ 2006; 113:1151-4

26. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): Circulation. 2006 Mar 21;113(11):e463-654, J Vasc Interv Rad 2006;17:1383-97

27. Fleisher LA, BeckmanJA, Brown KA Calkins H, Chaikof E,. Fleischmann KE, Freeman WK, Froehlich JB,. Kasper KA, Kersten JA, Riegel B, Robb B, Smith SC, Jacobs AJ, Adams SG,. Anderson JL,. Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy Circulation. 2006;113:2662-2674, JACC 2006;47:2343-55

28. Bonow R, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed D, Gaash WH, Little BA, Nishimura RA, O’Gara PT, O’Rourke RA, Otto KM, Shah PM, Shane JS, ACC/AHA 2006 guidelines for the management of valuluar heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circ 2006; 114:e84-231, JACC 2006; 48:e1-148

29. Krumholz, KM, Currie P, Riegel B, Phillips CO,Peterson ED, Smith R, Yancy CW, Faxon DP, A Taxonomy for Disease Management A Scientific Statement From the American Heart Association Disease Management Taxonomy Writing Group Circualtion 2006; 114:1432-45

30. Jacobs AK, Antman EM, Ellrodt G, Faxon DP, Gregory T, Mensah G, Moyer P, Ornato J, Peterson ED, Sadwin L, Smith SC, Recommendations for strategies to increase the munber of ST-segment elevation myocardial infarction patients with timely access to primary percutaneous coronary interventions, American Heart Association’s Acute Myocardial Infarction (AMI) Advisory Working A 76 David P. Faxon, M.D. Curriculum Vitae

Group, Circ 2006; 113:2152-63

31. Bufalino V, Peterson E, Krumholz H, Burke GL, LaBresh KA, JonesDL,, Faxon DP, Valadez AM, Solis P, SchwartzJS, Nonfinancial Incentives for Quality. A Policy Statement From the American Heart Association Circulation 2007 115:398-401

32. Jacobs AK, Antman EM, Faxon DP, Gregory T, Solis P, Development of Systems of Care for ST- Elevation Myocardial Infarction Patients. Executive Summary, Circulation. 2007 Jul 10;116(2):217- 30

33. Faxon DP, Development of Systems of Care for ST-Elevation Myocardial Infarction Patients. Current State of ST-Elevation Myocardial Infarction Care. Circulation. 2007 May 30; [Epub ahead of print]

34. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischman KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC, JAcobx AK, Adams CD, Anderson JL, ANtman EM, Buller CE, Creager MA, Ettinger SM Faxon DP. Fuster V, Halperin JL, Hirakzxka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Reigel B, Tarkington LG, Yancy CW, ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery):. Circulation. 2007 Oct 23;116(17):e418-99. Circulation. 2007 Oct 23;116(17):1971-1996. J Am Coll Cardiol. 2007 Oct 23;50(17):e159-241

35. ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures). Circulation. 2007 Jul 3;116(1):98-124. J Am Coll Cardiol. 2007 Jul 3;50(1):82-108 Catheter Cardiovasc Interv. 2007 Jun 25

36. Baughman KL, Duffy FD, Eagle KA, Faxon DP, Hillis LD, Lange RA, Task force 1: training in clinical cardiology. J Am Coll Cardiol. 2008 Jan 22;51(3):339-4

37. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery, Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW.ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation A 77 David P. Faxon, M.D. Curriculum Vitae

and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg. 2008 Mar;106(3):685-712.

38. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008 May 27;117(21):e350-408

39. Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O'Gara PT, O'Rourke RA, Shah PM. ACC/AHA 2008 Guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 Aug 19;52(8):676-85

40. Bonow R, Carabello B, Chatterjee K, de Leon Jr A ,Faxon D, Freed M , Gaasch W ,Lytle W, . Nishimura R, O'Gara P, 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart DiseaseA Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons JACC, 2008 ; 52 (13): e1 - e142

41. Coronary Revascularization Writing Group, Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA; Technical Panel, Masoudi FA, Dehmer GJ, Patel MR, Smith PK, Chambers CE, Ferguson TB Jr, Garcia MJ, Grover FL, Holmes DR Jr, Klein LW, Limacher MC, Mack MJ, Malenka DJ, Park MH, Ragosta M 3rd, Ritchie JL, Rose GA, Rosenberg AB, Russo AM, Shemin RJ, Weintraub WS; Appropriate Use Criteria Task Force, Wolk MJ, Bailey SR, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Shaw L, Stainback RF, Allen JM; American College of Cardiology Foundation; American College of Cardiology Foundation Appropriate Use Criteria Task Force; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Thoracic Surgery; American Heart Association; American Society of Nuclear Cardiology; Society of Cardiovascular Computed Tomography. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American A 78 David P. Faxon, M.D. Curriculum Vitae

College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography.J Thorac Cardiovasc Surg. 2012 Apr;143(4):780-803

42. Nallamothu BK, Tommaso CL, Anderson HV, Anderson JL, Cleveland JC Jr, Dudley RA, Duffy PL, Faxon DP, Gurm HS, Hamilton LA, Jensen NC, Josephson RA, Malenka DJ, Maniu CV, McCabe KW, Mortimer JD, Patel MR, Persell SD, Rumsfeld JS, Shunk KA, Smith SC Jr, Stanko SJ, Watts B. ACC/AHA/SCAI/AMA-Convened PCPI/NCQA 2013 performance measures for adults undergoing percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures, the Society for Cardiovascular Angiography and Interventions, the American Medical Association-Convened Physician Consortium for Performance Improvement, and the National Committee for Quality Assurance. J Am Coll Cardiol 2014;63:722-45

Major Trials- DSMB chairman or member

1. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, and the EPIC Investigators, Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994 Apr 9;343(8902):881-6. Chairman DSMB

2. The EPILOG Investigators, Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997 Jun 12;336(24):1689-96 Chairman DSMB

3. The IMPACT-II Investigators, Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention-IMPACT-II, Lancet 349 (1997), pp. 1422–1428. Member DSMB

4. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004 Apr 27;109(16):1942-7. Member DSMB

5. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA. 2005 Sep 14;294(10):1215-23. Member DSMB

6. Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME; TAXUS V ISR Investigators Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial JAMA. 2006 Mar 15;295(11):1253-63. Member DSMB A 79 David P. Faxon, M.D. Curriculum Vitae

7. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME; TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice Circulation. 2005 Nov 22;112(21):3306-13, Member DSMB

8. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA. 2008 Apr 23;299(16):1903-13. Chairman DSMB

9. Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whitlow P, St Goar F, Rodriguez L, Silvestry F, Schwartz A, Sanborn TA, Condado JA, Foster E Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol. 2005 Dec 6;46(11):2134-40, Member DSMB

10. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM; ACUITY Investigators Bivalirudin for patients with acute coronary syndromes N Engl J Med. 2006 Nov 23;355(21):2203-16, Member DSMB

11. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J. Polymer-based, paclitaxel-eluting TAXUS Liberté stent in de novo lesions: the pivotal TAXUS ATLAS trial.J Am Coll Cardiol. 2007 Apr 24;49(16):1676-83.Member DSMB

12. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial JAMA. 2007 Feb 14;297(6):591-602. Member DSMB

13. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med. 2008 May 22;358(21):2218-30. Member DSMB

14. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med. 2009 Mar 5;360(10):961-72. Member DSMB

15. Giugliano RP,Jennifer SM. White, Bode S, Armstrongpw, Montalescot G, Lewis GS, van `t Hof G, Berdan LG, Lee KL,Strony KL,Hildemann S, Veltri E,Van de Werf F, Braunwald E, Harrington RA,Califf RM, Newby KL for the EARLY ACS Investigators, Early versus Delayed, Provisional A 80 David P. Faxon, M.D. Curriculum Vitae

Eptifibatide in Acute Coronary Syndromes, N Engl J Med 2009; 360:2176-2190, Member DSMB

16. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL; SPIRIT III Investigators, Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation 2009 Feb 10;119(5):680-6, Chairman DSMB

17. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA; CHAMPION PLATFORM Investigators, Intravenous platelet blockade with cangrelor during PCI, NEJM 2009:361:2330-41, DSMB member

18. Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL., Platelet inhibition with cangrelor in patients undergoing PCI, NEJM 2009;361:2318-29, Member DSMB

19. Cannon LA, Kereiakes DJ, Mann T, Popma JJ, Mooney MR, Mishkel GJ, Lee TC, Wilson BH, Stuckey TD, Orlow S, McGarry T, Ring ME, Kellett MA, Underwood P, Dawkins KD. A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial.EuroIntervention. 2011 Mar;6(8):920-7, Member DSMB

20. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators, Standard vs. high-dose colopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS reandomized trial. JAMA 2011:305:1097-105, Chairman DSMB

21. Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RK, Dens J, Hagivara N, Allocco DJ, Dawkins KD and the PLATNUM Trial Investigators. A prospective, randomized evaluaton of a novel everolimus-elutign coronary stent. J Am Coll Card 2011;57:1700-8 member DSMB

22. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, Topol EJ; BRIDGE Investigators.Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.JAMA. 2012 Jan 18;307(3):265-74. Chairman DSMB

23. Ormiston JA, Charles O, Mann T, Hall JJ, McGarry T, Cannon LA, Webster MW, Mishkel GJ, Underwood PL, Dawkins KD. Final 5-year results of the TAXUS ATLAS, TAXUS ATLAS Small Vessel, and TAXUS ATLAS Long Lesion clinical trials of the TAXUS Liberté paclitaxel-eluting stent in de-novo coronary artery lesions. Coron Artery Dis. 2013 Jan;24(1):61-68. Member DSMB

A 81 David P. Faxon, M.D. Curriculum Vitae

24. Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, Kornowski R, Abizaid A, Wojdyła R, Maehara A, Dressler O, Brener SJ, Bar E, Dudek D. Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction: The MASTER Trial.J Am Coll Cardiol. 2012 Sep 28. Member DSMB

25. Deepak L. Bhatt, M.D., M.P.H., Gregg W. Stone, M.D., Kenneth W. Mahaffey, M.D., C. Michael Gibson, M.D., P. Gabriel Steg, M.D., Christian W. Hamm, M.D., Matthew J. Price, M.D., Sergio Leonardi, M.D., Dianne Gallup, M.S., Ezio Bramucci, M.D., Peter W. Radke, M.D., Petr Widimský, M.D., D.Sc., Frantisek Tousek, M.D., Jeffrey Tauth, M.D., Douglas Spriggs, M.D., Brent T. McLaurin, M.D., Dominick J. Angiolillo, M.D., Ph.D., Philippe Généreux, M.D., Tiepu Liu, M.D., Ph.D., Jayne Prats, Ph.D., Meredith Todd, B.Sc., Simona Skerjanec, Pharm.D., Harvey D. White, D.Sc., and Robert A. Harrington, M.D. for the CHAMPION PHOENIX Investigators Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events New Eng J Med March 10, 2013 DSMB member

26. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Ståhle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.Lancet. 2013 Feb 23;381(9867):629-38. DSMB member

27. Schofer J, Colombo A, Klugmann S, Fajadet J, DeMarco F, Tchétché D, Maisano F, Bruschi G, Latib A, Bijuklic K, Weissman N, Low R, Thomas M, Young C, Redwood S, Mullen M, Yap J, Grube E, Nickenig G, Sinning JM, Hauptmann KE, Friedrich I, Lauterbach M, Schmoeckel M, Davidson C, Lefevre T. Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve.J Am Coll Cardiol. 2014 Mar 4;63(8):763-8. doi: 10.1016/j.jacc.2013.10.013. Epub 2013 Nov 6. DSMB

28. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, Hermiller J Jr, Hughes GC, Harrison JK, Coselli J, Diez J, Kafi A, Schreiber T, Gleason TG, Conte J, Buchbinder M, Deeb GM, Carabello B, Serruys PW, Chenoweth S, Oh J; CoreValve United States Clinical Investigators. Transcatheter Aortic Valve Replacement Using A Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for Surgery. J Am Coll Cardiol. 2014 Mar 13. pii: S0735-1097 Chairman DSMB

29. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK; the U.S. CoreValve Clinical Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. N Engl J Med. 2014 Mar 29. [Epub ahead of print] Chairman DSMB

29. Reardon MJ, Adams DH, Coselli JS, Deeb GM, Kleiman NS, Chetcuti S, Yakubov SJ, Heimansohn D, Hermiller J Jr, Hughes GC, Harrison JK, Khabbaz K, Tadros P, Zorn GL 3rd, Merhi W, Heiser J, Petrossian G, Robinson N, Maini B, Mumtaz M, Lee JS, A 82 David P. Faxon, M.D. Curriculum Vitae

Gleason TG, Resar J, Conte J, Watson D, Chenoweth S, Popma JJ; CoreValve US Clinical Investigators. Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery. J Thorac Cardiovasc Surg. 2014 Dec;148(6):2869-76.e1-7. doi: Epub 2014 Jul 30. PMID: 25152474[PubMed - indexed for MEDLINE] Chairman DSMB

30. Newby LK, Marber MS, Melloni C, Sarov-Blat L, Aberle LH, Aylward PE, Cai G, de Winter RJ, Hamm CW, Heitner JF, Kim R, Lerman A, Patel MR, Tanguay JF, Lepore JJ, Al-Khalidi HR, Sprecher DL, Granger CB; SOLSTICE Investigators. Losmapimod, a novel p38 mitogen- activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.Lancet. 2014 Sep 27;384(9949):1187-95. doi: 10.1016/S0140- 6736(14)60417-7. Epub 2014 Jun 12. Erratum in: Lancet. 2014 Sep 27;384(9949):118 PMID: 24930728 [PubMed - indexed for MEDLINE] Chairman DSMB

31. Khoynezhad A, Azizzadeh A, Donayre CE, Matsumoto A, Velazquez O, White R; RESCUE investigators. Results of a multicenter, prospective trial of thoracic endovascular aortic repair. for blunt thoracic aortic injury (RESCUE trial) J Vasc Surg. 2013 Apr;57(4):899-905.e1. doi: 10.1016/j.jvs.2012.10.099. Epub 2013 Feb 4 Chairman DSMB

32. Schofer J, Colombo A, Klugmann S, Fajadet J, DeMarco F, Tchétché D, Maisano F, Bruschi G, Latib A, Bijuklic K, Weissman N, Low R, Thomas M, Young C, Redwood S, Mullen M, Yap J, Grube E, Nickenig G, Sinning JM, Hauptmann KE, Friedrich I, Lauterbach M, Schmoeckel M, Davidson C, Lefevre T. Prospective multicenter evaluation of the direct flow medical transcatheter aortic valve.J Am Coll Cardiol. 2014 Mar 4;63(8):763-8. doi: 10.1016/j.jacc.2013.10.013. Epub 2013 Nov 6 Chairman DSMB

33. Reardon MJ, Adams DH, Coselli JS, Deeb GM, Kleiman NS, Chetcuti S, Yakubov SJ, Heimansohn D, Hermiller J Jr, Hughes GC, Harrison JK, Khabbaz K, Tadros P, Zorn GL 3rd, Merhi W, Heiser J, Petrossian G, Robinson N, Maini B, Mumtaz M, Lee JS, Gleason TG, Resar J, Conte J, Watson D, Chenoweth S, Popma JJ; CoreValve US Clinical Investigators. Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery. J Thorac Cardiovasc Surg. 2014 Dec;148(6):2869-76.e1-7. doi: 10.1016/j.jtcvs.2014.07.020. Epub 2014 Jul 30 Chairman DSMB

34. Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M, West NE, Kelbæk H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD. Six-month IVUS and two year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting sten EuroIntervention. 2013 Jul;9(3):308-15. doi: 10.4244/EIJV9I3A52. Chairman DSMB

35. Meredith Am IT, Walters DL, Dumonteil N, Worthley SG, Tchétché D, Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefèvre T, Lange R, Müller R, Redwood S, Allocco DJ, Dawkins KD. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system : 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol. 2014 Sep 30;64(13):1339-48. doi: A 83 David P. Faxon, M.D. Curriculum Vitae

10.1016/j.jacc.2014.05.067. DSMB

36. Meredith IT, Worthley SG, Whitbourn RJ, Antonis P, Montarello JK, Newcomb AE, Lockwood S, Haratani N, Allocco DJ, Dawkins KD Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study. EuroIntervention. 2014 Mar 20;9(11):1264-70. doi: 10.4244/EIJV9I11A216, DSMB

37. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK; U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014 May 8;370(19):1790-8. doi: 10.1056/NEJMoa1400590. Epub 2014 Mar 29. DSMB

38. Garratt KN1, Weaver WD2, Jenkins RG2, Pow TK2, Mauri L2, Kereiakes DJ2, Winters KJ2, Christen T2, Allocco DJ2, Lee DP2. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement. Circulation 2015 Jan 6;131(1):62-73. doi: 10.1161/CIRCULATIONAHA.114.013570. Epub 2014 Nov 16. DSMB

39. Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW; RIVER- PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo- controlled trial.Lancet. 2015 Oct 12, DSMB

40. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transicent ischmic attack, N Engl J Med. 2016 Apr 7;374(14):1321-31, DSMB

41. Gibson M C, Korjian S, Tricoci KS Daaboul PY, Yee M, Jain P, Alexander JH, Steg PG, Lincoff AM, Kastelein JJ, Mehran R, D'Andrea DM, Deckelbaum LI, Merkely B, Zarebinski M, Ophuis TO, Harrington RA. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I, Circulation. 2016 Dec 13;134(24):1918-1930. DSMB

Clinical Communications

1. Bilazarian SD, Jacobs AK, Fonger JD, Faxon DP. Case report of a coronary anomaly: crossing obtuse marginal arteries. Cath CV Diag 1991;23:130-41.

A 84 David P. Faxon, M.D. Curriculum Vitae

2. American College of Cardiology Ad Hoc Task Force on Telemedicine, The White Paper - The cardiovascular specialist and telemedicine: issues for consideration. October 3, 1997

3. Faxon DP. Heart health updates. Newsweek Advertising Insert, You and Your Heart 2001;4-12.

4. Jolly N, Faxon DP, and Lang RM. Coronary artery compression caused by a large pseudoaneurysm complicating an acute myocardial infarction (case report). Echocardiography. 2004; 21:85-86.

5. Faxon DP, Science Updates at AHA Scientific Sessions New Orleans, October 8-11, 2009

Letters to the Editors

1. Currier JW, Faxon DP, Lafont A. Geometric Remodeling. Letter to the Editor, Circulation Correspondence 1995;92:3581

2. Coats WD, Whittaker P, Faxon DP. Collagen metabolism and restenosis. Letter to the Editor. Circulation 1997;96:3802-04.

3. Jacobs AK, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V. Response to Letter to the Editor. Circulation, 1997.

4. Faxon D, Alteplase for stroke. American Heart Association explains how guidelines were formulated, BMJ 2002;324:1581

5. Wu C, Hannan EL, Walford G, Faxon DP, Reply to ‘Unprotected left main conranry artery stenting vesus coronary artery bypass graft surgery’ Ann thorac Surg 2009; 87; 1652-1653

Educational Materials

1. Faxon DP. Drug Eluting Stents: Are They the Holy Grail? Clinical Update. AHA My American Heart (www.americanheart.org). 2002 Sept 14.

2. Faxon DP, Should All Patients at high Risk for Coronary Disease Receive a Statin? Clinical Update. AHA My American Heart (www.americanheart.org). 2002 Oct 2.

3. Faxon DP, The Updated Secondary Prevention Guidelines: What’s New and Why. Clinical Update. AHA My American Heart (www.americanheart.org). 2002 Oct 22.

4. Faxon DP. Evolution of the American College of Cardiology/American Heart Association Clinical Practice Guidelines. Clinical Update. AHA My American Heart (www.americanheart.org). 2003 Aug 8.

5. Faxon DP, Optimal Interhospital Transfer ACCEL (www.cardiosource.com) 8/29/04 A 85 David P. Faxon, M.D. Curriculum Vitae

6. Faxon DP. A Randomized Comparison of Off-Pump and On-Pump Multivessel Coronary Artery Bypass Surgery. Clinical Update. AHA My American Heart (www.americanheart.org). 2004 Jan 26

7. Faxon DP Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes, AHA My American Heart (www.americanheart.org). 10/28/2005.

8. B, Unprotected left main disease should be treated by surgery ACCEL (www.cardiosource.com) 3/8/05

9. Faxon DP Disease Management: Why is it important? ACCEL (www.cardiosource.com) 11/15/05

10. Faxon D Unprotected Left Main should be Treated with Coronary Artery Bypass Surgery- ACCEL Cardiosourse newsletter (www.cardiosource.com) March 17, 2006

11. Granger C, Fox AA, Yusuf S, Faxon D The mamagement of ACS in light of recent trials: The importance of bleeding (http://www.medscape.com/viewprogram/5225) May 2006

12. Faxon DP, Left main disease: CABG without question, TCTmd (http://www.tctmd.com) May 2006

13. Faxon DP, "Should Drug-Eluting Stent be Curtailed in the Milieu of Increased Safety Concerns - Protagonist" tctmd at http://www.tctmd.com/ Dec 2006

14. Faxon DP, "Is primary percutaneous coronary intervention really superior to thrombolysis in the real world?" (www.americanheart.org) Jan 26, 2007

15. Faxon DP, "Is prolonged dual antiplatelet therapy the answer to preventing late stent thrombosis after drug eluting stents?" (www.americanheart.org) Jan 26, 2007

16. Faxon DP, "Are the cardiovascular risks of Rosiglitazone significant?" (www.americanheart.org) July 20, 2007

17. Faxon DP, Exercise testing and angioplasty for ABC News ON-CALL-Coronary Artery Disease Nov 6, 2007

18. Faxon DP, Kinlay S, Stable angina and silent ischemia-ACC/AHA guidline synopsis, In ed D Moliterno, CathSAP3, ACCF: in press

19. Faxon D, Bauer K, Preventing venous thromboembolsm in the acutely ill medical patient: application of current and emerging therapeutic options. Making Better Informed VTE-Related Decisions 2007:1 (2):1-8

20. Faxon D, Bauer K, Emerging antithrobotic treatment options of acute cornary syndromes, Making Better Informed VTE-Related Decisions 2007: in press

21. Faxon D "Shortening the treatment times in Acute MI" ReachMD/XM 157 radio 11/20/07

A 86 David P. Faxon, M.D. Curriculum Vitae

22. Faxon D "FDA approves a new drug eluting stent: not the last 'Endeavor' (www.americanheart.org) 2/11/2008

23. Gersh B, Faxon DP, PROTECT-AF trial ACC 09, www.incirculation.net 4/6/09

24. Faxon D, Percutaneous Coronary Intervention versus Coronary Artery Bypass Grafting for Severe Coronary Artery Disease,(www.americanheart.org) 5/08/09

25. Faxon D, Reduction in acute myocardial infarction mortality in the united states: Risk-standardizzed mortality rates fom 1995-2006 (www.americanheart.org) 10/2/2009

26. Faxon D, Valvular heart disease Podcast, Allinace for Aging Research, (http://www.agingresearch.org/section/topic/valvular_disease.) 7/8/2010

27. Faxon DP, Platelet function testing; insights from the GRAVITAS study, Cardiology Today 2011

28. Faxon DP, David P. Faxon MD, Cardiologist with a committed passion for helping others, Cardiology Today 2011;14:4

29. Faxon DP, New antipatelet agents face hurdles in copidogrel-dominated market, Cardiology Today 2011;14:6

30. Faxon DP, Questions with Dr Bhatt, Cardiology Today 11/12 2011

Abstracts: (last 10 years, unpublished)

1. Cohen H, Williams DO, Holmes D, Faxon DP, King SB, Detre K, Use of drug-eluting stents in contemporary interventions: A comparison to bare metal stent use in the National Heart Lung and Blood Institute Dynamic Registry. JACC 2005;45:63A.

2. Holper LM, Selxer F, Jacobs AK, Srinivas V, Faxon DP. Temporal Changes in the Treatment of In- Stent Restenosis in the Dynamic Registry. Circ 2005;112(17):II-482.

3. Holper LM, Vlachos H, Selzer H, Jacobs AJ, Williams DO, King SK, Holmes DR, Wilensky RL, Abbott D, Slater J, Faxon DP, Outcomes for Mulitvessel Stenting with Bare Metal versus Drug Eluting Stents in the Dymanic Registry. Circ 2005;112(17):II-482.

4. Feit F, Kim LJ, Attubato MJ, Jacobs AK, Faxon D, Rihal C, Sing IRP, Abbott JD, Kent K, King SB, Kip K, Which patients with diabetes mellitus and multivessel coronary disease are selected for bypass surgey rather than percuataneous coronary intervention? Results from BARI-2D Circ 2006: 114;II-431

5. Hammon M, Mehta S, Steg G, Faxon D, Kerkar P, Rupprecht HJ, Tanguay JF, Afzal R, Yusuf Major bleeding in patients with acute coronary syndrome undergoing early invasive management can be reduced by fondaparinux, even in the context of trans-radial coronary intervention: insights from A 87 David P. Faxon, M.D. Curriculum Vitae

OASIS-5 Trial Circ 2006:114;II-552

6. Holper EM, Abbott JD, Mulukutla S, Vlachos H, Faxon DP, Laskey W, Srinivas V, Marroquin O, Jacobs AK Temporal changes in the outcomes of patient with diabetes mellitus undergoing PCI in the NHLBI dynamic registry Circ 2006; 114:II-587

7. Borden, WB, Faxon DP, Selzer F, Kip KE, Laskey WK, Holper EM, Effect of payer status on interventional utilization patterns: current results from the NHLBI dynamic registry, JACC 2007; 49: 295A

8. Steg GP, Ducrocq G, Afxal R, Faxon DP, Widimsky P, Yusuf S, Paradoxical Low Use of Coronary Interventions in High-Risk Non-ST Segment Acute Coronary Syndromes with Heart Failure. Data from the Oasis-5 Randomized Trial Circ 2008;118:S975

9. Holper E, Banerjee S, Selzer F, Abbott D, Naidu S, Welisky RL, Faxon DP, Jacobs AK , Persistent high risk of death and myocardial infarction in patients with peripheral arterial disease undergoing PCI: Resutls form the NHLBI Dynamic Registry Circ 2008; 118:S631

10. Iqbal SN, Selzer F, Naidu SS, Doucet, Faxon D, Jacobs A, Slater J, Presentation and outcomes after percutaneous intervention for acute myocardial infarction in the NHLBI Dynamic Registry: Saphenous vein grants versus native coranry arteries. JACC 2009:53:A75

11. Bainey KR, Selzer F, Cohen HA, Marroquin OC, Holper EM, Williams DO, Faxon DP, Impact of Age on the safety and efficacy of drug-eluting stents: A Report from the NHLBI Dynamic Registry Can J Cardiol 2009; 25: supplement SB

12. Bangalore S, Kip KE, Vlachos HE, Selzer F, Wilensky RL, Williams DO, Faxon DP, Bare Metal vs. Drug-Eluting Stents for Calcified Lesion: Findings From the NHLBI PCI Dynamic Registry, Circ 2009:120:S994

13. Bangalore S, Sawhney S, Kinlay S, Faxon DP, Complete Revascularization versus Culprit-only Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A Meta-Analysis Circ 2009:120:S987

14. Faxon DP, Kinlay S, Hernandez RK, Gaziano M, Lawler E, Prolonged use of clopidogrel reduces death and myocardial infarction following drug eluting stent but not bare metal stent placemnt:The VA DES study, Circ 2009:120:S970

15. Parikh S, Slezer F, Abbott D, MArroquin OC, Wilensky R, Srinivas S, Williams DO, Faxon DP, Holper EM, No long term clinical benefit of IVUS guided PCI: Results for the NHLBI Dynamic Registry, Circ 2009;120:S926

16. Bainey K, Selzer F, Bangalore S, Todoran T, Garg P, Slater J, Jacobs S, Wilensky R, Srinivas, S, Wiliams DO, Faxon D, The impact of vascular complications and advanced age on outcomes following percutaneous coronary intervention Circ 2009;120:S931

17. Banglaore S, Selzer F, Srinivas VS, Williams D, Faxon DP , Thin versus thick strut stent for A 88 David P. Faxon, M.D. Curriculum Vitae

percutaneous coronary intervention using bare metal stents: Insights from the NHLBI PCI Dynamic Regsitry JACC 2010;55:A195

18. Banglaore S, Selzer F, Williams D, Faxon DP , Stanless Steel verxus non-stanless steel stent for percutaneous coronary intervention using bare metal stents: Findings form the NHLBI PCI Dynamic Regsitry JACC 2010;55:A195

19. Bangalore S, Faxon D, Is multivessel revascularization in patients with ST-Segment myocardial infarction associated with increased risk of acute complication? Insights from the NHLBI PCI Dynamic registry. Circulation 2010:122;A

20. Kinlay S, Young M, Lawler E, Gaziano M, Faxon DP, Prolonged use of clopidogrel and risk of death and mocardial infarction 4 years after coronary stenting idatestes: the VA DES study Circulation 2011:124;A

21. Siddiqi O, Faxon DP, Gaziano M, Young M, Lawler E, , Kinlay S, Prolonged use of clopidogrel and the risk of death, MI and major bleeding 5 years after coronary stenting in patients with chronic kidney disease Circulation 2012;126:A16033

22. Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan E, Faxon DP, Feit F, Bangalore S, Bare Metal Stents, Durable Polymer Drug Eluting Stents or Biodegradable Polymer Stents for Coronary Artery Disease: A Mixed Treatment Comparison Analysis of 254 361 Patient-Years of Follow-up From Randomized Trials Circulation. 2013;128:A10908

23. Depta JP, Smoot J, Cho K, Sokolovskaya G, Gagnon DR, Ly S, Temiyasathit, S , Do K, Nava N , Ostrowski S, Gaziano M, Faxon DP, Kinlay S, The Impact of Prolonged Clopidogrel Beyond 12 Months After Coronary Stenting in Patients with Acute Coronary Syndromes, Circulation. 2014;130:A13013

24. Wimmer J, Smoot K, Cho K, Sokolovskaya G, Gagnon D, Ly S ,Temiyasathit S, Do J, Nava A, Ostrowski S, Gaziano JM, Faxon DP, Kinlay S, The Impact of Prolonged Clopidogrel Beyond 12 Months After Coronary Stenting in Patients with Acute Coronary Syndromes, Circulation. 2014;130:A13013

Part VIII: Narrative Report A 89 David P. Faxon, M.D. Curriculum Vitae

My focus during my career has been in the areas of translational and clinical research, public education and policy, patient care and teaching. Overall these areas have been balanced with greater emphasis on research initially followed by an active role in the national leadership of the American Heart Association over the past 15 years.

My initial interest was in cardiac hemodynamic and in collaboration with Dr. Harry Gavras at Boston University; we were the first to demonstrate the role of angiotensin converting enzyme inhibition in regulation of blood flow and in the treatment of congestive heart failure, now the standard of therapy. As one of the first US physicians to perform coronary angioplasty, I was interested in determining the mechanism of angioplasty and restenosis. In a series of experiments using a novel animal model, I was the first to describe that angioplasty worked by stretching and tearing the vessel wall. Further animal studies described the pathophysiological processes and agents that could prevent restenosis. I was the first to describe that unfavorable vascular remodeling was primarily responsible for restenosis following balloon angioplasty. We described the abnormalities of matrix formation particularly collagen biosynthesis that were found to contribute. Since 1980, I have participated in the NHLBI PTCA and Dynamic registries that have tracked the practice and outcomes of angioplasty. My investigation has focused on the role of PCI, CABG and medical therapy in the NHLBI BARI 1 and BARI 2D trials and the risk of drug eluting stents in the treatment of coronary disease in the VA population. In addition I have made contributions to the national guidelines for management of patients with cardiac disease as a member of the ACC/AHA Guidelines Committee and served as an expert reviewer on the current guideline updates.

Since 1979, I have been actively involved in the American Heart Association, the largest cardiovascular non-profit voluntary health organization in the world. I served as the President of the Massachusetts Affiliate, and the President of the Los Angeles Affiliate as well as on the Board of the Western States Affiliate. In these roles I was responsible for implementation of public and professional education, strategic direction and fund raising. I served as the Chairman of the AHA Scientific Publications Committee, which is responsible for all AHA scientific publications including its 5 major journals. I was elected to the national Board of Directors and became the President of the AHA from 2001-2002. As President I was responsible strategic planning, policy, and scientific oversight as well as the public spokesman for the organization. I have also served on numerous committees for the American College of Cardiology and NHLBI. I have been active in the Society of Cardiac Angiography and Interventions and served as President from 1997-8. I was member of the ABIM Cardiovascular Board and a member of the ACGME Residency Review Committee for Internal Medicine, which accredits internal medicine training programs. I have been on the Board of the Alliance for a Healthier Generation, a partnership between the AHA and the Clinton Foundations since 2006 and served as the Chairman of the Board in 2010-12. I have been on the Board of the Vascular Disease Foundation since 2004 and was President in 2013-2015.

I have held leadership positions since leaving my fellowship in 1996. First as the Director of the Cardiac Catheterization laboratory, then Director of Interventional Cardiology and Associate Chief of Cardiology at Boston Medical Center. I moved to the University of Southern California as Chief of Cardiology before moving to Chicago in 2000. At the University of Chicago, I served as Chief of Cardiology. In 2006, I moved to Boston and served as Chief of Cardiology at the Boston VA health system (West Roxbury) for two years and Vice Chair of Medicine at the Brigham and Women’s Hospital since then. I was the Interim Chief of Cardiology at the Boston VA Health System from A 90 David P. Faxon, M.D. Curriculum Vitae

2013 until 2015. In 2015, I was appointed the Clinical Director of the Ambulatory Cardiovascular Services and Associate Chief of Cardiology as well as Clinical Operations Chief of Cardiology in 2017

Clinically I have been active in the cardiac catheterization lab since 1976 and was one of the first to perform coronary angioplasty in the US. I have maintained an active clinical practice since 1976. I have been the Program Director for numerous GME course in cardiology and served on the Scientific Session Committee for the AHA Scientific Sessions, the largest cardiology meeting in the world.

I have continued to teach medical students, residents and cardiology fellow over the past 40 years and was program director for the cardiology fellowship program at USC. I have served on the ABIM Internal Medicine Cardiovascular Board and as a member on the ACGME Residency Review Committee. I participate in numerous editorial boards and have been the Editor in Chief of Reviews in Cardiovascular Medicine. I am the founding editor of AHA Clinical Updates. I served as an associate editor of Circulation from 2006 to 2016 and the founding Editor-in-Chief of Circulation: Cardiovascular Interventions since 2008.

A 91